The	O
effect	O
of	O
transforming	B
growth	I
factor	I
beta1	I
gene	O
polymorphisms	O
in	O
ankylosing	O
spondylitis	O
.	O

OBJECTIVES	O
:	O
To	O
determine	O
whether	O
genetic	O
polymorphisms	O
in	O
or	O
near	O
the	O
transforming	B
growth	I
factor	I
beta1	I
(	O
TGFB1	B
)	O
locus	O
were	O
associated	O
with	O
susceptibility	O
to	O
or	O
severity	O
of	O
ankylosing	O
spondylitis	O
(	O
AS	O
)	O
.	O

METHODS	O
:	O
Five	O
intragenic	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
and	O
three	O
microsatellite	O
markers	O
flanking	O
the	O
TGFB1	B
locus	O
were	O
genotyped	O
.	O

Seven	O
hundred	O
and	O
sixty	O
-	O
two	O
individuals	O
from	O
184	O
multiplex	O
families	O
were	O
genotyped	O
for	O
the	O
microsatellite	O
markers	O
and	O
two	O
of	O
the	O
promoter	O
SNPs	O
.	O

One	O
thousand	O
and	O
two	O
individuals	O
from	O
212	O
English	O
and	O
170	O
Finnish	O
families	O
with	O
AS	O
were	O
genotyped	O
for	O
all	O
five	O
intragenic	O
SNPs	O
.	O

A	O
structured	O
questionnaire	O
was	O
used	O
to	O
assess	O
the	O
age	O
of	O
symptom	O
onset	O
,	O
disease	O
duration	O
and	O
disease	O
severity	O
scores	O
,	O
including	O
the	O
BASDAI	O
(	O
Bath	O
Ankylosing	O
Spondylitis	O
Disease	O
Activity	O
Index	O
)	O
and	O
BASFI	O
(	O
Bath	O
Ankylosing	O
Spondylitis	O
Functional	O
Index	O
)	O
.	O

RESULTS	O
:	O
A	O
weak	O
association	O
was	O
noted	O
between	O
the	O
rare	O
TGFB1	B
+	O
1632	O
T	O
allele	O
and	O
AS	O
in	O
the	O
Finnish	O
population	O
(	O
P	O
=	O
0.04	O
)	O
and	O
in	O
the	O
combined	O
data	O
set	O
(	O
P	O
=	O
0.03	O
)	O
.	O

No	O
association	O
was	O
noted	O
between	O
any	O
other	O
SNPs	O
or	O
SNP	O
haplotype	O
and	O
AS	O
,	O
even	O
among	O
those	O
families	O
with	O
positive	O
non	O
-	O
parametric	O
linkage	O
scores	O
.	O

The	O
TGFB1	B
+	O
1632	O
polymorphism	O
was	O
also	O
associated	O
with	O
a	O
younger	O
age	O
of	O
symptom	O
onset	O
(	O
English	O
population	O
,	O
allele	O
2	O
associated	O
with	O
age	O
of	O
onset	O
greater	O
by	O
4.2	O
yr	O
,	O
P	O
=	O
0.05	O
;	O
combined	O
data	O
set	O
,	O
allele	O
2	O
associated	O
with	O
age	O
of	O
onset	O
greater	O
by	O
3.2	O
yr	O
,	O
P	O
=	O
0.02	O
)	O
.	O

A	O
haplotype	O
of	O
coding	O
region	O
SNPs	O
(	O
TGFB1	B
+	O
869	O
/	O
+915	O
+	O
1632	O
alleles	O
2	O
/	O
1	O
/	O
2	O
)	O
was	O
associated	O
with	O
age	O
of	O
symptom	O
onset	O
in	O
both	O
the	O
English	O
parent	O
-	O
case	O
trios	O
and	O
the	O
combined	O
data	O
set	O
(	O
English	O
data	O
set	O
,	O
haplotype	O
2	O
/	O
1	O
/	O
2	O
associated	O
with	O
age	O
of	O
onset	O
greater	O
by	O
4.9	O
yr	O
,	O
P	O
=	O
0.03	O
;	O
combined	O
data	O
set	O
,	O
haplotype	O
2	O
/	O
1	O
/	O
2	O
associated	O
with	O
greater	O
age	O
of	O
onset	O
by	O
4.2	O
yr	O
,	O
P	O
=	O
0.006	O
)	O
.	O

Weak	O
linkage	O
with	O
AS	O
susceptibility	O
was	O
noted	O
and	O
the	O
peak	O
LOD	O
score	O
was	O
1.3	O
at	O
distance	O
2	O
cM	O
centromeric	O
to	O
the	O
TGFB1	B
gene	O
.	O

No	O
other	O
linkage	O
or	O
association	O
was	O
found	O
between	O
quantitative	O
traits	O
and	O
the	O
markers	O
.	O

CONCLUSION	O
:	O
This	O
study	O
suggests	O
that	O
the	O
polymorphisms	O
within	O
the	O
TGFB1	B
gene	O
play	O
at	O
most	O
a	O
small	O
role	O
in	O
AS	O
and	O
that	O
other	O
genes	O
encoded	O
on	O
chromosome	O
19	O
are	O
involved	O
in	O
susceptibility	O
to	O
the	O
disease	O
.	O

SLC11A1	B
(	O
formerly	O
NRAMP1	B
)	O
and	O
susceptibility	O
to	O
visceral	O
leishmaniasis	O
in	O
The	O
Sudan	O
.	O

Genetic	O
susceptibility	O
to	O
visceral	O
leishmaniasis	O
(	O
VL	O
)	O
is	O
indicated	O
by	O
differences	O
in	O
incidence	O
and	O
clinical	O
phenotypes	O
between	O
ethnic	O
groups	O
in	O
Sudan	O
.	O

In	O
mice	O
,	O
innate	O
susceptibility	O
to	O
Leishmania	O
donovani	O
,	O
the	O
etiological	O
agent	O
of	O
VL	O
,	O
is	O
controlled	O
by	O
Slc11a1	O
(	O
formerly	O
Nramp1	O
)	O
.	O

We	O
therefore	O
examined	O
polymorphisms	O
at	O
SLC11A1	B
in	O
59	O
multicase	O
families	O
of	O
VL	O
from	O
the	O
high	O
-	O
incidence	O
Masalit	O
tribe	O
in	O
Sudan	O
.	O

Multipoint	O
nonparametric	O
analysis	O
in	O
ALLEGRO	O
shows	O
a	O
significant	O
linkage	O
across	O
SLC11A1	B
(	O
Zlr	O
scores	O
2.38	O
-	O
2.55	O
;	O
0.008	O
<	O
or	O
=	O
P	O
<	O
or	O
=	O
0.012	O
;	O
information	O
content	O
0.88	O
)	O
.	O

The	O
extended	O
transmission	O
disequilibrium	O
test	O
shows	O
biased	O
transmission	O
of	O
alleles	O
at	O
5	O
'	O
polymorphisms	O
in	O
the	O
promoter	O
(	O
P=0.0145	O
)	O
,	O
exon	O
3	O
(	O
P=0.0037	O
)	O
and	O
intron	O
4	O
(	O
P=0.0049	O
)	O
,	O
and	O
haplotypes	O
formed	O
by	O
them	O
(	O
P=0.0089	O
)	O
,	O
but	O
not	O
for	O
3	O
'	O
polymorphisms	O
at	O
exon	O
15	O
or	O
the	O
3'UTR	O
.	O

Stepwise	O
logistic	O
regression	O
analysis	O
using	O
a	O
case	O
/	O
pseudo	O
-	O
control	O
data	O
set	O
derived	O
from	O
the	O
59	O
families	O
was	O
consistent	O
with	O
main	O
effects	O
contributed	O
by	O
the	O
intron	O
4	O
469	O
+	O
14G	O
/	O
C	O
polymorphism	O
.	O

Although	O
the	O
two	O
alleles	O
for	O
469	O
+	O
14G	O
/	O
C	O
lie	O
on	O
haplotypes	O
carrying	O
different	O
alleles	O
for	O
the	O
functional	O
promoter	O
GTn	O
polymorphism	O
,	O
the	O
latter	O
did	O
not	O
itself	O
contribute	O
separate	O
main	O
effects	O
.	O

Sequence	O
analysis	O
of	O
36	O
individuals	O
failed	O
to	O
identify	O
new	O
putative	O
functional	O
polymorphisms	O
in	O
the	O
coding	O
region	O
,	O
intron	O
1	O
,	O
intron	O
/	O
exon	O
boundaries	O
,	O
intron	O
4	O
/	O
exon	O
4a	O
,	O
or	O
in	O
the	O
3'UTR	O
.	O

One	O
novel	O
promoter	O
polymorphism	O
(	O
-86G	O
/	O
A	O
)	O
was	O
located	O
within	O
a	O
putative	O
nuclear	B
factor	I
kappa	I
B	I
binding	O
site	O
that	O
could	O
be	O
functional	O
.	O

Further	O
work	O
will	O
determine	O
whether	O
additional	O
polymorphisms	O
occur	O
upstream	O
in	O
the	O
promoter	O
,	O
which	O
could	O
be	O
in	O
linkage	O
disequilibrium	O
with	O
the	O
intron	O
4	O
polymorphism	O
.	O

These	O
studies	O
contribute	O
to	O
knowledge	O
of	O
the	O
role	O
of	O
SLC11A1	B
in	O
infectious	O
disease	O
.	O

Association	O
of	O
Fcgamma	B
receptor	I
IIb	I
polymorphism	O
with	O
susceptibility	O
to	O
systemic	O
lupus	O
erythematosus	O
in	O
Chinese	O
:	O
a	O
common	O
susceptibility	O
gene	O
in	O
the	O
Asian	O
populations	O
.	O

The	O
association	O
of	O
Fcgamma	B
receptor	I
(	O
FcgammaR	B
)	O
polymorphisms	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
has	O
been	O
demonstrated	O
in	O
various	O
populations	O
;	O
however	O
,	O
the	O
results	O
have	O
been	O
inconsistent	O
.	O

We	O
recently	O
identified	O
a	O
single	O
-	O
nucleotide	O
polymorphism	O
encoding	O
a	O
non	O
-	O
synonymous	O
substitution	O
,	O
Ile232Thr	O
(	O
I232	O
T	O
)	O
,	O
of	O
FCGR2B	B
and	O
its	O
association	O
with	O
SLE	O
in	O
Japanese	O
and	O
in	O
Thais	O
.	O

Multiple	O
functional	O
FcgammaR	B
genes	O
with	O
polymorphisms	O
(	O
FCGR2A	B
,	O
FCGR2B	B
,	O
FCGR3A	B
,	O
and	O
FCGR3B	B
)	O
cluster	O
in	O
1q23	O
,	O
and	O
some	O
of	O
them	O
are	O
in	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
.	O

To	O
differentiate	O
contributions	O
from	O
multiple	O
-	O
linked	O
loci	O
,	O
comparison	O
of	O
different	O
populations	O
may	O
provide	O
useful	O
information	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
above	O
four	O
FCGR	B
polymorphisms	O
of	O
the	O
Chinese	O
patients	O
and	O
controls	O
for	O
the	O
association	O
with	O
SLE	O
.	O

FCGR2A	B
-	O
H131R	O
,	O
FCGR2B	B
-	O
I232	O
T	O
,	O
FCGR3A	B
-	O
F176V	O
,	O
and	O
FCGR3B	B
genotypes	O
were	O
determined	O
in	O
167	O
Chinese	O
patients	O
with	O
SLE	O
and	O
129	O
healthy	O
controls	O
.	O

Association	O
was	O
examined	O
using	O
case	O
-	O
control	O
analysis	O
.	O

Allele	O
frequencies	O
of	O
FCGR2B-232	B
T	O
and	O
FCGR3A-176F	B
were	O
significantly	O
increased	O
in	O
SLE	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
1.67	O
and	O
OR	O
=	O
1.41	O
,	O
respectively	O
]	O
.	O

Interestingly	O
,	O
while	O
these	O
alleles	O
had	O
a	O
tendency	O
of	O
positive	O
LD	O
in	O
the	O
controls	O
,	O
FCGR2B-232	B
T	O
was	O
in	O
positive	O
association	O
with	O
FCGR3A-176V	B
in	O
SLE	O
,	O
suggesting	O
that	O
these	O
two	O
alleles	O
were	O
associated	O
with	O
SLE	O
in	O
an	O
independent	O
manner	O
.	O

Comparison	O
between	O
SLE	O
with	O
and	O
without	O
nephritis	O
indicated	O
significant	O
association	O
of	O
FCGR2B-232	B
T	O
with	O
nephritis	O
(	O
OR	O
=	O
2.65	O
)	O
.	O

When	O
the	O
present	O
results	O
were	O
combined	O
with	O
our	O
previous	O
data	O
on	O
the	O
Japanese	O
and	O
the	O
Thais	O
using	O
meta	O
-	O
analytic	O
methods	O
,	O
highly	O
significant	O
and	O
independent	O
association	O
was	O
observed	O
for	O
FCGR2B	B
and	O
FCGR3A	B
genotypes	O
.	O

These	O
results	O
strongly	O
suggested	O
that	O
FCGR2B	B
is	O
a	O
common	O
susceptibility	O
factor	O
to	O
SLE	O
in	O
the	O
Asians	O
.	O

Chemokine	B
gene	O
polymorphisms	O
associate	O
with	O
gender	O
in	O
patients	O
with	O
uveitis	O
.	O

Uveitis	O
is	O
an	O
inflammatory	O
condition	O
of	O
ocular	O
tissue	O
characterized	O
by	O
leukocyte	O
infiltration	O
,	O
tissue	O
damage	O
,	O
and	O
decreased	O
visual	O
acuity	O
.	O

Chemokines	B
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
uveitis	O
.	O

Polymorphisms	O
in	O
the	O
genes	O
encoding	O
chemokines	B
have	O
been	O
described	O
as	O
affecting	O
chemokine	B
production	O
or	O
function	O
.	O

We	O
analyzed	O
the	O
frequency	O
of	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
genes	O
encoding	O
CCL2	B
(	O
-2518	O
and	O
-2076	O
)	O
and	O
CCL5	B
(	O
-403	O
and	O
-28	O
)	O
in	O
patients	O
with	O
Behcet	O
's	O
disease	O
(	O
BD	O
)	O
,	O
a	O
systemic	O
form	O
of	O
uveitis	O
,	O
and	O
patients	O
with	O
retinal	O
vasculitis	O
(	O
RV	O
)	O
,	O
an	O
organ	O
-	O
specific	O
form	O
of	O
disease	O
.	O

We	O
report	O
that	O
there	O
was	O
no	O
association	O
between	O
any	O
SNP	O
and	O
disease	O
.	O

However	O
,	O
when	O
segregated	O
on	O
the	O
basis	O
of	O
gender	O
the	O
CCR5	B
-403	O
AA	O
genotype	O
was	O
only	O
found	O
in	O
male	O
patients	O
with	O
BD	O
.	O

Similarly	O
,	O
CCL2	B
genotypes	O
1	O
/	O
2	O
were	O
predominant	O
in	O
males	O
,	O
while	O
genotype	O
4	O
was	O
significantly	O
associated	O
with	O
disease	O
in	O
female	O
patients	O
with	O
BD	O
.	O

Differences	O
in	O
disease	O
symptoms	O
and	O
severity	O
between	O
males	O
and	O
females	O
have	O
been	O
described	O
in	O
BD	O
and	O
gender	O
-	O
specific	O
genetic	O
differences	O
in	O
chemokine	O
gene	O
function	O
may	O
be	O
involved	O
.	O

Association	O
between	O
polymorphism	O
of	O
the	O
dopamine	B
transporter	I
gene	O
and	O
early	O
smoking	O
onset	O
:	O
an	O
interaction	O
risk	O
on	O
nicotine	O
dependence	O
.	O

Previous	O
studies	O
suggested	O
that	O
a	O
polymorphism	O
in	O
the	O
dopamine	B
transporter	I
gene	I
(	O
SLC6A3	B
)	O
is	O
associated	O
with	O
nicotine	O
dependence	O
and	O
age	O
of	O
smoking	O
onset	O
,	O
but	O
the	O
conclusion	O
was	O
controversial	O
.	O

To	O
detect	O
the	O
association	O
of	O
a	O
G-->A	O
polymorphism	O
(	O
NCBI	O
dbSNP	O
cluster	O
ID	O
:	O
rs27072	O
)	O
in	O
3'-untranslated	O
region	O
of	O
the	O
SLC6A3	O
with	O
nicotine	O
dependence	O
and	O
early	O
smoking	O
onset	O
,	O
we	O
recruited	O
253	O
sibships	O
including	O
668	O
nicotine	O
-	O
dependent	O
siblings	O
from	O
a	O
rural	O
district	O
of	O
China	O
.	O

The	O
sibship	O
disequilibrium	O
tests	O
(	O
SDT	O
)	O
showed	O
that	O
the	O
rs27072-A	O
allele	O
is	O
significantly	O
associated	O
with	O
smoking	O
onset	O
<	O
or	O
=	O
18	O
years	O
(	O
kappa2=9.78	O
,	O
p=0.003	O
in	O
severely	O
nicotine	O
-	O
dependent	O
smokers	O
,	O
and	O
kappa2=4.24	O
,	O
p=0.058	O
in	O
total	O
smokers	O
)	O
,	O
but	O
not	O
significantly	O
associated	O
with	O
severe	O
nicotine	O
dependence	O
.	O

Conditional	O
logistic	O
regression	O
showed	O
that	O
the	O
risk	O
of	O
early	O
smoking	O
onset	O
by	O
the	O
rs27072-A	O
allele	O
was	O
almost	O
three	O
times	O
greater	O
in	O
severely	O
nicotine	O
-	O
dependent	O
smokers	O
[	O
Odds	O
ratio	O
(	O
OR	O
)	O
=11.3	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=1.5	O
-	O
85.6	O
]	O
than	O
that	O
in	O
total	O
smokers	O
.	O

Linear	O
regression	O
showed	O
that	O
rs27072-A	O
allele	O
also	O
increased	O
the	O
risk	O
of	O
nicotine	O
dependence	O
by	O
early	O
smoking	O
onset	O
compared	O
with	O
homozygous	O
rs27072-G	O
genotype	O
.	O

Although	O
these	O
findings	O
are	O
preliminary	O
and	O
need	O
validation	O
,	O
the	O
results	O
suggest	O
that	O
a	O
polymorphism	O
in	O
the	O
SLC6A3	B
may	O
play	O
important	O
roles	O
in	O
smoking	O
onset	O
,	O
and	O
there	O
may	O
be	O
an	O
interactive	O
effect	O
between	O
the	O
SLC6A3	B
and	O
early	O
smoking	O
onset	O
on	O
modulating	O
the	O
susceptibility	O
of	O
nicotine	O
dependence	O
.	O

Genetic	O
variation	O
at	O
the	O
adiponectin	B
locus	O
and	O
risk	O
of	O
type	O
2	O
diabetes	O
in	O
women	O
.	O

Previous	O
data	O
suggesting	O
that	O
polymorphisms	O
in	O
the	O
adiponectin	B
gene	O
were	O
associated	O
with	O
insulin	B
resistance	O
or	O
type	O
2	O
diabetes	O
have	O
been	O
inconsistent	O
.	O

We	O
assessed	O
the	O
relationship	O
between	O
five	O
common	O
haplotype	O
-	O
tagging	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
adiponectin	B
gene	O
(	O
-11365C	O
>	O
G	O
,	O
-4034A	O
>	O
C	O
,	O
-3964A	O
>	O
G	O
,	O
+	O
45T	O
>	O
G	O
,	O
and	O
+	O
276G	O
>	O
T	O
)	O
,	O
haplotypes	O
defined	O
by	O
these	O
SNPs	O
,	O
and	O
the	O
risk	O
of	O
type	O
2	O
diabetes	O
by	O
conducting	O
a	O
nested	O
case	O
-	O
control	O
study	O
of	O
642	O
incident	O
cases	O
of	O
type	O
2	O
diabetes	O
and	O
995	O
matching	O
control	O
subjects	O
in	O
the	O
Nurses	O
'	O
Health	O
Study	O
.	O

Overall	O
,	O
we	O
did	O
not	O
observe	O
significant	O
differences	O
in	O
genotype	O
or	O
allele	O
frequencies	O
for	O
the	O
five	O
SNPs	O
between	O
the	O
case	O
and	O
control	O
subjects	O
.	O

After	O
adjustment	O
for	O
diabetes	O
risk	O
factors	O
,	O
the	O
-4034	O
C	O
/	O
C	O
genotype	O
was	O
associated	O
with	O
a	O
reduced	O
risk	O
of	O
diabetes	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
compared	O
with	O
the	O
A	O
/	O
A	O
genotype	O
=	O
0.70	O
,	O
95	O
%	O
CI	O
0.50	O
-	O
0.99	O
,	O
P	O
=	O
0.04	O
)	O
.	O

In	O
subgroup	O
analyses	O
,	O
the	O
+	O
276	O
genotype	O
was	O
significantly	O
associated	O
with	O
diabetes	O
risk	O
only	O
among	O
subjects	O
with	O
peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
-	I
gamma	I
(	O
PPAR	B
gamma	I
)	O
variant	O
12Ala	O
allele	O
(	O
OR	O
comparing	O
+	O
276	O
T	O
alleles	O
with	O
the	O
G	O
/	O
G	O
genotype	O
=	O
1.69	O
,	O
1.04	O
-	O
2.75	O
,	O
P	O
=	O
0.035	O
)	O
or	O
among	O
obese	O
subjects	O
(	O
1.46	O
,	O
1.03	O
-	O
2.08	O
,	O
P	O
=	O
0.03	O
)	O
.	O

These	O
data	O
suggest	O
a	O
potential	O
interaction	O
between	O
the	O
adiponectin	B
genotype	O
and	O
PPAR	B
gamma	I
genotype	O
or	O
obesity	O
,	O
but	O
these	O
analyses	O
should	O
be	O
considered	O
exploratory	O
and	O
require	O
further	O
investigation	O
in	O
larger	O
studies	O
.	O

Interleukin	B
1alpha	I
single	O
-	O
nucleotide	O
polymorphism	O
associated	O
with	O
systemic	O
sclerosis	O
.	O

OBJECTIVE	O
:	O
In	O
systemic	O
sclerosis	O
(	O
SSc	O
)	O
,	O
constitutive	O
expression	O
of	O
the	O
proinflammatory	O
and	O
fibrogenic	O
cytokine	O
interleukin	B
1alpha	I
(	O
IL-1alpha	B
)	O
by	O
dermal	O
fibroblasts	O
from	O
the	O
affected	O
skin	O
has	O
been	O
observed	O
.	O

We	O
investigated	O
the	O
association	O
of	O
a	O
single	O
-	O
nucleotide	O
polymorphism	O
at	O
position	O
-889	O
in	O
the	O
IL-1alpha	B
gene	O
in	O
patients	O
with	O
SSc	O
.	O

METHODS	O
:	O
Genotyping	O
of	O
IL-1alpha-889	B
polymorphism	O
was	O
performed	O
in	O
46	O
patients	O
with	O
SSc	O
and	O
in	O
150	O
healthy	O
controls	O
by	O
polymerase	O
chain	O
reaction	O
with	O
sequence	O
-	O
specific	O
primers	O
.	O

All	O
subjects	O
were	O
unrelated	O
Slovak	O
Caucasians	O
.	O

RESULTS	O
:	O
In	O
SSc	O
patients	O
,	O
carriers	O
of	O
the	O
IL-1alpha-889	B
T	O
allele	O
were	O
significantly	O
overrepresented	O
in	O
comparison	O
with	O
controls	O
(	O
63.0	O
%	O
vs	O
42.0	O
%	O
;	O
p	O
=	O
0.01	O
,	O
OR	O
2.3	O
,	O
95	O
%	O
CI	O
1.2	O
-	O
4.6	O
)	O
.	O

The	O
frequency	O
of	O
the	O
IL-1alpha-889	B
T	O
allele	O
was	O
increased	O
in	O
SSc	O
patients	O
(	O
38.0	O
%	O
)	O
in	O
comparison	O
with	O
controls	O
(	O
25.7	O
%	O
;	O
p	O
=	O
0.02	O
)	O
.	O

CONCLUSION	O
:	O
The	O
IL-1alpha-889	O
polymorphism	O
,	O
previously	O
shown	O
to	O
predispose	O
to	O
increased	O
IL-1	B
protein	O
expression	O
,	O
may	O
be	O
involved	O
in	O
susceptibility	O
to	O
SSc	O
.	O

Association	O
of	O
gene	O
polymorphisms	O
with	O
coronary	O
artery	O
disease	O
in	O
individuals	O
with	O
or	O
without	O
nonfamilial	O
hypercholesterolemia	O
.	O

A	O
substantial	O
proportion	O
of	O
individuals	O
with	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
has	O
concomitant	O
hypercholesterolemia	O
.	O

A	O
large	O
-	O
scale	O
association	O
study	O
was	O
performed	O
to	O
identify	O
separately	O
genes	O
that	O
confer	O
susceptibility	O
to	O
CAD	O
in	O
the	O
absence	O
or	O
presence	O
of	O
nonfamilial	O
hypercholesterolemia	O
.	O

The	O
study	O
population	O
comprised	O
5248	O
unrelated	O
Japanese	O
individuals	O
,	O
including	O
3085	O
subjects	O
with	O
CAD	O
(	O
2350	O
men	O
,	O
735	O
women	O
)	O
and	O
2163	O
controls	O
(	O
1329	O
men	O
,	O
834	O
women	O
)	O
.	O

Among	O
all	O
study	O
subjects	O
,	O
2541	O
individuals	O
(	O
1688	O
men	O
,	O
853	O
women	O
)	O
had	O
nonfamilial	O
hypercholesterolemia	O
,	O
and	O
2707	O
individuals	O
(	O
1991	O
men	O
,	O
716	O
women	O
)	O
did	O
not	O
have	O
this	O
condition	O
.	O

The	O
genotypes	O
for	O
33	O
polymorphisms	O
of	O
27	O
candidate	O
genes	O
were	O
determined	O
with	O
a	O
fluorescence-	O
or	O
colorimetry	O
-	O
based	O
allele	O
-	O
specific	O
DNA	O
primer	O
-	O
probe	O
assay	O
system	O
.	O

Multivariate	O
logistic	O
regression	O
analysis	O
with	O
adjustment	O
for	O
age	O
,	O
body	O
mass	O
index	O
,	O
and	O
the	O
prevalence	O
of	O
smoking	O
,	O
hypertension	O
,	O
diabetes	O
mellitus	O
,	O
and	O
hyperuricemia	O
revealed	O
that	O
three	O
polymorphisms	O
[	O
994	O
G	O
--	O
>	O
T	O
(	O
Val279Phe	O
)	O
in	O
the	O
platelet	B
-	I
activating	I
factor	I
acetylhydrolase	I
gene	O
,	O
242C	O
--	O
>	O
T	O
(	O
His72Tyr	O
)	O
in	O
the	O
NADH	B
/	I
NADPH	I
oxidase	I
p22	I
phox	I
gene	O
,	O
and	O
1100C	O
--	O
>	O
T	O
in	O
the	O
apolipoprotein	B
C	I
-	I
III	I
gene	O
]	O
were	O
significantly	O
associated	O
with	O
CAD	O
in	O
men	O
with	O
hypercholesterolemia	O
.	O

Genotyping	O
of	O
these	O
three	O
polymorphisms	O
may	O
prove	O
informative	O
for	O
prediction	O
of	O
the	O
genetic	O
risk	O
for	O
CAD	O
in	O
men	O
with	O
nonfamilial	O
hypercholesterolemia	O
.	O

Polymorphisms	O
in	O
the	O
interleukin-20	B
gene	O
:	O
relationships	O
to	O
plaque	O
-	O
type	O
psoriasis	O
.	O

We	O
analyzed	O
the	O
frequency	O
of	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
at	O
positions	O
-1053	O
(	O
rs	O
2981572	O
)	O
,	O
1380	O
(	O
rs	O
2981573	O
)	O
,	O
1462	O
(	O
rs	O
2232360	O
)	O
,	O
and	O
3978	O
(	O
rs	O
1518108	O
)	O
of	O
the	O
human	O
interleukin-20	B
(	O
IL-20	B
)	O
gene	O
by	O
tetraprimer	O
ARMS	O
-	O
PCR	O
method	O
.	O

A	O
significant	O
association	O
between	O
patients	O
with	O
psoriasis	O
and	O
the	O
G	O
allele	O
at	O
position	O
-1053	O
(	O
P<0.05	O
)	O
was	O
established	O
.	O

The	O
pairwise	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
matrix	O
showed	O
that	O
the	O
nearly	O
complete	O
LD	O
was	O
present	O
within	O
the	O
polymorphisms	O
at	O
positions	O
-1053	O
,	O
1380	O
,	O
and	O
1462	O
of	O
the	O
IL-20	B
gene	O
.	O

We	O
found	O
that	O
patients	O
with	O
plaque	O
psoriasis	O
had	O
a	O
higher	O
frequency	O
of	O
the	O
HT3	B
GAA	O
haplotype	O
(	O
P<0.01	O
,	O
OR	O
2.341	O
,	O
95	O
%	O
CI	O
:	O
1.346	O
-	O
4.074	O
)	O
compared	O
to	O
the	O
control	O
group	O
.	O

Likewise	O
,	O
the	O
HT3	B
GAA	O
haplotype	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
early	O
-	O
onset	O
psoriasis	O
(	O
P<0.01	O
,	O
OR	O
2.305	O
,	O
95	O
%	O
CI	O
:	O
1.285	O
-	O
4.132	O
)	O
,	O
late	O
onset	O
of	O
disease	O
(	O
P<0.01	O
,	O
OR	O
2.542	O
,	O
95	O
%	O
CI	O
:	O
1.266	O
-	O
5.102	O
)	O
,	O
familial	O
psoriasis	O
(	O
P<0.02	O
,	O
OR	O
2.220	O
,	O
95	O
%	O
CI	O
:	O
1.249	O
-	O
3.945	O
)	O
,	O
and	O
sporadic	O
disease	O
(	O
P<0.01	O
,	O
OR	O
2.523	O
,	O
95	O
%	O
CI	O
:	O
1.390	O
-	O
4.580	O
)	O
.	O

Our	O
data	O
indicate	O
that	O
IL-20	B
gene	O
polymorphisms	O
should	O
have	O
a	O
role	O
in	O
determining	O
susceptibility	O
to	O
plaque	O
-	O
type	O
psoriasis	O
.	O

The	O
possible	O
role	O
of	O
the	O
studied	O
SNPs	O
in	O
the	O
regulation	O
of	O
the	O
expression	O
of	O
IL-20	B
is	O
unknown	O
yet	O
and	O
needs	O
further	O
studies	O
.	O

APOA5	B
gene	O
variants	O
,	O
lipoprotein	O
particle	O
distribution	O
,	O
and	O
progression	O
of	O
coronary	O
heart	O
disease	O
:	O
results	O
from	O
the	O
LOCAT	O
study	O
.	O

Animal	O
and	O
human	O
studies	O
support	O
a	O
role	O
for	O
apolipoprotein	B
A	I
-	I
V	I
(	O
apoA	B
-	I
V	I
)	O
in	O
triglyceride	O
(	O
TG	O
)	O
metabolism	O
.	O

We	O
examined	O
the	O
relationship	O
of	O
APOA5	B
-1131T	O
>	O
C	O
and	O
S19W	O
with	O
lipid	O
subfractions	O
and	O
progression	O
of	O
atherosclerosis	O
in	O
the	O
Lopid	O
Coronary	O
Angiography	O
Trial	O
.	O

Compared	O
with	O
-1131TT	O
men	O
(	O
n	O
=	O
242	O
)	O
,	O
carriers	O
of	O
the	O
-1131C	O
allele	O
(	O
n	O
=	O
54	O
)	O
had	O
significantly	O
higher	O
total	O
TG	O
(	O
P	O
=	O
0.03	O
)	O
,	O
reflected	O
in	O
significantly	O
increased	O
VLDL	O
mass	O
[	O
higher	O
VLDL	O
-	O
TG	O
,	O
VLDL	O
-	O
cholesterol	O
,	O
VLDL	O
-	O
protein	O
,	O
and	O
surface	O
lipids	O
(	O
all	O
P	O
<	O
0.05	O
)	O
]	O
.	O

Because	O
apoB	B
levels	O
were	O
unaffected	O
by	O
genotype	O
,	O
this	O
suggests	O
an	O
increase	O
in	O
VLDL	O
size	O
and	O
not	O
number	O
.	O

Compared	O
with	O
19SS	O
men	O
(	O
n	O
=	O
268	O
)	O
,	O
19W	O
carriers	O
(	O
n	O
=	O
44	O
)	O
had	O
higher	O
intermediate	O
density	O
lipoprotein	O
(	O
IDL	O
)	O
-TG	O
,	O
IDL	O
-	O
cholesterol	O
(	O
P	O
=	O
0.04	O
)	O
,	O
and	O
IDL	O
-	O
surface	O
components	O
[	O
free	O
cholesterol	O
(	O
P	O
=	O
0.005	O
)	O
and	O
phospholipids	O
(	O
P	O
=	O
0.017	O
)	O
]	O
but	O
not	O
protein	O
content	O
,	O
suggesting	O
an	O
increase	O
in	O
IDL	O
lipid	O
enrichment	O
resulting	O
in	O
an	O
increase	O
in	O
IDL	O
size	O
.	O

19W	O
carriers	O
also	O
showed	O
a	O
trend	O
toward	O
increased	O
progression	O
of	O
atherogenesis	O
,	O
as	O
measured	O
by	O
change	O
in	O
average	O
diameter	O
of	O
segments	O
(	O
-0.46	O
+	O
/-	O

0.011	O
mm	O
compared	O
with	O
-0.016	O
+	O
/-	O

0.006	O
mm	O
)	O
in	O
19SS	O
men	O
(	O
P	O
=	O
0.08	O
)	O
.	O

There	O
was	O
no	O
effect	O
of	O
genotype	O
on	O
the	O
response	O
of	O
these	O
parameters	O
to	O
gemfibrozil	O
treatment	O
.	O

These	O
results	O
shed	O
new	O
light	O
on	O
the	O
role	O
of	O
APOA5	B
variants	O
in	O
TG	O
metabolism	O
and	O
coronary	O
heart	O
disease	O
risk	O
.	O

Both	O
risk	O
alleles	O
for	O
FcgammaRIIA	B
and	O
FcgammaRIIIA	B
are	O
susceptibility	O
factors	O
for	O
SLE	O
:	O
a	O
unifying	O
hypothesis	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
in	O
families	O
with	O
SLE	O
for	O
the	O
presence	O
of	O
linkage	O
and	O
the	O
structure	O
and	O
transmission	O
of	O
haplotypes	O
containing	O
alleles	O
for	O
the	O
low	O
-	O
affinity	O
Fcgamma	B
receptors	I
.	O

The	O
Fcgamma	B
receptor	I
polymorphisms	O
FcgammaRIIA-131R	B
/	O
H	O
,	O
FcgammaRIIIA-176F	B
/	O
V	O
and	O
FcgammaRIIIB	B
-	O
NA1	O
/	O
2	O
and	O
a	O
polymorphism	O
in	O
the	O
FcgammaRIIB	B
gene	O
were	O
genotyped	O
with	O
RFLP	O
,	O
allele	O
-	O
specific	O
PCR	O
or	O
pyrosequencing	O
.	O

Individual	O
SNPs	O
and	O
haplotypes	O
were	O
tested	O
for	O
linkage	O
in	O
multicase	O
families	O
and	O
for	O
association	O
using	O
contingency	O
tables	O
,	O
transmission	O
disequilibrium	O
test	O
and	O
affected	O
family	O
-	O
based	O
control	O
groups	O
in	O
Swedish	O
and	O
Mexican	O
single	O
-	O
case	O
families	O
.	O

No	O
linkage	O
or	O
association	O
could	O
be	O
detected	O
using	O
the	O
FcgammaR	B
polymorphisms	O
in	O
the	O
multicase	O
families	O
.	O

However	O
,	O
an	O
association	O
was	O
found	O
for	O
both	O
FcgammaRIIA-131R	B
and	O
IIIA-176F	B
alleles	O
in	O
the	O
single	O
-	O
case	O
families	O
,	O
but	O
not	O
for	O
IIIB	B
or	O
IIB	O
.	O

Allelic	O
association	O
to	O
SLE	O
was	O
found	O
for	O
a	O
haplotype	O
that	O
included	O
both	O
risk	O
alleles	O
,	O
but	O
not	O
in	O
haplotypes	O
where	O
only	O
one	O
or	O
the	O
other	O
was	O
present	O
.	O

We	O
propose	O
that	O
FcgammaRIIA-131R	B
and	O
FcgammaRIIIA-176F	B
are	O
both	O
risk	O
alleles	O
for	O
SLE	O
transmitted	O
primarily	O
,	O
but	O
not	O
exclusively	O
on	O
a	O
single	O
major	O
haplotype	O
that	O
behaves	O
functionally	O
in	O
a	O
situation	O
similar	O
to	O
that	O
of	O
compound	O
heterozygozity	O
.	O

Relationship	O
between	O
postrenal	O
transplant	O
osteonecrosis	O
of	O
the	O
femoral	O
head	O
and	O
gene	O
polymorphisms	O
related	O
to	O
the	O
coagulation	O
and	O
fibrinolytic	O
systems	O
in	O
Japanese	O
subjects	O
.	O

BACKGROUND	O
:	O
Nontraumatic	O
osteonecrosis	O
of	O
the	O
femoral	O
head	O
(	O
ONFH	O
)	O
is	O
one	O
of	O
the	O
complications	O
that	O
may	O
occur	O
after	O
renal	O
transplantation	O
.	O

We	O
investigated	O
the	O
relationship	O
between	O
the	O
incidence	O
of	O
ONFH	O
and	O
polymorphisms	O
in	O
the	O
genes	O
for	O
plasminogen	B
activator	I
inhibitor	I
(	I
PAI	I
)	I
-1	I
,	O
which	O
is	O
one	O
of	O
the	O
major	O
regulatory	O
proteins	O
of	O
the	O
fibrinolytic	O
system	O
,	O
and	O
5,10-methylenetetrahydrofolate	B
reductase	I
(	O
MTHFR	B
)	O
,	O
which	O
is	O
associated	O
with	O
the	O
plasma	O
levels	O
of	O
homocysteine	O
in	O
Japanese	O
subjects	O
.	O

METHODS	O
:	O
Thirty	O
-	O
one	O
patients	O
with	O
postrenal	O
transplant	O
ONFH	O
and	O
106	O
patients	O
without	O
ONFH	O
were	O
selected	O
.	O

Genotypes	O
of	O
PAI-1	B
4G	O
/	O
5	O
G	O
and	O
MTHFR	B
C677	O
T	O
were	O
determined	O
by	O
direct	O
sequencing	O
of	O
genomic	O
DNA	O
.	O

In	O
addition	O
,	O
plasma	O
PAI-1	B
antigen	O
(	O
Ag	O
)	O
levels	O
and	O
plasma	O
total	O
homocysteine	O
(	O
tHcy	O
)	O
levels	O
at	O
the	O
steady	O
state	O
were	O
measured	O
.	O

The	O
relationships	O
between	O
the	O
incidence	O
of	O
ONFH	O
and	O
these	O
genotypes	O
,	O
as	O
well	O
as	O
plasma	O
levels	O
of	O
the	O
gene	O
products	O
,	O
were	O
investigated	O
.	O

RESULTS	O
:	O
Plasma	O
PAI-1	B
Ag	O
levels	O
were	O
the	O
highest	O
in	O
patients	O
with	O
the	O
4G	O
/	O
4	O
G	O
genotype	O
,	O
and	O
plasma	O
tHcy	O
levels	O
were	O
the	O
highest	O
in	O
patients	O
with	O
TT	O
genotypes	O
of	O
MTHFR	B
C677	O
T	O
.	O

However	O
,	O
the	O
relationship	O
between	O
the	O
incidence	O
of	O
ONFHH	O
and	O
PAI-1	B
4G	O
/	O
5	O
G	O
or	O
MTHFR	B
C677	O
T	O
was	O
not	O
observed	O
.	O

The	O
relationship	O
between	O
the	O
incidence	O
of	O
ONFH	O
and	O
plasma	O
levels	O
of	O
PAI-1	B
Ag	O
or	O
tHcy	O
was	O
not	O
observed	O
.	O

CONCLUSIONS	O
:	O
Genotypes	O
of	O
PAI-1	B
4G	O
/	O
5	O
G	O
and	O
MTHFR	B
C677	O
T	O
or	O
plasma	O
concentrations	O
of	O
PAI-1	B
Ag	O
and	O
tHcy	O
had	O
no	O
effect	O
on	O
the	O
incidence	O
of	O
ONFH	O
in	O
Japanese	O
subjects	O
,	O
unlike	O
the	O
results	O
of	O
studies	O
performed	O
in	O
white	O
subjects	O
.	O

The	O
effect	O
of	O
genetic	O
background	O
on	O
the	O
pathologic	O
conditions	O
that	O
developed	O
in	O
patients	O
with	O
postrenal	O
transplant	O
ONFH	O
may	O
differ	O
according	O
to	O
race	O
.	O

MDR1	B
haplotypes	O
modify	O
BEN	O
disease	O
risk	O
:	O
a	O
study	O
in	O
Bulgarian	O
patients	O
with	O
Balkan	O
endemic	O
nephropathy	O
compared	O
to	O
healthy	O
controls	O
.	O

BACKGROUND	O
:	O
Balkan	O
endemic	O
nephropathy	O
(	O
BEN	O
)	O
is	O
a	O
slow	O
progressive	O
nephropathy	O
with	O
frequent	O
occurrence	O
of	O
uroepithelial	O
tumors	O
in	O
the	O
upper	O
urinary	O
tract	O
.	O

Genetic	O
factors	O
involved	O
in	O
xenobiotic	O
detoxification	O
mechanisms	O
may	O
cause	O
genetic	O
predisposition	O
to	O
BEN	O
and	O
influence	O
the	O
risk	O
for	O
this	O
disease	O
.	O

Polymorphic	O
MDR1	B
variants	O
with	O
decreased	O
P	B
-	I
glycoprotein	I
(	O
P	B
-	I
gp	I
)	O
activity	O
modulate	O
the	O
risk	O
for	O
renal	O
neoplasm	O
.	O

We	O
have	O
therefore	O
investigated	O
the	O
impact	O
of	O
MDR1	B
polymorphisms	O
on	O
BEN	O
manifestation	O
.	O

METHODS	O
:	O
The	O
constitutional	O
genotype	O
frequencies	O
of	O
two	O
SNPs	O
(	O
C3435	O
T	O
and	O
G2677	O
T	O
)	O
in	O
the	O
MDR1	B
gene	O
in	O
112	O
healthy	O
control	O
subjects	O
were	O
investigated	O
and	O
compared	O
with	O
those	O
of	O
96	O
patients	O
with	O
BEN	O
.	O

Identification	O
of	O
the	O
SNPs	O
was	O
done	O
with	O
rapid	O
cycle	O
real	O
-	O
time	O
PCR	O
and	O
melting	O
curve	O
analysis	O
with	O
allele	O
-	O
specific	O
probes	O
.	O

RESULTS	O
:	O
The	O
frequency	O
of	O
mutant	O
alleles	O
was	O
comparable	O
in	O
both	O
groups	O
.	O

Significant	O
differences	O
were	O
revealed	O
when	O
the	O
MDR1	B
haplotypes	O
were	O
analyzed	O
.	O

Individuals	O
with	O
a	O
predicted	O
haplotype	O
12	O
(	O
2677G	O
/	O
3435	O
T	O
)	O
were	O
less	O
frequent	O
in	O
BEN	O
cases	O
(	O
frequency	O
7.3	O
%	O
)	O
than	O
in	O
controls	O
(	O
16.1	O
%	O
,	O
p	O
=	O
0.006	O
)	O
.	O

We	O
found	O
that	O
carriers	O
of	O
the	O
haplotype	O
12	O
had	O
a	O
decreased	O
risk	O
for	O
BEN	O
(	O
OR	O
=	O
0.411	O
;	O
0.21	O
-	O
0.78	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
suggest	O
that	O
haplotype	O
12	O
is	O
protective	O
against	O
BEN	O
.	O

There	O
is	O
no	O
clear	O
molecular	O
explanation	O
of	O
the	O
MDR1	B
haplotype	O
effects	O
on	O
the	O
protein	O
activity	O
,	O
which	O
can	O
explain	O
the	O
modified	O
effect	O
of	O
the	O
haplotype	O
12	O
on	O
BEN	O
risk	O
.	O

No	O
association	O
between	O
the	O
insulin	B
degrading	I
enzyme	I
gene	O
and	O
Alzheimer	O
's	O
disease	O
in	O
a	O
Japanese	O
population	O
.	O

Susceptibility	O
to	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
is	O
thought	O
to	O
be	O
regulated	O
by	O
multiple	O
genetic	O
factors	O
.	O

Recently	O
,	O
three	O
independent	O
studies	O
have	O
reported	O
that	O
loci	O
on	O
chromosome	O
10q	O
are	O
linked	O
with	O
AD	O
,	O
and	O
the	O
insulin	B
degrading	I
enzyme	I
(	O
IDE	B
;	O
MIM	O
146680	O
)	O
gene	O
located	O
on	O
chromosome	O
10q23-q25	O
;	O
IDE	B
is	O
located	O
close	O
to	O
the	O
maker	O
D10S583	O
,	O
which	O
exhibits	O
a	O
maximum	O
LOD	O
score	O
for	O
late	O
-	O
onset	O
AD	O
.	O

We	O
examined	O
seven	O
polymorphisms	O
in	O
the	O
IDE	B
gene	O
,	O
the	O
marker	O
D10S583	O
in	O
the	O
5	O
'	O
flanking	O
region	O
,	O
and	O
SNPs	O
in	O
introns	O
1	O
,	O
3	O
,	O
11	O
,	O
20	O
,	O
21	O
,	O
and	O
22	O
(	O
rs#1999764	O
,	O
1855915	O
,	O
1970244	O
,	O
538469	O
,	O
551266	O
,	O
and	O
489517	O
,	O
respectively	O
)	O
.	O

Four	O
SNPs	O
in	O
introns	O
3	O
,	O
11	O
,	O
20	O
,	O
and	O
22	O
did	O
not	O
exhibit	O
any	O
polymorphisms	O
in	O
the	O
Japanese	O
population	O
that	O
was	O
studied	O
.	O

D10S583	O
and	O
two	O
SNPs	O
in	O
introns	O
1	O
and	O
21	O
did	O
not	O
exhibit	O
a	O
significant	O
association	O
with	O
early-	O
or	O
late	O
-	O
onset	O
AD	O
.	O

In	O
addition	O
,	O
no	O
associations	O
were	O
observed	O
for	O
subgroups	O
of	O
AD	O
grouped	O
according	O
to	O
APOE	B
status	O
.	O

The	O
present	O
study	O
indicates	O
that	O
the	O
IDE	B
gene	O
polymorphisms	O
do	O
not	O
confer	O
susceptibility	O
to	O
early-	O
or	O
late	O
-	O
onset	O
AD	O
at	O
least	O
in	O
a	O
Japanese	O
population	O
.	O

Common	O
variants	O
in	O
glutamine	B
:	I
fructose-6-phosphate	I
amidotransferase	I
2	I
(	O
GFPT2	B
)	O
gene	O
are	O
associated	O
with	O
type	O
2	O
diabetes	O
,	O
diabetic	O
nephropathy	O
,	O
and	O
increased	O
GFPT2	B
mRNA	O
levels	O
.	O

Increased	O
flux	O
of	O
glucose	O
through	O
the	O
hexosamine	O
biosynthetic	O
pathway	O
has	O
been	O
implicated	O
in	O
insulin	B
resistance	O
,	O
altered	O
insulin	B
secretion	O
,	O
and	O
diabetic	O
nephropathy	O
.	O

Glutamine	B
:	I
fructose-6-phosphate	I
amidotransferase	I
(	O
GFPT	B
)	O
,	O
the	O
rate	O
limiting	O
enzyme	O
in	O
hexosamine	O
biosynthesis	O
,	O
is	O
encoded	O
by	O
the	O
unlinked	O
but	O
highly	O
homologous	O
genes	O
GFPT1	B
and	O
GFPT2	B
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
GFPT2	B
sequence	O
variation	O
contributed	O
to	O
the	O
susceptibility	O
to	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
and	O
diabetic	O
nephropathy	O
in	O
Caucasian	O
and	O
African	O
-	O
American	O
individuals	O
.	O

We	O
identified	O
11	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
,	O
of	O
which	O
seven	O
were	O
common	O
.	O

A	O
single	O
variant	O
in	O
exon	O
14	O
,	O
I471V	O
,	O
altered	O
the	O
amino	O
acid	O
sequence	O
,	O
is	O
conserved	O
between	O
human	O
and	O
mouse	O
genes	O
,	O
and	O
was	O
associated	O
with	O
T2DM	O
among	O
Caucasians	O
(	O
P	O
=	O
0.05	O
)	O
.	O

A	O
trend	O
to	O
an	O
association	O
was	O
noted	O
with	O
diabetic	O
nephropathy	O
among	O
African	O
-	O
American	O
individuals	O
(	O
P	O
=	O
0.15	O
)	O
.	O

Several	O
variants	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
and	O
exon	O
18	O
were	O
also	O
associated	O
with	O
T2DM	O
in	O
Caucasian	O
individuals	O
(	O
P	O
<	O
0.05	O
)	O
,	O
and	O
the	O
SNP	O
in	O
the	O
3	O
'	O
UTR	O
was	O
associated	O
with	O
diabetic	O
nephropathy	O
in	O
African	O
-	O
American	O
subjects	O
(	O
P	O
=	O
0.047	O
)	O
.	O

GFPT2	B
mRNA	O
levels	O
in	O
transformed	O
lymphocytes	O
from	O
study	O
subjects	O
were	O
significantly	O
increased	O
among	O
African	O
-	O
American	O
subjects	O
compared	O
with	O
Caucasian	O
individuals	O
,	O
regardless	O
of	O
diagnosis	O
.	O

Furthermore	O
,	O
the	O
associated	O
allele	O
of	O
the	O
3	O
'	O
UTR	O
SNP	O
was	O
approximately	O
2-fold	O
overexpressed	O
.	O

We	O
propose	O
that	O
the	O
3	O
'	O
UTR	O
variant	O
results	O
in	O
increased	O
GFPT2	B
mRNA	O
levels	O
with	O
resultant	O
increased	O
hexosamine	O
flux	O
.	O

The	O
I471V	O
variant	O
may	O
contribute	O
to	O
altered	O
protein	O
function	O
or	O
may	O
simply	O
be	O
in	O
linkage	O
disequilibrium	O
with	O
the	O
3	O
'	O
UTR	O
.	O

KCNJ11	B
polymorphisms	O
and	O
sudden	O
cardiac	O
death	O
in	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
.	O

PURPOSE	O
:	O
Patients	O
with	O
an	O
acute	O
myocardial	O
infarction	O
(	O
AMI	O
)	O
are	O
of	O
high	O
risk	O
to	O
develop	O
ischemia	O
-	O
induced	O
ventricular	O
arrhythmias	O
,	O
leading	O
to	O
sudden	O
cardiac	O
death	O
(	O
SCD	O
)	O
in	O
about	O
one	O
third	O
of	O
all	O
AMI	O
patients	O
.	O

The	O
individual	O
susceptibility	O
to	O
ischemia	O
-	O
induced	O
arrhythmias	O
may	O
be	O
modified	O
by	O
polymorphisms	O
in	O
genes	O
encoding	O
ion	O
channels	O
.	O

The	O
cardiac	O
ATP	O
-	O
dependent	O
potassium	O
channel	O
(	O
K	O
(	O
ATP	O
)	O
)	O
current	O
is	O
generated	O
by	O
ion	O
channels	O
encoded	O
by	O
the	O
KCNJ11	B
gene	O
and	O
the	O
SUR2a	B
gene	O
.	O

Opening	O
of	O
the	O
K	O
(	O
ATP	O
)	O
channel	O
during	O
ischemia	O
results	O
in	O
action	O
potential	O
shortening	O
in	O
various	O
studies	O
and	O
may	O
therefore	O
influence	O
the	O
outcome	O
of	O
AMI	O
patients	O
.	O

METHODS	O
:	O
Using	O
a	O
three	O
-	O
primer	O
strategy	O
,	O
we	O
sequenced	O
the	O
complete	O
coding	O
and	O
adjacent	O
5	O
'	O
and	O
3	O
'	O
sequences	O
of	O
the	O
intronless	O
KCNJ11	B
gene	O
(	O
1.3	O
kb	O
)	O
prospectively	O
in	O
two	O
groups	O
.	O

Patients	O
of	O
group	O
1	O
(	O
n	O
=	O
84	O
)	O
survived	O
three	O
or	O
more	O
transmyocardial	O
infarctions	O
without	O
developing	O
any	O
ventricular	O
arrhythmias	O
.	O

Patients	O
of	O
group	O
2	O
died	O
suddenly	O
from	O
their	O
first	O
myocardial	O
infarction	O
(	O
n	O
=	O
86	O
)	O
,	O
most	O
of	O
them	O
witnessed	O
SCDs	O
.	O

RESULTS	O
:	O
We	O
identified	O
a	O
total	O
of	O
six	O
known	O
polymorphisms	O
(	O
K23E	O
,	O
A190A	O
,	O
L267V	O
,	O
L270V	O
,	O
I337V	O
,	O
and	O
K281	O
K	O
)	O
and	O
two	O
new	O
polymorphisms	O
(	O
L267L	O
,	O
3'UTR	O
+	O
62	O
G	O
/	O
A	O
)	O
.	O

The	O
allele	O
,	O
genotype	O
,	O
and	O
haplotype	O
frequencies	O
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
.	O

All	O
polymorphisms	O
were	O
found	O
to	O
be	O
in	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
.	O

In	O
addition	O
,	O
we	O
identified	O
two	O
novel	O
missense	O
mutations	O
in	O
a	O
highly	O
conserved	O
region	O
of	O
the	O
gene	O
in	O
two	O
patients	O
of	O
group	O
2	O
(	O
P266	O
T	O
and	O
R371H	O
)	O
with	O
yet	O
unknown	O
functional	O
consequences	O
.	O

CONCLUSION	O
:	O
In	O
this	O
study	O
of	O
AMI	O
patients	O
,	O
SCD	O
was	O
not	O
related	O
to	O
polymorphisms	O
in	O
the	O
KCNJ11	B
gene	O
.	O

Functional	O
MxA	B
promoter	O
polymorphism	O
associated	O
with	O
subacute	O
sclerosing	O
panencephalitis	O
.	O

BACKGROUND	O
:	O
The	O
antivirally	O
active	O
MxA	B
protein	O
is	O
induced	O
by	O
interferon	B
(	I
IFN	I
)	I
alpha	I
/	I
beta	I
and	O
inhibits	O
the	O
replication	O
of	O
single	O
-	O
stranded	O
RNA	O
viruses	O
including	O
measles	O
virus	O
(	O
MV	O
)	O
.	O

The	O
authors	O
investigated	O
whether	O
the	O
MxA	B
gene	O
contributed	O
to	O
the	O
development	O
of	O
subacute	O
sclerosing	O
panencephalitis	O
(	O
SSPE	O
)	O
in	O
Japanese	O
individuals	O
.	O

METHODS	O
:	O
Single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
in	O
the	O
promoter	O
region	O
of	O
the	O
MxA	O
gene	O
were	O
screened	O
,	O
association	O
studies	O
were	O
performed	O
between	O
two	O
SNP	O
and	O
SSPE	O
,	O
and	O
then	O
a	O
functional	O
difference	O
in	O
the	O
promoter	O
activities	O
of	O
the	O
two	O
SNP	O
was	O
investigated	O
by	O
a	O
dual	O
luciferase	O
reporter	O
assay	O
.	O

RESULTS	O
:	O
Four	O
SNP	O
were	O
found	O
(	O
-88	O
G	O
/	O
T	O
,	O
-123	O
C	O
/	O
A	O
,	O
-200	O
T	O
/	O
C	O
,	O
and	O
-213	O
G	O
/	O
T	O
)	O
,	O
and	O
SSPE	O
patients	O
exhibited	O
a	O
higher	O
frequency	O
of	O
both	O
the	O
-88	O
T	O
allele	O
and	O
the	O
-88TT	O
genotype	O
than	O
controls	O
(	O
p	O
=	O
0.040	O
and	O
0.003	O
)	O
.	O

The	O
IFN	B
-	O
induced	O
up	O
-	O
regulation	O
of	O
the	O
MxA	B
promoter	O
activity	O
of	O
the	O
sequence	O
with	O
-88	O
T	O
was	O
found	O
to	O
be	O
significantly	O
higher	O
than	O
that	O
with	O
G.	O
CONCLUSIONS	O
:	O
MxA	B
promoter	O
-88	O
G	O
/	O
T	O
SNP	O
may	O
confer	O
host	O
genetic	O
susceptibility	O
to	O
SSPE	O
in	O
Japanese	O
individuals	O
.	O

The	O
finding	O
that	O
homozygotes	O
of	O
the	O
MxA	B
-88	O
T	O
allele	O
with	O
a	O
high	O
MxA	B
-	O
producing	O
capability	O
were	O
more	O
frequently	O
seen	O
in	O
SSPE	O
patients	O
suggests	O
that	O
the	O
MxA	B
protein	O
promotes	O
the	O
establishment	O
of	O
persistent	O
MV	O
infection	O
of	O
neural	O
cells	O
.	O

-160C	O
/	O
A	O
polymorphism	O
in	O
the	O
E	B
-	I
cadherin	I
gene	O
promoter	O
and	O
risk	O
of	O
hereditary	O
,	O
familial	O
and	O
sporadic	O
prostate	O
cancer	O
.	O

The	O
E	B
-	I
cadherin	I
(	O
CDH1	B
)	O
gene	O
has	O
been	O
associated	O
with	O
prostate	O
carcinogenesis	O
.	O

The	O
C	O
/	O
A	O
polymorphism--160	O
base	O
pairs	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
has	O
been	O
shown	O
to	O
decrease	O
gene	O
transcription	O
.	O

We	O
analyzed	O
the	O
association	O
between	O
this	O
polymorphism	O
and	O
the	O
risk	O
of	O
sporadic	O
,	O
familial	O
(	O
2	O
close	O
relatives	O
)	O
and	O
hereditary	O
(	O
3	O
or	O
more	O
close	O
relatives	O
)	O
prostate	O
cancer	O
.	O

We	O
combined	O
data	O
from	O
3	O
population	O
-	O
based	O
epidemiologic	O
studies	O
in	O
Sweden	O
encompassing	O
altogether	O
1,036	O
prostate	O
cancer	O
cases	O
and	O
669	O
controls	O
that	O
were	O
genotyped	O
for	O
the	O
short	O
nucleotide	O
polymorphism	O
.	O

Odds	O
ratios	O
with	O
95	O
%	O
confidence	O
intervals	O
were	O
estimated	O
through	O
unconditional	O
logistic	O
regression	O
.	O

We	O
found	O
no	O
significant	O
association	O
between	O
the	O
A	O
-	O
allele	O
and	O
sporadic	O
(	O
OR	O
=	O
1.0	O
;	O
95	O
%	O
CI	O
=	O
0.8	O
-	O
1.2	O
)	O
or	O
familial	O
(	O
OR	O
=	O
1.4	O
;	O
95	O
%	O
CI	O
=	O
0.9	O
-	O
2.2	O
)	O
prostate	O
cancer	O
.	O

In	O
contrast	O
,	O
risk	O
of	O
hereditary	O
cancer	O
was	O
increased	O
among	O
heterozygote	O
CA	O
carriers	O
(	O
OR	O
=	O
1.7	O
;	O
95	O
%	O
CI	O
=	O
1.0	O
-	O
2.7	O
)	O
and	O
particularly	O
among	O
homozygote	O
AA	O
carriers	O
(	O
OR	O
=	O
2.6	O
;	O
95	O
%	O
CI	O
=	O
1.4	O
-	O
4.9	O
)	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
-160	O
single	O
nucleotide	O
polymorphism	O
in	O
CDH1	B
is	O
a	O
low	O
-	O
penetrant	O
prostate	O
cancer	O
susceptibility	O
gene	O
that	O
might	O
explain	O
a	O
proportion	O
of	O
familial	O
and	O
notably	O
hereditary	O
prostate	O
cancer	O
.	O

Polymorphisms	O
of	O
the	O
interleukin-1	B
beta	I
gene	O
are	O
associated	O
with	O
increased	O
risk	O
of	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

Lung	O
cancer	O
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
cancer	O
death	O
worldwide	O
.	O

Tobacco	O
smoking	O
is	O
the	O
main	O
risk	O
factor	O
for	O
lung	O
cancer	O
.	O

Less	O
than	O
20	O
%	O
of	O
smokers	O
develop	O
lung	O
cancer	O
in	O
their	O
lifetime	O
,	O
however	O
,	O
indicating	O
individual	O
variations	O
in	O
lung	O
cancer	O
risk	O
.	O

Pro	O
-	O
inflammatory	O
cytokines	O
produced	O
by	O
inflammatory	O
cells	O
have	O
been	O
associated	O
with	O
inflammatory	O
diseases	O
and	O
cancer	O
.	O

The	O
IL1B	B
gene	O
,	O
encoding	O
IL-1beta	B
cytokine	O
,	O
contains	O
several	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
.	O

Two	O
of	O
these	O
are	O
in	O
the	O
promoter	O
region	O
,	O
at	O
positions	O
-511	O
(	O
C	O
-	O
T	O
)	O
and	O
-31	O
(	O
T	O
-	O
C	O
)	O
.	O

These	O
polymorphisms	O
have	O
been	O
associated	O
with	O
increased	O
risk	O
of	O
developing	O
a	O
number	O
of	O
inflammatory	O
diseases	O
and	O
gastric	O
carcinoma	O
.	O

We	O
genotyped	O
the	O
2	O
polymorphisms	O
in	O
251	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
patients	O
from	O
Norway	O
and	O
272	O
healthy	O
controls	O
chosen	O
from	O
the	O
general	O
Norwegian	O
population	O
.	O

The	O
T	O
allele	O
at	O
the	O
-31	O
SNP	O
(	O
p	O
=	O
0.01	O
)	O
and	O
C	O
allele	O
at	O
-511	O
SNP	O
(	O
p	O
<	O
0.01	O
)	O
were	O
over	O
represented	O
in	O
lung	O
cancer	O
cases	O
.	O

The	O
homozygote	O
subjects	O
were	O
particularly	O
at	O
higher	O
risk	O
of	O
lung	O
cancer	O
with	O
odds	O
ratio	O
of	O
2.39	O
(	O
95	O
%	O
CI	O
=	O
1.29	O
-	O
4.44	O
)	O
for	O
-31T	O
/	O
T	O
and	O
2.51	O
(	O
95	O
%	O
CI	O
=	O
1.47	O
-	O
4.58	O
)	O
for	O
-511C	O
/	O
C	O
genotypes	O
.	O

In	O
view	O
of	O
the	O
significance	O
of	O
the	O
p53	B
gene	O
in	O
lung	O
carcinogenesis	O
,	O
we	O
also	O
analyzed	O
the	O
IL1B	B
genotypes	O
in	O
relation	O
to	O
p53	B
mutations	O
in	O
the	O
tumors	O
.	O

The	O
results	O
indicated	O
that	O
subjects	O
having	O
homozygote	O
genotypes	O
were	O
more	O
likely	O
to	O
have	O
a	O
mutation	O
in	O
the	O
p53	B
gene	O
(	O
p	O
=	O
0.05	O
)	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
provide	O
evidence	O
for	O
an	O
association	O
of	O
1L1B	B
gene	O
polymorphisms	O
with	O
lung	O
cancer	O
risk	O
.	O

Evaluation	O
of	O
the	O
IRF-2	B
gene	O
as	O
a	O
candidate	O
for	O
PSORS3	B
.	O

Type	B
1	I
interferon	I
can	O
trigger	O
flares	O
of	O
psoriasis	O
.	O

Hypersensitivity	O
to	O
type	B
1	I
interferon	I
signaling	O
causes	O
a	O
psoriasis	O
-	O
like	O
skin	O
disease	O
in	O
mice	O
deficient	O
for	O
the	O
transcription	O
factor	O
interferon	B
regulatory	I
factor	I
2	I
(	O
IRF2	B
)	O
.	O

The	O
human	O
IRF2	B
gene	O
is	O
located	O
at	O
a	O
previously	O
identified	O
candidate	O
psoriasis	O
susceptibility	O
locus	O
on	O
chromosome	O
4q	O
(	O
PSORS3	B
at	I
D4S1535	I
)	O
.	O

Therefore	O
,	O
we	O
tested	O
association	O
of	O
psoriasis	O
with	O
IRF2	B
.	O

We	O
generated	O
a	O
sample	O
consisting	O
of	O
157	O
families	O
with	O
a	O
total	O
of	O
521	O
individuals	O
.	O

Five	O
novel	O
microsatellite	O
markers	O
were	O
developed	O
and	O
typed	O
,	O
and	O
complemented	O
with	O
three	O
known	O
markers	O
to	O
yield	O
a	O
set	O
of	O
eight	O
markers	O
spaced	O
within	O
600	O
kb	O
around	O
the	O
IRF2	O
gene	O
,	O
three	O
of	O
which	O
are	O
located	O
in	O
the	O
gene	O
.	O

We	O
detected	O
association	O
of	O
IRF2	B
with	O
type	O
1	O
psoriasis	O
at	O
two	O
markers	O
in	O
the	O
IRF2	B
gene	O
.	O

Haplotype	O
sharing	O
analysis	O
confirmed	O
association	O
of	O
IRF2	B
with	O
type	O
1	O
psoriasis	O
(	O
p=0.0017	O
;	O
pcorr=0.03	O
)	O
.	O

The	O
921G	O
/	O
A	O
SNP	O
in	O
exon	O
9	O
was	O
found	O
to	O
obliterate	O
a	O
predicted	O
exon	O
splice	O
enhancer	O
in	O
an	O
allele	O
-	O
specific	O
manner	O
.	O

There	O
was	O
a	O
suggestive	O
increase	O
of	O
homozygosity	O
for	O
the	O
splicing	O
-	O
deficient	O
allele	O
in	O
type	O
1	O
psoriasis	O
patients	O
.	O

Our	O
data	O
identify	O
IRF2	B
as	O
a	O
potential	O
susceptibility	O
gene	O
for	O
psoriasis	O
.	O

In	O
-	O
depth	O
haplotype	O
analysis	O
of	O
ABCA1	B
gene	O
polymorphisms	O
in	O
relation	O
to	O
plasma	O
ApoA1	B
levels	O
and	O
myocardial	O
infarction	O
.	O

OBJECTIVE	O
:	O
By	O
regulating	O
the	O
cellular	O
cholesterol	O
efflux	O
from	O
peripheral	O
cells	O
to	O
high	O
-	O
density	O
lipoprotein	O
,	O
the	O
ABCA1	B
protein	O
is	O
suspected	O
to	O
play	O
a	O
key	O
role	O
in	O
lipid	O
homeostasis	O
and	O
atherosclerosis	O
.	O

Twenty	O
-	O
six	O
polymorphisms	O
of	O
the	O
ABCA1	B
gene	O
were	O
genotyped	O
and	O
tested	O
for	O
association	O
with	O
plasma	O
levels	O
of	O
ApoA1	B
and	O
myocardial	O
infarction	O
(	O
MI	O
)	O
in	O
the	O
ECTIM	O
study	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
In	O
addition	O
to	O
single	O
-	O
locus	O
analysis	O
,	O
a	O
systematic	O
exploration	O
of	O
all	O
possible	O
haplotype	O
effects	O
was	O
performed	O
,	O
with	O
this	O
exploration	O
being	O
performed	O
on	O
a	O
minimal	O
set	O
of	O
""""	O
tag	O
""""	O
polymorphisms	O
that	O
define	O
the	O
haplotype	O
structure	O
of	O
the	O
gene	O
.	O

Two	O
polymorphisms	O
were	O
associated	O
with	O
plasma	O
levels	O
of	O
ApoA1	B
,	O
1	O
in	O
the	O
promoter	O
(	O
C-564	O
T	O
)	O
and	O
1	O
in	O
the	O
coding	O
(	O
R1587	O
K	O
)	O
regions	O
,	O
whereas	O
only	O
1	O
polymorphism	O
(	O
R219	O
K	O
)	O
was	O
associated	O
with	O
the	O
risk	O
of	O
MI	O
.	O

However	O
,	O
no	O
haplotype	O
effect	O
was	O
detected	O
on	O
ApoA1	B
variability	O
or	O
on	O
the	O
risk	O
of	O
MI	O
.	O

CONCLUSIONS	O
:	O
ABCA1	B
gene	O
polymorphisms	O
but	O
not	O
haplotypes	O
are	O
involved	O
in	O
the	O
variability	O
of	O
plasma	O
ApoA1	B
and	O
the	O
susceptibility	O
to	O
coronary	O
artery	O
disease	O
.	O

Three	O
single	O
-	O
nucleotide	O
polymorphisms	O
of	O
the	O
angiotensinogen	B
gene	O
and	O
susceptibility	O
to	O
hypertension	O
:	O
single	O
locus	O
genotype	O
vs.	O
haplotype	O
analysis	O
.	O

Although	O
some	O
single	O
polymorphism	O
analyses	O
of	O
the	O
angiotensinogen	B
(	O
AGT	B
)	O
gene	O
have	O
been	O
found	O
to	O
be	O
associated	O
with	O
hypertension	O
,	O
the	O
results	O
are	O
still	O
inconsistent	O
.	O

The	O
objectives	O
of	O
this	O
study	O
are	O
to	O
evaluate	O
the	O
association	O
of	O
the	O
genotype	O
and	O
haplotype	O
distributions	O
of	O
three	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
(	O
G-217A	O
,	O
A-6	O
G	O
,	O
and	O
M235	O
T	O
)	O
in	O
the	O
AGT	B
gene	O
with	O
hypertension	O
.	O

In	O
a	O
sample	O
of	O
461	O
hypertensive	O
and	O
327	O
normotensive	O
patients	O
in	O
Taiwan	O
,	O
we	O
found	O
that	O
-217AA	O
and	O
-6GG	O
homozygotes	O
conferred	O
independently	O
an	O
increased	O
risk	O
to	O
hypertension	O
(	O
P	O
=	O
0.008	O
and	O
P	O
=	O
0.037	O
,	O
respectively	O
)	O
,	O
as	O
illustrated	O
by	O
their	O
significant	O
associations	O
with	O
hypertension	O
in	O
both	O
single	O
SNP	O
and	O
pair	O
-	O
wise	O
SNPs	O
analyses	O
.	O

Meanwhile	O
,	O
a	O
very	O
weak	O
linkage	O
disequilibrium	O
was	O
found	O
between	O
the	O
G-217A	O
and	O
the	O
A-6	O
G	O
polymorphisms	O
in	O
terms	O
of	O
r2	O
(	O
<	O
0.05	O
)	O
.	O

On	O
the	O
basis	O
of	O
likelihood	O
ratio	O
test	O
,	O
only	O
the	O
set	O
of	O
haplotypes	O
that	O
constituted	O
the	O
A-6	O
G	O
and	O
the	O
M235	O
T	O
polymorphisms	O
was	O
associated	O
with	O
hypertension	O
(	O
chi2	O
=	O
20.91	O
,	O
P	O
=	O
0.0008	O
)	O
,	O
which	O
was	O
mainly	O
due	O
to	O
the	O
increased	O
frequency	O
of	O
the	O
recombinant	O
haplotypes	O
(	O
-6A	O
identical	O
with	O
235	O
M	O
and	O
-6	O
G	O
identical	O
with	O
235	O
T	O
)	O
,	O
and	O
a	O
pathophysiological	O
role	O
in	O
the	O
predisposition	O
to	O
hypertension	O
was	O
hence	O
indicated	O
.	O

In	O
functional	O
assays	O
,	O
the	O
promoter	O
activities	O
of	O
the	O
haplotypes	O
-217A	O
identical	O
with	O
-6A	O
and	O
-217	O
G	O
identical	O
with	O
-6	O
G	O
were	O
significantly	O
higher	O
than	O
the	O
most	O
common	O
haplotype	O
-217	O
G	O
identical	O
with	O
-6A	O
.	O

These	O
results	O
highlight	O
the	O
necessity	O
of	O
a	O
thorough	O
analysis	O
of	O
all	O
reported	O
variants	O
of	O
a	O
candidate	O
gene	O
in	O
the	O
elucidation	O
of	O
genetic	O
susceptibility	O
to	O
a	O
complex	O
disease	O
like	O
hypertension	O
,	O
even	O
when	O
the	O
variants	O
are	O
in	O
the	O
same	O
haplotype	O
block	O
.	O

Melanocortin-4	B
receptor	I
gene	O
variant	O
I103	O
is	O
negatively	O
associated	O
with	O
obesity	O
.	O

Several	O
rare	O
mutations	O
in	O
the	O
melanocortin-4	B
receptor	I
gene	O
(	O
MC4R	B
)	O
predispose	O
to	O
obesity	O
.	O

For	O
the	O
most	O
common	O
missense	O
variant	O
V103I	O
(	O
rs2229616	O
)	O
,	O
however	O
,	O
the	O
previously	O
reported	O
similar	O
carrier	O
frequencies	O
in	O
obese	O
and	O
nonobese	O
individuals	O
are	O
in	O
line	O
with	O
in	O
vitro	O
studies	O
,	O
which	O
have	O
not	O
shown	O
a	O
functional	O
implication	O
of	O
this	O
variant	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
initially	O
performed	O
a	O
transmission	O
/	O
disequilibrium	O
test	O
on	O
520	O
trios	O
with	O
obesity	O
,	O
and	O
we	O
observed	O
a	O
lower	O
transmission	O
rate	O
of	O
the	O
I103	O
allele	O
(	O
P=.017	O
)	O
,	O
which	O
was	O
an	O
unexpected	O
finding	O
.	O

Therefore	O
,	O
we	O
initiated	O
two	O
large	O
case	O
-	O
control	O
studies	O
(	O
N=2,334	O
and	O
N=661	O
)	O
and	O
combined	O
the	O
data	O
with	O
those	O
from	O
12	O
published	O
studies	O
,	O
for	O
a	O
total	O
of	O
7,713	O
individuals	O
.	O

The	O
resulting	O
meta	O
-	O
analysis	O
provides	O
evidence	O
for	O
a	O
negative	O
association	O
of	O
the	O
I103	O
allele	O
with	O
obesity	O
(	O
odds	O
ratio	O
0.69	O
;	O
95	O
%	O
confidence	O
interval	O
0.50	O
-	O
0.96	O
;	O
P=.03	O
)	O
,	O
mainly	O
comprising	O
samples	O
of	O
European	O
origin	O
.	O

Additional	O
screening	O
of	O
four	O
other	O
ethnic	O
groups	O
showed	O
comparable	O
I103	O
carrier	O
frequencies	O
well	O
below	O
10	O
%	O
.	O

Genomic	O
sequencing	O
of	O
the	O
MC4R	B
gene	O
revealed	O
three	O
polymorphisms	O
in	O
the	O
noncoding	O
region	O
that	O
displayed	O
strong	O
linkage	O
disequilibrium	O
with	O
V103I	O
.	O

In	O
our	O
functional	O
in	O
vitro	O
assays	O
,	O
the	O
variant	O
was	O
indistinguishable	O
from	O
the	O
wild	O
-	O
type	O
allele	O
,	O
as	O
was	O
the	O
result	O
in	O
previous	O
studies	O
.	O

This	O
report	O
on	O
an	O
SNP	O
/	O
haplotype	O
that	O
is	O
negatively	O
associated	O
with	O
obesity	O
expands	O
the	O
successful	O
application	O
of	O
meta	O
-	O
analysis	O
of	O
modest	O
effects	O
in	O
common	O
diseases	O
to	O
a	O
variant	O
with	O
a	O
carrier	O
frequency	O
well	O
below	O
10	O
%	O
.	O

The	O
respective	O
protective	O
effect	O
against	O
obesity	O
implies	O
that	O
variation	O
in	O
the	O
MC4R	B
gene	O
entails	O
both	O
loss	O
and	O
gain	O
of	O
function	O
.	O

Molecular	O
and	O
functional	O
characterization	O
of	O
common	O
polymorphisms	O
in	O
HERG	B
(	O
KCNH2	B
)	I
)	O
potassium	O
channels	O
.	O

Long	O
QT	O
syndrome	O
(	O
LQTS	O
)	O
is	O
a	O
cardiac	O
repolarization	O
disorder	O
that	O
can	O
lead	O
to	O
arrhythmias	O
and	O
sudden	O
death	O
.	O

Chromosome	O
7-linked	O
inherited	O
LQTS	O
(	O
LQT2	O
)	O
is	O
caused	O
by	O
mutations	O
in	O
human	O
ether	O
-	O
a	O
-	O
go	O
-	O
go	O
-	O
related	O
gene	O
(	O
HERG	B
;	O
KCNH2	B
)	O
,	O
whereas	O
drug	O
-	O
induced	O
LQTS	O
is	O
caused	O
primarily	O
by	O
HERG	B
channel	O
block	O
.	O

Many	O
common	O
polymorphisms	O
are	O
functionally	O
silent	O
and	O
have	O
been	O
traditionally	O
regarded	O
as	O
benign	O
and	O
without	O
physiological	O
consequence	O
.	O

However	O
,	O
the	O
identification	O
of	O
common	O
nonsynonymous	O
single	O
nucleotide	O
polymorphisms	O
(	O
nSNPs	O
;	O
i.e.	O
,	O
amino	O
-	O
acid	O
coding	O
variants	O
)	O
with	O
functional	O
phenotypes	O
in	O
the	O
SCN5A	B
Na	I
(	I
+	I
)	I
channel	I
and	O
MiRP1	B
K	I
(	I
+	I
)	I
channel	I
beta	I
-	I
subunit	I
have	O
challenged	O
this	O
viewpoint	O
.	O

In	O
this	O
report	O
,	O
we	O
test	O
the	O
hypothesis	O
that	O
common	O
missense	O
HERG	B
polymorphisms	O
alter	O
channel	O
physiology	O
.	O

Comprehensive	O
mutational	O
analysis	O
of	O
HERG	B
was	O
performed	O
on	O
genomic	O
DNA	O
derived	O
from	O
a	O
population	O
-	O
based	O
cohort	O
of	O
sudden	O
infant	O
death	O
syndrome	O
and	O
two	O
reference	O
allele	O
cohorts	O
derived	O
from	O
100	O
African	O
American	O
and	O
100	O
Caucasian	O
individuals	O
.	O

Amino	O
acid	O
-	O
encoding	O
variants	O
were	O
considered	O
common	O
polymorphisms	O
if	O
they	O
were	O
present	O
in	O
at	O
least	O
two	O
of	O
the	O
three	O
study	O
cohorts	O
with	O
an	O
allelic	O
frequency	O
>	O
0.5	O
%	O
.	O

Four	O
nSNPs	O
were	O
identified	O
:	O
K897	O
T	O
,	O
P967L	O
,	O
R1047L	O
,	O
and	O
Q1068R	O
.	O

Wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
polymorphic	O
channels	O
were	O
heterologously	O
expressed	O
in	O
human	O
embryonic	O
kidney	O
cells	O
,	O
and	O
biochemical	O
and	O
voltage	O
-	O
clamp	O
techniques	O
were	O
used	O
to	O
characterize	O
their	O
functional	O
properties	O
.	O

All	O
channel	O
types	O
were	O
processed	O
similarly	O
,	O
but	O
several	O
electrophysiological	O
differences	O
were	O
identified	O
:	O
1	O
)	O
K897	O
T	O
current	O
density	O
was	O
lower	O
than	O
the	O
other	O
polymorphic	O
channels	O
;	O
2	O
)	O
K897	O
T	O
channels	O
activated	O
at	O
more	O
negative	O
potentials	O
than	O
WT	O
and	O
R1047L	O
;	O
3	O
)	O
K897	O
T	O
and	O
Q1068R	O
channels	O
inactivated	O
and	O
recovered	O
from	O
inactivation	O
faster	O
than	O
WT	O
,	O
P967L	O
,	O
and	O
R1047L	O
channels	O
;	O
and	O
4	O
)	O
K897	O
T	O
channels	O
showed	O
subtle	O
differences	O
compared	O
with	O
WT	O
channels	O
when	O
stimulated	O
with	O
an	O
action	O
potential	O
waveform	O
.	O

In	O
contrast	O
to	O
K897	O
T	O
and	O
Q1068R	O
channels	O
,	O
P967L	O
and	O
R1047L	O
channels	O
were	O
electrophysiologically	O
indistinguishable	O
from	O
WT	O
channels	O
.	O

All	O
HERG	B
channels	O
had	O
similar	O
sensitivity	O
to	O
block	O
by	O
cisapride	O
.	O

Therefore	O
,	O
some	O
HERG	B
polymorphic	O
channels	O
are	O
electrophysiologically	O
different	O
from	O
WT	O
channels	O
.	O

A	O
functional	O
C	O
-	O
G	O
polymorphism	O
in	O
the	O
CYP7B1	B
promoter	O
region	O
and	O
its	O
different	O
distribution	O
in	O
Orientals	O
and	O
Caucasians	O
.	O

Cytochrome	B
P450	I
(	I
CYP	I
)	I
7B1	I
is	O
involved	O
in	O
many	O
metabolic	O
processes	O
including	O
androgen	O
metabolism	O
.	O

Genetic	O
variation	O
in	O
the	O
CYP7B1	B
gene	O
may	O
play	O
a	O
role	O
in	O
predisposition	O
to	O
prostate	O
cancer	O
.	O

Here	O
,	O
we	O
screened	O
the	O
human	O
CYP7B1	B
gene	O
for	O
possible	O
polymorphisms	O
.	O

Only	O
one	O
single	O
polymorphism	O
was	O
detected	O
,	O
a	O
C	O
-	O
G	O
change	O
in	O
the	O
promoter	O
-104	O
base	O
pair	O
from	O
the	O
transcription	O
start	O
site	O
.	O

The	O
allele	O
frequency	O
was	O
investigated	O
in	O
Swedish	O
men	O
and	O
compared	O
to	O
a	O
Korean	O
population	O
,	O
as	O
it	O
is	O
known	O
that	O
the	O
frequency	O
of	O
prostate	O
cancer	O
is	O
low	O
among	O
Orientals	O
.	O

We	O
found	O
that	O
the	O
frequency	O
of	O
the	O
G	O
-	O
allele	O
was	O
4.04	O
%	O
in	O
Swedes	O
(	O
n=150	O
)	O
but	O
only	O
0.33	O
%	O
among	O
Koreans	O
(	O
n=153	O
)	O
.	O

Computer	O
analysis	O
indicated	O
that	O
the	O
two	O
variants	O
bind	O
with	O
different	O
affinities	O
to	O
a	O
CCAAT	B
-	I
box	I
binding	I
protein	I
.	O

Expression	O
studies	O
with	O
reporter	O
constructs	O
showed	O
significantly	O
higher	O
transcriptional	O
activity	O
of	O
the	O
G	O
variant	O
in	O
Hek293	O
cells	O
(	O
2.7-fold	O
,	O
P<0.05	O
)	O
.	O

In	O
conclusion	O
,	O
we	O
report	O
here	O
for	O
the	O
first	O
time	O
the	O
detection	O
of	O
a	O
single	O
polymorphism	O
in	O
the	O
CYP7B1	B
gene	O
.	O

This	O
polymorphism	O
is	O
associated	O
with	O
phenotypic	O
differences	O
in	O
an	O
expression	O
system	O
and	O
a	O
widely	O
different	O
allele	O
frequency	O
in	O
two	O
ethnic	O
populations	O
,	O
with	O
great	O
differences	O
in	O
the	O
incidence	O
of	O
prostate	O
cancer	O
.	O

Population	O
differences	O
in	O
DNA	O
sequence	O
variation	O
and	O
linkage	O
disequilibrium	O
at	O
the	O
PON1	B
gene	O
.	O

Polymorphisms	O
of	O
the	O
promoter	O
region	O
(	O
-108C	O
/	O
T	O
)	O
and	O
the	O
coding	O
region	O
(	O
192Q	O
/	O
R	O
)	O
of	O
the	O
paraoxonase	B
1	I
gene	O
(	O
PON1	B
)	O
showed	O
differences	O
in	O
association	O
with	O
cardiovascular	O
disease	O
risk	O
in	O
various	O
populations	O
.	O

To	O
characterize	O
the	O
genetic	O
variation	O
underlying	O
these	O
important	O
polymorphisms	O
,	O
we	O
examined	O
DNA	O
sequence	O
variation	O
both	O
in	O
a	O
1.3-kb	O
promoter	O
region	O
16.5	O
kb	O
from	O
codon	O
192	O
,	O
and	O
in	O
a	O
1.7-kb	O
region	O
centered	O
on	O
the	O
192Q	O
/	O
R	O
polymorphic	O
site	O
of	O
the	O
coding	O
region	O
of	O
PON1	B
,	O
in	O
30	O
Africans	O
,	O
30	O
Europeans	O
and	O
64	O
Japanese	O
.	O

We	O
found	O
10	O
polymorphic	O
sites	O
and	O
11	O
haplotypes	O
in	O
the	O
1.3-kb	O
promoter	O
region	O
and	O
10	O
biallelic	O
polymorphic	O
sites	O
and	O
10	O
haplotypes	O
in	O
the	O
1.7-kb	O
region	O
.	O

From	O
the	O
PON1	B
sequences	O
of	O
chimpanzees	O
and	O
an	O
orangutan	O
,	O
the	O
ancestral	O
type	O
of	O
codon	O
192	O
was	O
found	O
to	O
be	O
R.	O
The	O
number	O
of	O
pairs	O
of	O
polymorphic	O
sites	O
between	O
the	O
promoter	O
and	O
1.7-kb	O
regions	O
that	O
were	O
in	O
significant	O
linkage	O
disequilibrium	O
was	O
much	O
higher	O
in	O
a	O
Japanese	O
population	O
than	O
in	O
African	O
and	O
European	O
populations	O
.	O

In	O
addition	O
,	O
the	O
pairs	O
of	O
polymorphic	O
sites	O
in	O
linkage	O
disequilibrium	O
differed	O
among	O
the	O
three	O
populations	O
.	O

These	O
results	O
suggest	O
that	O
some	O
of	O
the	O
population	O
differences	O
in	O
association	O
with	O
risk	O
for	O
coronary	O
heart	O
disease	O
can	O
be	O
explained	O
by	O
population	O
differences	O
in	O
haplotype	O
frequency	O
of	O
PON1	B
haplotypes	O
.	O

Single	O
nucleotide	O
polymorphisms	O
of	O
the	O
inflammatory	O
cytokine	O
genes	O
in	O
adults	O
with	O
chronic	O
immune	O
thrombocytopenic	O
purpura	O
.	O

Single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
of	O
inflammatory	O
cytokine	O
genes	O
were	O
examined	O
in	O
84	O
adult	O
Japanese	O
patients	O
with	O
chronic	O
immune	O
thrombocytopenic	O
purpura	O
(	O
ITP	O
)	O
and	O
56	O
race	O
-	O
matched	O
healthy	O
controls	O
.	O

The	O
SNPs	O
examined	O
were	O
within	O
the	O
genes	O
encoding	O
tumour	B
necrosis	I
factor	I
(	I
TNF	I
)	I
-alpha	I
(	O
-238	O
G	O
/	O
A	O
and	O
-308	O
G	O
/	O
A	O
)	O
,	O
TNF	B
-	I
beta	I
(	O
+	O
252	O
G	O
/	O
A	O
)	O
,	O
and	O
interleukin	B
(	I
IL	I
)	I
-1beta	I
(	O
-511	O
C	O
/	O
T	O
and	O
+	O
3953	O
T	O
/	O
C	O
)	O
.	O

Of	O
these	O
SNPs	O
,	O
the	O
frequency	O
of	O
the	O
TNF	B
-	I
beta	I
(	O
+	O
252	O
)	O
G	O
/	O
G	O
phenotype	O
was	O
significantly	O
higher	O
in	O
ITP	O
patients	O
than	O
in	O
healthy	O
controls	O
(	O
21	O
%	O
vs.	O
7	O
%	O
,	O
P	O
=	O
0.04	O
,	O
odds	O
ratio	O
=	O
3.6	O
,	O
95	O
%	O
confidence	O
interval	O
1.1	O
-	O
11.1	O
)	O
,	O
while	O
no	O
significant	O
association	O
was	O
detected	O
for	O
the	O
other	O
SNPs	O
.	O

The	O
distribution	O
of	O
the	O
TNF	B
-	I
beta	I
(	O
+	O
252	O
)	O
phenotype	O
was	O
not	O
associated	O
with	O
human	O
leucocyte	O
antigen	O
class	O
II	O
alleles	O
or	O
the	O
therapeutic	O
response	O
in	O
ITP	O
patients	O
.	O

The	O
frequency	O
of	O
circulating	O
anti	O
-	O
glycoprotein	O
IIb	O
/	O
IIIa	O
antibody	O
-	O
producing	O
B	O
cells	O
was	O
significantly	O
higher	O
in	O
ITP	O
patients	O
with	O
the	O
TNF	B
-	I
beta	I
(	O
+	O
252	O
)	O
G	O
/	O
G	O
phenotype	O
than	O
in	O
those	O
with	O
the	O
G	O
/	O
A	O
or	O
A	O
/	O
A	O
phenotype	O
(	O
11.9	O
+	O
/-	O

4.9	O
vs.	O
6.8	O
+	O
/-	O

4.9	O
and	O
3.7	O
+	O
/-	O

2.8	O
per	O
10	O
(	O
5	O
)	O
peripheral	O
blood	O
mononuclear	O
cells	O
;	O
P	O
=	O
0.02	O
and	O
P	O
<	O
0.001	O
,	O
respectively	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
SNP	O
located	O
at	O
TNF	B
-	I
beta	I
(	O
+	O
252	O
)	O
contributes	O
to	O
susceptibility	O
to	O
chronic	O
ITP	O
by	O
controlling	O
the	O
autoreactive	O
B	O
-	O
cell	O
responses	O
to	O
platelet	O
membrane	O
glycoproteins	O
.	O

Crohn	O
disease	O
:	O
frequency	O
and	O
nature	O
of	O
CARD15	B
mutations	O
in	O
Ashkenazi	O
and	O
Sephardi	O
/	O
Oriental	O
Jewish	O
families	O
.	O

Crohn	O
disease	O
(	O
CD	O
)	O
,	O
an	O
inflammatory	O
bowel	O
disease	O
,	O
is	O
a	O
multifactorial	O
trait	O
with	O
the	O
highest	O
frequency	O
in	O
Ashkenazi	O
Jewish	O
(	O
AJ	O
)	O
individuals	O
of	O
Central	O
European	O
origin	O
.	O

Recently	O
,	O
three	O
common	O
predisposing	O
CARD15	B
mutations	O
(	O
R702W	O
,	O
G908R	O
,	O
and	O
1007fs	O
)	O
and	O
a	O
polymorphism	O
(	O
P268S	O
)	O
were	O
identified	O
.	O

To	O
determine	O
whether	O
CARD15	B
mutations	O
account	O
for	O
the	O
higher	O
prevalence	O
of	O
CD	O
in	O
AJ	O
individuals	O
,	O
the	O
haplotypes	O
and	O
allele	O
frequencies	O
of	O
the	O
common	O
mutations	O
and	O
variants	O
were	O
assessed	O
in	O
219	O
members	O
of	O
50	O
AJ	O
and	O
53	O
members	O
of	O
10	O
Sephardi	O
/	O
Oriental	O
Jewish	O
(	O
SOJ	O
)	O
multiplex	O
families	O
with	O
CD	O
,	O
in	O
36	O
AJ	O
patients	O
with	O
sporadic	O
CD	O
,	O
and	O
in	O
246	O
AJ	O
and	O
82	O
SOJ	O
controls	O
.	O

A	O
higher	O
frequency	O
of	O
CARD15	B
mutations	O
was	O
found	O
in	O
AJ	O
patients	O
from	O
multiplex	O
families	O
with	O
CD	O
from	O
Central	O
(	O
44.0	O
%	O
)	O
versus	O
Eastern	O
(	O
24.0	O
%	O
)	O
Europe	O
,	O
especially	O
for	O
G908R	O
and	O
1007fs	O
,	O
and	O
in	O
SOJ	O
patients	O
(	O
34.5	O
%	O
)	O
compared	O
with	O
AJ	O
(	O
10.1	O
%	O
)	O
or	O
SOJ	O
(	O
5.4	O
%	O
)	O
controls	O
.	O

Contrary	O
to	O
expectation	O
,	O
the	O
frequency	O
of	O
the	O
common	O
mutations	O
was	O
slightly	O
lower	O
in	O
AJ	O
patients	O
with	O
CD	O
(	O
30.1	O
%	O
)	O
than	O
in	O
SOJ	O
patients	O
with	O
CD	O
(	O
34.5	O
%	O
)	O
.	O

The	O
702W	O
allele	O
was	O
associated	O
with	O
both	O
the	O
P268	O
and	O
268S	O
alleles	O
.	O

CARD15	B
mutation	O
frequencies	O
were	O
greater	O
in	O
affected	O
sib	O
pairs	O
than	O
in	O
sporadic	O
CD	O
cases	O
but	O
actually	O
decreased	O
in	O
families	O
with	O
three	O
or	O
more	O
affected	O
sibs	O
,	O
raising	O
the	O
possibility	O
of	O
genetic	O
heterogeneity	O
.	O

Similarly	O
,	O
our	O
linkage	O
evidence	O
on	O
chromosome	O
16	O
was	O
diminished	O
in	O
the	O
families	O
with	O
three	O
or	O
more	O
affected	O
sibs	O
compared	O
with	O
sib	O
pairs	O
.	O

Screening	O
the	O
CARD15	B
gene	O
for	O
rare	O
variants	O
revealed	O
five	O
novel	O
changes	O
(	O
D113N	O
,	O
D357A	O
,	O
I363F	O
,	O
L550V	O
,	O
and	O
N852S	O
)	O
of	O
which	O
N852S	O
occurred	O
only	O
in	O
AJ	O
individuals	O
and	O
may	O
be	O
disease	O
predisposing	O
.	O

Also	O
,	O
there	O
was	O
no	O
evidence	O
for	O
increased	O
risk	O
associated	O
with	O
the	O
recently	O
described	O
IVS	O
(	O
+158	O
)	O
single	O
-	O
nucleotide	O
polymorphism	O
.	O

Although	O
the	O
AJ	O
controls	O
appear	O
to	O
have	O
a	O
higher	O
frequency	O
of	O
CARD15	B
mutations	O
than	O
the	O
SOJ	O
controls	O
,	O
it	O
is	O
unlikely	O
that	O
this	O
difference	O
fully	O
explains	O
the	O
excess	O
frequency	O
of	O
CD	O
in	O
the	O
AJ	O
population	O
.	O

A	O
polymorphism	O
in	O
the	O
CDKN1B	B
gene	O
is	O
associated	O
with	O
increased	O
risk	O
of	O
hereditary	O
prostate	O
cancer	O
.	O

The	O
loss	O
of	O
cell	O
cycle	O
control	O
is	O
believed	O
to	O
be	O
an	O
important	O
mechanism	O
in	O
the	O
promotion	O
of	O
carcinogenesis	O
.	O

CDKN1B	B
(	O
p27	B
)	O
belongs	O
to	O
the	O
Cip	O
/	O
Kip	O
family	O
and	O
functions	O
as	O
an	O
important	O
cell	O
cycle	O
gatekeeper	O
.	O

Several	O
lines	O
of	O
evidence	O
from	O
clinical	O
studies	O
and	O
laboratory	O
experiments	O
demonstrate	O
that	O
CDKN1B	B
is	O
an	O
important	O
tumor	O
suppressor	O
gene	O
in	O
prostate	O
cancer	O
etiology	O
.	O

In	O
addition	O
,	O
a	O
case	O
-	O
control	O
study	O
has	O
shown	O
that	O
the	O
326T	O
/	O
G	O
(	O
V109	O
G	O
)	O
polymorphism	O
in	O
CDKN1B	B
is	O
associated	O
with	O
advanced	O
prostate	O
cancer	O
.	O

In	O
light	O
of	O
the	O
evidence	O
for	O
linkage	O
between	O
the	O
chromosomal	O
location	O
of	O
the	O
CDKN1B	B
gene	O
(	O
12p13	O
)	O
and	O
prostate	O
cancer	O
susceptibility	O
in	O
several	O
hereditary	O
prostate	O
cancer	O
(	O
HPC	O
)	O
populations	O
,	O
we	O
hypothesized	O
that	O
sequence	O
variants	O
of	O
CDKN1B	B
play	O
a	O
role	O
in	O
HPC	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
first	O
resequenced	O
this	O
gene	O
in	O
96	O
HPC	O
probands	O
to	O
identify	O
germ	O
-	O
line	O
mutations	O
and	O
sequence	O
variants	O
.	O

We	O
then	O
genotyped	O
the	O
identified	O
sequence	O
variants	O
among	O
all	O
family	O
members	O
of	O
188	O
HPC	O
families	O
and	O
tested	O
for	O
their	O
cosegregation	O
with	O
prostate	O
cancer	O
.	O

In	O
total	O
,	O
10	O
sequence	O
variants	O
were	O
identified	O
,	O
including	O
three	O
nonsynonymous	O
changes	O
.	O

A	O
family	O
-	O
based	O
test	O
,	O
which	O
is	O
free	O
from	O
the	O
effects	O
of	O
population	O
stratification	O
,	O
revealed	O
a	O
significant	O
association	O
between	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
-79C	O
/	O
T	O
and	O
prostate	O
cancer	O
(	O
with	O
a	O
nominal	O
P	O
of	O
0.0005	O
)	O
.	O

The	O
C	O
allele	O
of	O
-79C	O
/	O
T	O
was	O
overtransmitted	O
from	O
parents	O
to	O
their	O
affected	O
offspring	O
.	O

Evidence	O
for	O
this	O
association	O
was	O
primarily	O
contributed	O
by	O
affected	O
offspring	O
whose	O
age	O
at	O
diagnosis	O
was	O
<	O
65	O
years	O
.	O

Together	O
with	O
the	O
previous	O
association	O
study	O
in	O
a	O
sporadic	O
prostate	O
cancer	O
population	O
,	O
our	O
new	O
findings	O
additionally	O
suggest	O
that	O
germ	O
-	O
line	O
variants	O
of	O
this	O
gene	O
play	O
a	O
role	O
in	O
prostate	O
cancer	O
susceptibility	O
.	O

Additional	O
gene	O
variants	O
reduce	O
effectiveness	O
of	O
beta	O
-	O
blockers	O
in	O
the	O
LQT1	O
form	O
of	O
long	O
QT	O
syndrome	O
.	O

INTRODUCTION	O
:	O
Beta	O
-	O
blockers	O
are	O
widely	O
used	O
to	O
prevent	O
the	O
lethal	O
cardiac	O
events	O
associated	O
with	O
the	O
long	O
QT	O
syndrome	O
(	O
LQTS	O
)	O
,	O
especially	O
in	O
KCNQ1-related	B
LQTS	O
(	O
LQT1	O
)	O
patients	O
.	O

Some	O
LQT1	O
patients	O
,	O
however	O
,	O
are	O
refractory	O
to	O
this	O
therapy	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Eighteen	O
symptomatic	O
LQTS	O
patients	O
(	O
12	O
families	O
)	O
were	O
genetically	O
diagnosed	O
as	O
having	O
heterozygous	O
KCNQ1	B
variants	O
and	O
received	O
beta	O
-	O
blocker	O
therapy	O
.	O

Cardiac	O
events	O
recurred	O
in	O
4	O
members	O
(	O
3	O
families	O
)	O
despite	O
continued	O
therapy	O
during	O
mean	O
follow	O
-	O
up	O
of	O
70	O
months	O
.	O

Three	O
of	O
these	O
patients	O
(	O
2	O
families	O
)	O
had	O
the	O
same	O
mutation	O
[	O
A341V	O
(	O
KCNQ1	B
)	O
]	O
;	O
and	O
the	O
other	O
had	O
R243H	O
(	O
KCNQ1	B
)	O
.	O

The	O
latter	O
patient	O
took	O
aprindine	O
,	O
which	O
seemed	O
to	O
be	O
responsible	O
for	O
the	O
event	O
.	O

By	O
functional	O
assay	O
using	O
a	O
heterologous	O
mammalian	O
expression	O
system	O
,	O
we	O
found	O
that	O
A341V	O
(	O
KCNQ1	B
)	O
is	O
a	O
loss	O
-	O
of	O
-	O
function	O
type	O
mutation	O
(	O
not	O
dominant	O
negative	O
)	O
.	O

Further	O
genetic	O
screening	O
revealed	O
that	O
one	O
A341V	O
(	O
KCNQ1	B
)	O
family	O
cosegregated	O
with	O
S706C	O
(	O
KCNH2	B
)	O
and	O
another	O
with	O
G144S	O
(	O
KCNJ2	B
)	O
.	O

Functional	O
assay	O
of	O
the	O
S706C	O
(	O
KCNH2	B
)	O
mutation	O
was	O
found	O
to	O
reduce	O
the	O
current	O
density	O
of	O
expressed	O
heterozygous	O
KCNH2	B
channels	O
with	O
a	O
positive	O
shift	O
(	O
+	O
8	O
mV	O
)	O
of	O
the	O
activation	O
curve	O
.	O

Action	O
potential	O
simulation	O
study	O
was	O
conducted	O
based	O
on	O
the	O
KYOTO	O
model	O
to	O
estimate	O
the	O
influence	O
of	O
additional	O
gene	O
modifiers	O
.	O

In	O
both	O
models	O
mimicking	O
LQT1	O
plus	O
2	O
and	O
LQT1	O
plus	O
7	O
,	O
the	O
incidence	O
of	O
early	O
afterdepolarization	O
was	O
increased	O
compared	O
with	O
the	O
LQT1	O
model	O
under	O
the	O
setting	O
of	O
beta	O
-	O
adrenergic	O
stimulation	O
.	O

CONCLUSION	O
:	O
Multiple	O
mutations	O
in	O
different	O
LQTS	O
-	O
related	O
genes	O
may	O
modify	O
clinical	O
characteristics	O
.	O

Expanded	O
gene	O
survey	O
may	O
be	O
required	O
in	O
LQT1	O
patients	O
who	O
are	O
resistant	O
to	O
beta	O
-	O
blocker	O
therapy	O
.	O

Polymorphisms	O
at	O
positions	O
-22	O
and	O
-348	O
in	O
the	O
promoter	O
of	O
the	O
BAT1	O
gene	O
affect	O
transcription	O
and	O
the	O
binding	O
of	O
nuclear	O
factors	O
.	O

BAT1	B
(	O
D6S81E	O
,	O
UAP56	B
)	O
lies	O
in	O
the	O
central	O
MHC	O
between	O
TNF	B
and	O
HLA	B
-	I
B	I
,	O
a	O
region	O
containing	O
genes	O
that	O
affect	O
susceptibility	O
to	O
immunopathologic	O
disorders	O
.	O

BAT1	B
protein	O
may	O
be	O
directly	O
responsible	O
for	O
the	O
genetic	O
association	O
,	O
as	O
antisense	O
studies	O
show	O
it	O
can	O
down	O
-	O
regulate	O
inflammatory	O
cytokines	O
.	O

Here	O
we	O
investigate	O
polymorphisms	O
at	O
positions	O
-22	O
and	O
-348	O
relative	O
to	O
the	O
BAT1	O
transcription	O
start	O
site	O
.	O

DNA	O
samples	O
from	O
healthy	O
donors	O
were	O
used	O
to	O
confirm	O
haplotypic	O
associations	O
with	O
the	O
type	O
1	O
diabetes	O
-	O
susceptible	O
8.1	O
ancestral	O
haplotype	O
(	O
AH	O
;	O
HLA	O
-	O
A1,B8,BAT1	O
-	O
22*C	O
,	O
BAT1	B
-	O
348*C	O
,	O
DR3	O
)	O
and	O
the	O
diabetes	O
-	O
resistant	O
7.1	O
AH	O
(	O
HLA	O
-	O
A3,B7	O
,	O
BAT1	B
-	O
22*C	O
,	O
BAT1	B
-	O
348*T	O
,	O
DR15	O
)	O
.	O

Alleles	O
carried	O
at	O
BAT1	B
-	O
22	O
and	O
-348	O
were	O
in	O
linkage	O
disequilibrium	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
using	O
nuclear	O
proteins	O
from	O
T	O
-	O
cells	O
(	O
Jurkat	O
and	O
HT2	O
)	O
,	O
monocytes	O
(	O
THP1	O
,	O
U937	O
)	O
and	O
epithelial	O
cells	O
(	O
HeLa	O
and	O
MDA468	O
)	O
demonstrated	O
DNA	O
:	O
protein	O
complexes	O
binding	O
oligonucleotides	O
spanning	O
positions	O
-22	O
and	O
-348	O
on	O
the	O
7.1	O
AH	O
only	O
.	O

Competition	O
assays	O
,	O
supershifts	O
and	O
molecular	O
weight	O
determinations	O
suggest	O
the	O
complexes	O
include	O
the	O
transcription	O
factors	O
YY1	B
(	O
at	O
-348	O
)	O
and	O
Oct1	B
(	O
at	O
-22	O
)	O
.	O

Promoter	O
activity	O
was	O
demonstrated	O
using	O
520	O
bp	O
and	O
336	O
bp	O
fragments	O
cloned	O
from	O
immediately	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
and	O
carrying	O
all	O
combinations	O
of	O
-22	O
and	O
-348	O
alleles	O
,	O
suggesting	O
an	O
unidentified	O
non	O
-	O
polymorphic	O
sequence	O
within	O
336	O
bp	O
of	O
the	O
start	O
site	O
drives	O
transcription	O
.	O

The	O
520	O
bp	O
fragment	O
of	O
the	O
BAT1	B
promoter	O
cloned	O
from	O
the	O
8.1	O
AH	O
was	O
slightly	O
less	O
efficient	O
than	O
the	O
equivalent	O
from	O
the	O
7.1	O
AH	O
,	O
whilst	O
the	O
reverse	O
was	O
observed	O
with	O
336	O
bp	O
fragments	O
.	O

This	O
suggests	O
BAT1	B
transcription	O
on	O
the	O
7.1	O
AH	O
is	O
modified	O
by	O
interactions	O
involving	O
DNA	O
flanking	O
positions	O
-22	O
and	O
-348	O
.	O

Genetic	O
variation	O
near	O
the	O
hepatocyte	B
nuclear	I
factor-4	I
alpha	I
gene	O
predicts	O
susceptibility	O
to	O
type	O
2	O
diabetes	O
.	O

The	O
Finland	O
-	O
United	O
States	O
Investigation	O
Of	O
NIDDM	O
Genetics	O
(	O
FUSION	O
)	O
study	O
aims	O
to	O
identify	O
genetic	O
variants	O
that	O
predispose	O
to	O
type	O
2	O
diabetes	O
by	O
studying	O
affected	O
sibling	O
pair	O
families	O
from	O
Finland	O
.	O

Chromosome	O
20	O
showed	O
our	O
strongest	O
initial	O
evidence	O
for	O
linkage	O
.	O

It	O
currently	O
has	O
a	O
maximum	O
logarithm	O
of	O
odds	O
(	O
LOD	O
)	O
score	O
of	O
2.48	O
at	O
70	O
cM	O
in	O
a	O
set	O
of	O
495	O
families	O
.	O

In	O
this	O
study	O
,	O
we	O
searched	O
for	O
diabetes	O
susceptibility	O
variant	O
(	O
s	O
)	O
at	O
20q13	O
by	O
genotyping	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
markers	O
in	O
case	O
and	O
control	O
DNA	O
pools	O
.	O

Of	O
291	O
SNPs	O
successfully	O
typed	O
in	O
a	O
7.5-Mb	O
interval	O
,	O
the	O
strongest	O
association	O
confirmed	O
by	O
individual	O
genotyping	O
was	O
with	O
SNP	O
rs2144908	O
,	O
located	O
1.3	O
kb	O
downstream	O
of	O
the	O
primary	O
beta	O
-	O
cell	O
promoter	O
P2	O
of	O
hepatocyte	B
nuclear	I
factor-4	I
alpha	I
(	O
HNF4A	B
)	O
.	O

This	O
SNP	O
showed	O
association	O
with	O
diabetes	O
disease	O
status	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
1.33	O
,	O
95	O
%	O
CI	O
1.06	O
-	O
1.65	O
,	O
P	O
=	O
0.011	O
)	O
and	O
with	O
several	O
diabetes	O
-	O
related	O
traits	O
.	O

Most	O
of	O
the	O
evidence	O
for	O
linkage	O
at	O
20q13	O
could	O
be	O
attributed	O
to	O
the	O
families	O
carrying	O
the	O
risk	O
allele	O
.	O

We	O
subsequently	O
found	O
nine	O
additional	O
associated	O
SNPs	O
spanning	O
a	O
64-kb	O
region	O
,	O
including	O
the	O
P2	O
and	O
P1	O
promoters	O
and	O
exons	O
1	O
-	O
3	O
.	O

Our	O
results	O
and	O
the	O
independent	O
observation	O
of	O
association	O
of	O
SNPs	O
near	O
the	O
P2	O
promoter	O
with	O
diabetes	O
in	O
a	O
separate	O
study	O
population	O
of	O
Ashkenazi	O
Jewish	O
origin	O
suggests	O
that	O
variant	O
(	O
s	O
)	O
located	O
near	O
or	O
within	O
HNF4A	B
increases	O
susceptibility	O
to	O
type	O
2	O
diabetes	O
.	O

Serum	O
concentration	O
and	O
genetic	O
polymorphism	O
in	O
the	O
5'-untraslated	O
region	O
of	O
VEGF	B
is	O
not	O
associated	O
with	O
susceptibility	O
to	O
HTLV	O
-	O
I	O
associated	O
myelopathy	O
/	O
tropical	O
spastic	O
paraparesis	O
(	O
HAM	O
/	O
TSP	O
)	O
in	O
HTLV	O
-	O
I	O
infected	O
individuals	O
.	O

HTLV	O
-	O
I-	O
associated	O
myelopathy	O
/	O
tropical	O
spastic	O
paraparesis	O
(	O
HAM	O
/	O
TSP	O
)	O
is	O
one	O
outcome	O
of	O
human	O
T	O
-	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
infection	O
.	O

It	O
remains	O
unknown	O
why	O
the	O
majority	O
of	O
infected	O
people	O
remain	O
healthy	O
whereas	O
only	O
approximately	O
2	O
-	O
3	O
%	O
of	O
infected	O
individuals	O
develop	O
the	O
disease	O
.	O

Recently	O
,	O
it	O
has	O
been	O
reported	O
that	O
increased	O
plasma	O
concentrations	O
of	O
VEGF	B
were	O
significantly	O
related	O
to	O
high	O
ATL	O
cell	O
infiltration	O
,	O
and	O
the	O
viral	O
transactivator	O
Tax	B
activates	O
the	O
VEGF	B
promoter	O
,	O
linking	O
the	O
induction	O
of	O
angiogenesis	O
to	O
viral	O
gene	O
expression	O
.	O

To	O
investigate	O
whether	O
VEGF	B
promoter	O
-634C	O
/	O
G	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
and	O
serum	O
concentration	O
of	O
VEGF	B
are	O
associated	O
with	O
the	O
development	O
of	O
HAM	O
/	O
TSP	O
,	O
we	O
studied	O
a	O
group	O
of	O
202	O
HAM	O
/	O
TSP	O
patients	O
,	O
202	O
asymptomatic	O
HTLV	O
-	O
I	O
seropositive	O
carriers	O
(	O
HCs	O
)	O
and	O
108	O
seronegative	O
healthy	O
controls	O
(	O
NCs	O
)	O
in	O
Kagoshima	O
,	O
Japan	O
by	O
using	O
PCR	O
-	O
RFLP	O
analysis	O
.	O

The	O
serum	O
concentration	O
of	O
VEGF	B
was	O
also	O
compared	O
among	O
patients	O
with	O
HAM	O
/	O
TSP	O
,	O
ATL	O
,	O
HCs	O
as	O
well	O
as	O
with	O
NCs	O
.	O

Our	O
results	O
indicate	O
that	O
both	O
VEGF	B
gene	O
polymorphism	O
and	O
serum	O
VEGF	B
levels	O
are	O
not	O
specifically	O
associated	O
with	O
the	O
risk	O
of	O
HAM	O
/	O
TSP	O
in	O
our	O
cohort	O
.	O

Candidate	O
gene	O
approach	O
in	O
association	O
studies	O
:	O
would	O
the	O
factor	O
V	O
Leiden	O
mutation	O
have	O
been	O
found	O
by	O
this	O
approach	O
?	O

A	O
re	O
-	O
emerging	O
strategy	O
in	O
the	O
search	O
for	O
disease	O
susceptibility	O
genes	O
is	O
the	O
evaluation	O
of	O
candidate	O
genes	O
,	O
which	O
are	O
thought	O
to	O
play	O
a	O
role	O
in	O
disease	O
pathogenesis	O
.	O

Candidate	O
genes	O
are	O
screened	O
for	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
a	O
case	O
-	O
control	O
study	O
.	O

The	O
factor	O
V	O
Leiden	O
(	O
FVL	O
)	O
mutation	O
(	O
1691	O
G	O
--	O
>	O
A	O
in	O
the	O
F5	B
gene	O
)	O
is	O
an	O
important	O
risk	O
factor	O
for	O
venous	O
thrombosis	O
.	O

We	O
asked	O
ourselves	O
whether	O
the	O
FVL	O
mutation	O
would	O
have	O
been	O
found	O
using	O
the	O
candidate	O
gene	O
approach	O
in	O
the	O
absence	O
of	O
prior	O
knowledge	O
of	O
the	O
haplotype	O
structure	O
of	O
the	O
F5	B
gene	O
.	O

We	O
typed	O
four	O
SNPs	O
in	O
the	O
F5	B
gene	O
in	O
the	O
Leiden	O
Thrombophilia	O
study	O
,	O
that	O
is	O
,	O
promoter	O
(	O
99930	O
G	O
--	O
>	O
A	O
)	O
,	O
exon	O
13	O
(	O
55907A	O
--	O
>	O
G	O
)	O
,	O
exon	O
16	O
(	O
42855A	O
--	O
>	O
G	O
)	O
,	O
and	O
intron	O
19	O
(	O
37833	O
T	O
--	O
>	O
G	O
)	O
.	O

These	O
SNPs	O
were	O
known	O
to	O
have	O
different	O
population	O
frequencies	O
,	O
making	O
their	O
presence	O
in	O
distinct	O
haplotypes	O
likely	O
.	O

None	O
of	O
these	O
SNPs	O
has	O
previously	O
been	O
associated	O
with	O
venous	O
thrombotic	O
risk	O
.	O

Subsequently	O
we	O
derived	O
haplotypes	O
.	O

One	O
haplotype	O
was	O
clearly	O
more	O
frequent	O
in	O
patients	O
than	O
controls	O
(	O
GAAT	O
;	O
20	O
versus	O
9	O
%	O
)	O
,	O
suggesting	O
that	O
a	O
polymorphism	O
in	O
or	O
near	O
the	O
F5	B
gene	O
in	O
this	O
haplotype	O
is	O
associated	O
with	O
an	O
increased	O
thrombotic	O
risk	O
.	O

If	O
we	O
had	O
sequenced	O
the	O
F5	B
gene	O
in	O
patients	O
homozygous	O
for	O
this	O
haplotype	O
,	O
in	O
order	O
to	O
locate	O
the	O
possible	O
causal	O
polymorphism	O
,	O
we	O
would	O
have	O
found	O
that	O
16	O
(	O
76	O
%	O
)	O
patients	O
were	O
homozygous	O
or	O
heterozygous	O
for	O
a	O
missense	O
mutation	O
in	O
exon	O
10	O
(	O
1691	O
G	O
--	O
>	O
A	O
)	O
,	O
which	O
predicts	O
the	O
replacement	O
of	O
Arg506	O
by	O
Gln	O
in	O
one	O
of	O
the	O
cleavage	O
sites	O
for	O
activated	B
protein	I
C	I
,	O
a	O
mutation	O
that	O
we	O
now	O
know	O
as	O
the	O
FVL	O
mutation	O
.	O

Variation	O
of	O
hepatic	O
glucuronidation	O
:	O
Novel	O
functional	O
polymorphisms	O
of	O
the	O
UDP	B
-	I
glucuronosyltransferase	I
UGT1A4	I
.	O

UDP	B
-	I
glucuronosyltransferases	I
are	O
a	O
family	O
of	O
drug	O
metabolizing	O
enzymes	O
contributing	O
to	O
hepatic	O
drug	O
metabolism	O
and	O
protection	O
against	O
environmental	O
toxins	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
polymorphisms	O
at	O
the	O
human	O
UGT1A	B
gene	O
locus	O
and	O
to	O
characterize	O
their	O
function	O
and	O
potential	O
association	O
with	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
.	O

Genomic	O
DNA	O
from	O
the	O
blood	O
of	O
363	O
subjects	O
(	O
128	O
patients	O
with	O
HCC	O
,	O
235	O
blood	O
donors	O
)	O
was	O
analyzed	O
for	O
polymorphisms	O
of	O
the	O
UGT1A3	B
,	O
UGT1A4	B
,	O
UGT1A8	B
,	O
UGT1A9	B
,	O
UGT1A1	B
,	O
UGT1A10	B
genes	O
using	O
polymerase	O
chain	O
reaction	O
,	O
sequencing	O
analysis	O
.	O

Recombinant	O
variant	O
UGT	B
protein	O
was	O
analyzed	O
by	O
activity	O
assays	O
.	O

In	O
the	O
UGT1A8	B
gene	O
an	O
A173	O
G	O
variant	O
and	O
a	O
conserved	O
G	O
to	O
A	O
exchange	O
at	O
position	O
765	O
were	O
detected	O
in	O
25	O
%	O
and	O
15	O
%	O
.	O

UGT1A9	B
exhibited	O
two	O
variants	O
C3Y	O
and	O
M33	O
T	O
in	O
1	O
%	O
and	O
3	O
%	O
.	O

UGT1A1	B
,	O
UGT1A10	B
exhibited	O
conserved	O
nucleotide	O
exchanges	O
(	O
128	O
G-->A	O
and	O
696	O
C-->T	O
)	O
in	O
2	O
%	O
and	O
13	O
%	O
.	O

In	O
the	O
UGT1A3	B
gene	O
a	O
W11R	O
,	O
a	O
V47A	O
variant	O
,	O
and	O
a	O
conserved	O
G	O
to	O
A	O
exchange	O
at	O
position	O
81	O
with	O
an	O
incidence	O
of	O
65	O
%	O
,	O
58	O
%	O
,	O
and	O
65	O
%	O
,	O
respectively	O
,	O
were	O
identified	O
.	O

UGT1A4	B
exhibited	O
a	O
P24	O
T	O
and	O
an	O
L48V	O
variant	O
in	O
8	O
%	O
and	O
9	O
%	O
.	O

UGT1A	B
SNPs	O
were	O
not	O
associated	O
with	O
HCC	O
.	O

UGT1A4	O
P24	O
T	O
and	O
L48V	O
exhibited	O
reduced	O
glucuronidation	O
activities	O
:	O
beta	O
-	O
naphthylamine	O
30	O
%	O
and	O
50	O
%	O
,	O
and	O
dihydrotestosterone	O
50	O
%	O
and	O
0	O
%	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
the	O
high	O
prevalence	O
of	O
SNPs	O
throughout	O
the	O
human	O
UGT1A	B
gene	O
locus	O
illustrates	O
a	O
genetic	O
basis	O
of	O
interindividual	O
variations	O
of	O
hepatic	O
metabolism	O
.	O

Two	O
polymorphisms	O
of	O
the	O
hepatic	O
UGT1A4	B
protein	O
show	O
a	O
differential	O
metabolic	O
activity	O
toward	O
mutagenic	O
amines	O
and	O
endogenous	O
steroids	O
,	O
altering	O
hepatic	O
metabolism	O
and	O
detoxification	O
.	O

A	O
single	O
-	O
nucleotide	O
polymorphism	O
in	O
the	O
human	O
p27kip1	B
gene	O
(	O
-838C	O
>	O
A	O
)	O
affects	O
basal	O
promoter	O
activity	O
and	O
the	O
risk	O
of	O
myocardial	O
infarction	O
.	O

BACKGROUND	O
:	O
Excessive	O
proliferation	O
of	O
vascular	O
smooth	O
muscle	O
cells	O
and	O
leukocytes	O
within	O
the	O
artery	O
wall	O
is	O
a	O
major	O
event	O
in	O
the	O
development	O
of	O
atherosclerosis	O
.	O

The	O
growth	O
suppressor	O
p27kip1	B
associates	O
with	O
several	O
cyclin	O
-	O
dependent	O
kinase	O
/	O
cyclin	O
complexes	O
,	O
thereby	O
abrogating	O
their	O
capacity	O
to	O
induce	O
progression	O
through	O
the	O
cell	O
cycle	O
.	O

Recent	O
studies	O
have	O
implicated	O
p27kip1	B
in	O
the	O
control	O
of	O
neointimal	O
hyperplasia	O
.	O

For	O
instance	O
,	O
p27kip1	B
ablation	O
in	O
apolipoprotein	B
-	I
E	I
-	O
null	O
mice	O
enhanced	O
arterial	O
cell	O
proliferation	O
and	O
accelerated	O
atherogenesis	O
induced	O
by	O
dietary	O
cholesterol	O
.	O

Therefore	O
,	O
p27kip1	B
is	O
a	O
candidate	O
gene	O
to	O
modify	O
the	O
risk	O
of	O
developing	O
atherosclerosis	O
and	O
associated	O
ischaemic	O
events	O
(	O
i.e.	O
,	O
myocardial	O
infarction	O
and	O
stroke	O
)	O
.	O

RESULTS	O
:	O
In	O
this	O
study	O
we	O
found	O
three	O
common	O
single	O
-	O
nucleotide	O
polymorphisms	O
in	O
the	O
human	O
p27kip1	B
gene	O
(	O
+	O
326T	O
>	O
G	O
[	O
V109	O
G	O
]	O
,	O
-79C	O
>	O
T	O
,	O
and	O
-838C	O
>	O
A	O
)	O
.	O

The	O
frequency	O
of	O
-838A	O
carriers	O
was	O
significantly	O
increased	O
in	O
myocardial	O
infarction	O
patients	O
compared	O
to	O
healthy	O
controls	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
1.73	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
95%CI	O
]	O
=	O
1.12	O
-	O
2.70	O
)	O
.	O

In	O
addition	O
,	O
luciferase	O
reporter	O
constructs	O
driven	O
by	O
the	O
human	O
p27kip1	B
gene	O
promoter	O
containing	O
A	O
at	O
position	O
-838	O
had	O
decreased	O
basal	O
transcriptional	O
activity	O
when	O
transiently	O
transfected	O
in	O
Jurkat	O
cells	O
,	O
compared	O
with	O
constructs	O
bearing	O
C	O
in	O
-838	O
(	O
P	O
=	O
0.04	O
)	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
suggest	O
that	O
-838A	O
is	O
associated	O
with	O
reduced	O
p27kip1	B
promoter	O
activity	O
and	O
increased	O
risk	O
of	O
myocardial	O
infarction	O
.	O

Chromosome	O
11	O
monosomy	O
in	O
conjunction	O
with	O
a	O
mutated	O
SDHD	B
initiation	O
codon	O
in	O
nonfamilial	O
paraganglioma	O
cases	O
.	O

Paragangliomas	O
of	O
the	O
head	O
and	O
neck	O
region	O
are	O
a	O
group	O
of	O
rare	O
,	O
usually	O
benign	O
,	O
slow	O
-	O
growing	O
tumors	O
developing	O
from	O
paraganglionic	O
chemoreceptors	O
in	O
most	O
patients	O
.	O

Mutations	O
in	O
a	O
subunit	O
of	O
the	O
mitochondrial	B
enzyme	I
II	I
complex	I
(	O
succinate	B
dehydrogenase	I
[	I
SDHD	I
]	I
)	O
were	O
shown	O
to	O
be	O
responsible	O
for	O
the	O
formation	O
of	O
paragangliomas	O
.	O

In	O
addition	O
,	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
on	O
chromosome	O
11	O
,	O
mainly	O
in	O
11q23	O
(	O
PGL1	B
)	O
,	O
was	O
observed	O
recently	O
.	O

We	O
analyzed	O
DNA	O
derived	O
from	O
tumor	O
sections	O
of	O
three	O
unrelated	O
paraganglioma	O
patients	O
(	O
one	O
case	O
with	O
multiple	O
paragangliomas	O
,	O
two	O
cases	O
with	O
single	O
tumors	O
;	O
all	O
of	O
them	O
sporadic	O
cases	O
)	O
for	O
mutations	O
in	O
the	O
SDHD	B
gene	O
by	O
direct	O
sequencing	O
.	O

Microsatellite	O
-	O
based	O
LOH	O
was	O
performed	O
,	O
and	O
events	O
of	O
chromosomal	O
loss	O
were	O
validated	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
on	O
paraffin	O
-	O
embedded	O
tumor	O
and	O
normal	O
tissue	O
by	O
using	O
centromeric	O
satellite	O
DNA	O
.	O

Sequence	O
analysis	O
revealed	O
mutations	O
in	O
SDHD	B
exon	O
1	O
in	O
all	O
patients	O
,	O
affecting	O
the	O
initiation	O
codon	O
(	O
M1V	O
)	O
.	O

Another	O
alteration	O
was	O
detected	O
in	O
exon	O
2	O
but	O
was	O
lacking	O
in	O
tumor	O
DNA	O
and	O
therefore	O
classified	O
as	O
polymorphism	O
(	O
H50R	O
)	O
.	O

LOH	O
and	O
FISH	O
analyses	O
demonstrated	O
partial	O
/	O
total	O
monosomy	O
for	O
chromosome	O
11	O
in	O
the	O
tumor	O
samples	O
tested	O
.	O

A	O
common	O
genetic	O
mechanism	O
appears	O
to	O
be	O
the	O
pathophysiologic	O
basis	O
for	O
sporadic	O
tumor	O
development	O
because	O
the	O
proposed	O
two	O
-	O
hit	O
model	O
comprising	O
both	O
LOH	O
and	O
point	O
mutation	O
is	O
manifest	O
in	O
our	O
patients	O
.	O

Loss	O
of	O
chromosome	O
11	O
regions	O
,	O
including	O
the	O
deletion	O
of	O
PGL1	B
and	O
PGL2	B
loci	O
,	O
may	O
result	O
in	O
a	O
more	O
severe	O
phenotype	O
,	O
as	O
exemplified	O
by	O
the	O
development	O
of	O
multiple	O
tumors	O
in	O
one	O
of	O
the	O
patients	O
.	O

The	O
glutathione	B
S	I
-	I
transferase	I
polymorphisms	O
in	O
a	O
control	O
population	O
and	O
in	O
Alzheimer	O
's	O
disease	O
patients	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
glutathione	B
S	I
-	I
transferase	I
P1	I
(	O
GSTP1	B
)	O
polymorphisms	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

We	O
genotyped	O
the	O
GSTP1	B
polymorphisms	O
in	O
exon	O
5	O
(	O
A313	O
G	O
)	O
and	O
exon	O
6	O
(	O
C341	O
T	O
)	O
by	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
in	O
56	O
Croatian	O
patients	O
with	O
AD	O
and	O
231	O
controls	O
.	O

Distributions	O
and	O
frequencies	O
of	O
GSTP1	B
genetic	O
variants	O
were	O
not	O
statistically	O
different	O
between	O
AD	O
patients	O
and	O
healthy	O
controls	O
.	O

Higher	O
frequencies	O
of	O
the	O
mutant	O
genotypes	O
were	O
observed	O
in	O
AD	O
patients	O
(	O
13	O
%	O
for	O
both	O
A313	O
G	O
and	O
C341	O
T	O
)	O
when	O
compared	O
with	O
control	O
subjects	O
(	O
7	O
%	O
for	O
A313	O
G	O
and	O
8	O
%	O
for	O
C341	O
T	O
)	O
,	O
but	O
association	O
of	O
GSTP1	B
GG	O
(	O
OR	O
2.057	O
,	O
95	O
%	O
CI	O
0.796	O
-	O
5.315	O
,	O
p=0.094	O
)	O
and	O
TT	O
(	O
OR	O
1.691	O
,	O
95	O
%	O
CI	O
0.669	O
-	O
4.270	O
,	O
p=0.514	O
)	O
genotypes	O
with	O
an	O
increased	O
risk	O
of	O
AD	O
was	O
not	O
confirmed	O
by	O
statistical	O
analysis	O
.	O

The	O
frequencies	O
of	O
GSTP1	B
alleles	O
(	O
A	O
,	O
B	O
,	O
C	O
,	O
D	O
)	O
did	O
not	O
significantly	O
differ	O
between	O
AD	O
patients	O
and	O
controls	O
and	O
they	O
were	O
indicated	O
as	O
follows	O
:	O
52.7	O
%	O
,	O
15.2	O
%	O
,	O
12.5	O
%	O
and	O
19.6	O
%	O
for	O
AD	O
cases	O
and	O
58.4	O
%	O
,	O
14.1	O
%	O
,	O
14.1	O
%	O
and	O
13.4	O
%	O
for	O
controls	O
.	O

The	O
estimation	O
of	O
the	O
GSTP1	B
haplotype	O
distribution	O
showed	O
that	O
GSTP1*A	B
/	O
GSTP1*B	B
and	O
GSTP1*A	B
/	O
GSTP1*C	B
haplotypes	O
were	O
less	O
frequent	O
,	O
while	O
GSTP1*B	B
/	O
GSTP1*B	B
and	O
GSTP1*C	B
/	O
GSTP1*D	B
haplotypes	O
were	O
more	O
frequent	O
in	O
AD	O
patients	O
than	O
in	O
controls	O
.	O

In	O
conclusion	O
,	O
the	O
involvement	O
of	O
GSTP1	B
alleles	O
in	O
individual	O
susceptibility	O
to	O
AD	O
was	O
not	O
confirmed	O
as	O
statistically	O
significant	O
in	O
the	O
tested	O
Croatian	O
Caucasian	O
population	O
.	O

A	O
possible	O
role	O
of	O
GSTP1	B
in	O
the	O
complex	O
etiopathogenesis	O
of	O
AD	O
is	O
further	O
discussed	O
,	O
based	O
on	O
observed	O
differences	O
in	O
haplotype	O
distribution	O
and	O
higher	O
frequencies	O
of	O
mutant	O
genotypes	O
in	O
AD	O
patients	O
.	O

Estrogen	B
receptor	I
-	I
alpha	I
polymorphism	O
in	O
a	O
Taiwanese	O
clinical	O
breast	O
cancer	O
population	O
:	O
a	O
case	O
-	O
control	O
study	O
.	O

INTRODUCTION	O
:	O
Receptor	O
-	O
mediated	O
estrogen	O
activation	O
participates	O
in	O
the	O
development	O
and	O
progression	O
of	O
breast	O
cancer	O
.	O

Estrogen	B
receptor	I
(	I
ER	I
)	I
-alpha	I
polymorphism	O
has	O
been	O
found	O
to	O
be	O
associated	O
with	O
breast	O
cancer	O
and	O
clinical	O
features	O
of	O
the	O
disease	O
in	O
Caucasians	O
.	O

Epidemiologic	O
studies	O
have	O
revealed	O
that	O
age	O
-	O
incidence	O
patterns	O
of	O
breast	O
cancer	O
in	O
Asians	O
differ	O
from	O
those	O
in	O
Caucasians	O
.	O

Genomic	O
data	O
for	O
ER	B
-	I
alpha	I
in	O
either	O
population	O
is	O
therefore	O
of	O
value	O
in	O
the	O
clinical	O
setting	O
for	O
that	O
ethnic	O
group	O
.	O

METHODS	O
:	O
A	O
case	O
-	O
control	O
study	O
was	O
conducted	O
to	O
establish	O
a	O
database	O
of	O
ER	B
-	I
alpha	I
polymorphisms	O
in	O
a	O
Taiwanese	O
population	O
in	O
order	O
to	O
compare	O
Western	O
and	O
Taiwanese	O
(	O
Asian	O
)	O
distributions	O
and	O
to	O
evaluate	O
ER	B
-	I
alpha	I
polymorphism	O
as	O
an	O
indicator	O
of	O
clinical	O
outcome	O
.	O

The	O
ER	B
-	I
alpha	I
gene	O
was	O
scanned	O
in	O
a	O
Taiwanese	O
clinical	O
breast	O
cancer	O
group	O
(	O
189	O
patients	O
)	O
and	O
in	O
healthy	O
individuals	O
(	O
177	O
healthy	O
control	O
individuals	O
)	O
.	O

PCR	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
technology	O
was	O
employed	O
and	O
real	O
-	O
time	O
PCR	O
melting	O
curve	O
analysis	O
was	O
performed	O
.	O

RESULTS	O
:	O
Three	O
sites	O
of	O
silent	O
single	O
nucleotide	O
polymorphism	O
(	O
SNPs	O
)	O
were	O
found	O
,	O
as	O
reported	O
previously	O
in	O
Western	O
studies	O
,	O
but	O
at	O
significantly	O
different	O
frequencies	O
.	O

Among	O
the	O
three	O
SNPs	O
,	O
the	O
frequency	O
of	O
allele	O
1	O
(	O
TCT	O
--	O
>	O
TCC	O
)	O
in	O
codon	O
10	O
was	O
significantly	O
lower	O
in	O
breast	O
cancer	O
patients	O
(	O
32.0	O
%	O
)	O
than	O
in	O
control	O
individuals	O
(	O
40.4	O
%	O
;	O
P	O
=	O
0.018	O
)	O
.	O

We	O
found	O
that	O
allele	O
1	O
(	O
ACG	O
--	O
>	O
ACA	O
)	O
in	O
codon	O
594	O
was	O
less	O
common	O
in	O
breast	O
cancer	O
patients	O
with	O
a	O
family	O
history	O
of	O
breast	O
cancer	O
(	O
5.9	O
%	O
)	O
than	O
in	O
those	O
without	O
such	O
a	O
history	O
(	O
19.6	O
%	O
;	O
P	O
=	O
0.049	O
)	O
.	O

Individually	O
,	O
both	O
allele	O
1	O
in	O
codon	O
325	O
(	O
CCC	O
--	O
>	O
CCG	O
)	O
and	O
allele	O
1	O
in	O
codon	O
594	O
exhibited	O
a	O
reverse	O
association	O
with	O
the	O
occurrence	O
of	O
lymph	O
node	O
metastasis	O
.	O

Furthermore	O
,	O
incorporation	O
of	O
both	O
SNP	O
markers	O
further	O
increased	O
predictive	O
accuracy	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
ER	B
-	I
alpha	I
polymorphisms	O
are	O
correlated	O
with	O
various	O
aspects	O
of	O
breast	O
cancer	O
in	O
Taiwan	O
.	O

ER	B
-	I
alpha	I
genotype	O
,	O
as	O
determined	O
during	O
presurgical	O
evaluation	O
,	O
might	O
represent	O
a	O
surrogate	O
marker	O
for	O
predicting	O
breast	O
cancer	O
lymph	O
node	O
metastasis	O
.	O

Is	O
NOTCH4	B
associated	O
with	O
schizophrenia	O
?	O

The	O
NOTCH4	B
locus	O
was	O
reported	O
to	O
be	O
associated	O
with	O
schizophrenia	O
in	O
our	O
previous	O
study	O
but	O
the	O
subsequent	O
replication	O
by	O
other	O
workers	O
has	O
been	O
inconsistent	O
.	O

To	O
find	O
out	O
possible	O
reasons	O
for	O
the	O
poor	O
replication	O
,	O
the	O
present	O
work	O
was	O
undertaken	O
to	O
analyse	O
four	O
functional	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
(	O
rs367398	O
,	O
rs915894	O
,	O
rs520692	O
and	O
rs422951	O
)	O
at	O
the	O
NOTCH4	B
locus	O
among	O
141	O
schizophrenic	O
family	O
trios	O
of	O
Chinese	O
Han	O
descent	O
.	O

Of	O
these	O
four	O
SNPs	O
,	O
rs520692	O
was	O
the	O
only	O
one	O
associated	O
with	O
schizophrenia	O
(	O
P	O
=	O
0.017	O
)	O
;	O
the	O
other	O
three	O
,	O
however	O
,	O
did	O
not	O
show	O
any	O
association	O
with	O
the	O
illness	O
,	O
including	O
rs367398	O
located	O
in	O
the	O
promoter	O
region	O
,	O
which	O
had	O
shown	O
a	O
strong	O
association	O
with	O
the	O
illness	O
in	O
our	O
previous	O
study	O
conducted	O
with	O
British	O
samples	O
.	O

Although	O
these	O
four	O
SNPs	O
analysed	O
lie	O
within	O
a	O
less	O
than	O
4	O
kb	O
segment	O
of	O
genomic	O
DNA	O
,	O
the	O
pattern	O
of	O
linkage	O
disequilibrium	O
between	O
them	O
was	O
unexpected	O
.	O

The	O
strongest	O
linkage	O
disequilibrium	O
was	O
shown	O
only	O
between	O
rs367398	O
and	O
rs520692	O
and	O
between	O
rs520692	O
and	O
rs422951	O
in	O
both	O
parent	O
and	O
patient	O
groups	O
.	O

This	O
study	O
raises	O
the	O
possibility	O
that	O
there	O
might	O
be	O
two	O
or	O
more	O
disease	O
-	O
underlying	O
variants	O
at	O
the	O
NOTCH4	B
locus	O
or	O
at	O
a	O
nearby	O
locus	O
,	O
and	O
that	O
the	O
allelic	O
or	O
locus	O
heterogeneity	O
may	O
be	O
one	O
of	O
the	O
possible	O
reasons	O
for	O
the	O
poor	O
replication	O
of	O
the	O
NOTCH4	B
finding	O
.	O

Polymorphisms	O
of	O
microsomal	B
triglyceride	I
transfer	I
protein	I
gene	O
and	O
manganese	B
superoxide	I
dismutase	I
gene	O
in	O
non	O
-	O
alcoholic	O
steatohepatitis	O
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
The	O
pathogenesis	O
of	O
non	O
-	O
alcoholic	O
steatohepatitis	O
(	O
NASH	O
)	O
is	O
poorly	O
understood	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
genetic	O
influences	O
on	O
NASH	O
pathogenesis	O
.	O

METHODS	O
:	O
Blood	O
samples	O
from	O
63	O
patients	O
with	O
biopsy	O
-	O
proven	O
NASH	O
and	O
150	O
healthy	O
controls	O
were	O
analyzed	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
.	O

Two	O
functional	O
polymorphisms	O
were	O
studied	O
:	O
the	O
-493	O
G	O
/	O
T	O
polymorphism	O
in	O
the	O
promoter	O
of	O
microsomal	B
triglyceride	I
transfer	I
protein	I
(	O
MTP	B
)	O
and	O
the	O
1183	O
T	O
/	O
C	O
polymorphism	O
in	O
the	O
mitochondrial	O
targeting	O
sequence	O
of	O
manganese	B
superoxide	I
dismutase	I
(	O
MnSOD	B
)	O
.	O

RESULTS	O
:	O
NASH	O
patients	O
had	O
a	O
much	O
higher	O
incidence	O
of	O
the	O
MTP	B
gene	O
G	O
allele	O
(	O
P=0.001	O
)	O
and	O
of	O
the	O
G	O
/	O
G	O
genotype	O
(	O
P=0.002	O
)	O
compared	O
to	O
the	O
controls	O
.	O

Fat	O
occupied	O
more	O
area	O
in	O
liver	O
lobules	O
and	O
the	O
stage	O
of	O
NASH	O
was	O
advanced	O
in	O
patients	O
with	O
the	O
G	O
/	O
G	O
-	O
genotype	O
than	O
in	O
patients	O
with	O
G	O
/	O
T	O
-	O
genotype	O
(	O
P=0.04	O
)	O
.	O

NASH	O
patients	O
also	O
had	O
a	O
higher	O
incidence	O
of	O
the	O
MnSOD	B
T	O
/	O
T	O
genotype	O
(	O
P=0.016	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
G	O
allele	O
in	O
the	O
MTP	B
promoter	O
leads	O
to	O
decreased	O
MTP	B
transcription	O
,	O
less	O
export	O
of	O
triglyceride	O
from	O
hepatocytes	O
,	O
and	O
greater	O
intracellular	O
triglyceride	O
accumulation	O
.	O

The	O
T	O
allele	O
in	O
MnSOD	B
mitochondrial	O
targeting	O
sequence	O
leads	O
to	O
less	O
transport	O
of	O
MnSOD	B
to	O
the	O
mitochondria	O
.	O

Therefore	O
,	O
functional	O
polymorphisms	O
in	O
MTP	B
and	O
MnSOD	B
may	O
be	O
involved	O
in	O
determining	O
susceptibility	O
of	O
NASH	O
.	O

The	O
894	O
G	O
>	O
T	O
variant	O
of	O
endothelial	B
nitric	I
oxide	I
synthase	I
(	O
eNOS	B
)	O
increases	O
the	O
risk	O
of	O
recurrent	O
venous	O
thrombosis	O
through	O
interaction	O
with	O
elevated	O
homocysteine	O
levels	O
.	O

BACKGROUND	O
:	O
Venous	O
thrombosis	O
is	O
a	O
multicausal	O
disease	O
involving	O
both	O
genetic	O
as	O
well	O
as	O
acquired	O
risk	O
factors	O
.	O

Hyperhomocysteinemia	O
is	O
associated	O
with	O
a	O
2-fold	O
increased	O
risk	O
of	O
recurrent	O
venous	O
thrombosis	O
(	O
RVT	O
)	O
.	O

Recently	O
,	O
the	O
894	O
G	O
>	O
T	O
variant	O
of	O
endothelial	B
nitric	I
oxide	I
synthase	I
(	O
eNOS	B
)	O
was	O
postulated	O
to	O
be	O
associated	O
with	O
hyperhomocysteinemia	O
.	O

OBJECTIVES	O
:	O
We	O
hypothesized	O
an	O
interrelation	O
of	O
hyperhomocysteinemia	O
,	O
the	O
eNOS	B
894	O
G	O
>	O
T	O
variant	O
and	O
RVT	O
risk	O
.	O

METHODS	O
:	O
The	O
eNOS	B
894	O
G	O
>	O
T	O
variant	O
was	O
studied	O
in	O
170	O
cases	O
with	O
a	O
history	O
of	O
RVT	O
and	O
433	O
controls	O
from	O
the	O
general	O
population	O
.	O

RESULTS	O
:	O
The	O
eNOS	B
894	O
TT	O
genotype	O
may	O
increase	O
RVT	O
risk	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
1.3	O
(	O
0.7	O
-	O
2.6	O
)	O
]	O
,	O
but	O
no	O
association	O
of	O
the	O
eNOS	B
894	O
G	O
>	O
T	O
variant	O
with	O
elevated	O
homocysteine	O
was	O
found	O
in	O
controls	O
.	O

Interestingly	O
,	O
in	O
RVT	O
cases	O
the	O
coexistence	O
of	O
both	O
the	O
894	O
TT	O
genotype	O
and	O
elevated	O
tHcy	O
levels	O
(	O
>	O
90th	O
percentile	O
)	O
was	O
more	O
frequently	O
present	O
than	O
in	O
controls	O
,	O
which	O
led	O
to	O
a	O
substantially	O
increased	O
risk	O
of	O
recurrent	O
venous	O
thrombosis	O
[	O
fasting	O
tHcy	O
OR	O
5.3	O
(	O
1.1	O
-	O
24.1	O
)	O
,	O
postload	O
tHcy	O
OR	O
6.5	O
(	O
1.6	O
-	O
29.5	O
)	O
]	O
.	O

CONCLUSION	O
:	O
The	O
results	O
of	O
the	O
present	O
study	O
demonstrate	O
that	O
the	O
eNOS	B
894	O
G	O
>	O
T	O
variation	O
interacts	O
with	O
elevated	O
tHcy	O
levels	O
,	O
leading	O
to	O
an	O
increased	O
risk	O
of	O
recurrent	O
thrombotic	O
events	O
.	O

This	O
interaction	O
points	O
in	O
the	O
direction	O
of	O
S	O
-	O
nitrosation	O
as	O
a	O
mechanism	O
by	O
which	O
homocysteine	O
exerts	O
its	O
detrimental	O
effects	O
on	O
the	O
hemostatic	O
system	O
.	O

Association	O
between	O
-250G	O
/	O
A	O
polymorphism	O
of	O
the	O
hepatic	B
lipase	I
gene	O
promoter	O
and	O
coronary	O
artery	O
disease	O
and	O
HDL	O
-	O
C	O
levels	O
in	O
a	O
Southern	O
Brazilian	O
population	O
.	O

Hepatic	B
lipase	I
(	O
HL	B
)	O
is	O
a	O
glycoprotein	O
that	O
plays	O
a	O
major	O
role	O
in	O
remodeling	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
.	O

The	O
effect	O
of	O
the	O
-250G	O
/	O
A	O
promoter	O
polymorphism	O
on	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
and	O
lipid	O
levels	O
was	O
studied	O
in	O
231	O
male	O
CAD	O
patients	O
and	O
in	O
a	O
population	O
-	O
based	O
sample	O
of	O
men	O
and	O
women	O
(	O
n	O
=	O
514	O
)	O
.	O

A	O
sample	O
of	O
140	O
men	O
was	O
chosen	O
among	O
those	O
included	O
in	O
the	O
population	O
-	O
based	O
sample	O
as	O
controls	O
for	O
the	O
CAD	O
sample	O
.	O

In	O
the	O
total	O
group	O
of	O
CAD	O
patients	O
,	O
the	O
frequency	O
of	O
the	O
-250A	O
allele	O
was	O
somewhat	O
lower	O
(	O
25	O
%	O
in	O
CAD	O
patients	O
and	O
32	O
%	O
in	O
controls	O
;	O
p	O
=	O
0.06	O
)	O
,	O
but	O
when	O
the	O
control	O
samples	O
were	O
compared	O
only	O
with	O
the	O
CAD	O
(	O
+	O
)	O
sample	O
(	O
more	O
than	O
60	O
%	O
of	O
luminal	O
stenosis	O
in	O
at	O
least	O
one	O
coronary	O
artery	O
or	O
major	O
branch	O
segment	O
)	O
the	O
-250A	O
allele	O
was	O
significantly	O
less	O
frequent	O
(	O
23	O
%	O
in	O
the	O
patients	O
vs	O
32	O
%	O
in	O
controls	O
;	O
p	O
=	O
0.02	O
)	O
.	O

A	O
multiple	O
logistic	O
regression	O
analysis	O
showed	O
that	O
this	O
association	O
was	O
independent	O
of	O
classical	O
CAD	O
risk	O
factors	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
1.79	O
,	O
p	O
=	O
0.025	O
]	O
.	O

Using	O
multiple	O
linear	O
regression	O
analyses	O
,	O
it	O
has	O
been	O
shown	O
that	O
this	O
polymorphism	O
was	O
a	O
significant	O
factor	O
affecting	O
HDL	O
-	O
C	O
levels	O
in	O
men	O
from	O
the	O
population	O
-	O
based	O
sample	O
(	O
p	O
=	O
0.001	O
)	O
,	O
an	O
interaction	O
between	O
-250G	O
/	O
A	O
variant	O
and	O
wine	O
consumption	O
was	O
also	O
detected	O
(	O
p	O
=	O
0.001	O
)	O
.	O

Thus	O
,	O
our	O
results	O
show	O
that	O
the	O
-250G	O
/	O
A	O
polymorphism	O
in	O
the	O
HL	B
gene	O
is	O
associated	O
with	O
significant	O
variations	O
in	O
HDL	O
-	O
C	O
levels	O
and	O
CAD	O
risk	O
in	O
males	O
.	O

p53	B
and	O
p21	B
genetic	O
polymorphisms	O
and	O
susceptibility	O
to	O
endometrial	O
cancer	O
.	O

OBJECTIVE	O
:	O
Recently	O
,	O
there	O
has	O
been	O
considerable	O
interest	O
in	O
the	O
association	O
of	O
specific	O
cancers	O
with	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
.	O

In	O
this	O
regard	O
,	O
genetic	O
polymorphism	O
at	O
codon	O
72	O
(	O
CCC	O
/	O
proline	O
to	O
CGC	O
/	O
arginine	O
[	O
Pro	O
(	O
72	O
)	O
Arg	O
]	O
)	O
of	O
the	O
p53	B
gene	O
is	O
one	O
of	O
the	O
most	O
frequently	O
studied	O
subjects	O
.	O

An	O
association	O
between	O
endometrial	O
cancer	O
and	O
the	O
polymorphism	O
at	O
codon	O
31	O
(	O
AGC	O
/	O
serine	O
to	O
AGA	O
/	O
arginine	O
[	O
Ser	O
(	O
31	O
)	O
Arg	O
]	O
)	O
of	O
the	O
p21	B
gene	O
,	O
which	O
is	O
known	O
to	O
be	O
a	O
downstream	O
mediator	O
of	O
p53	B
,	O
has	O
also	O
been	O
reported	O
.	O

METHODS	O
:	O
The	O
authors	O
designed	O
a	O
hospital	O
-	O
based	O
case	O
-	O
control	O
study	O
of	O
95	O
endometrial	O
cancer	O
patients	O
and	O
285	O
non	O
-	O
cancer	O
controls	O
.	O

For	O
the	O
determination	O
of	O
p53	B
and	O
p21	B
polymorphism	O
,	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
PCR	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
assay	O
was	O
applied	O
,	O
respectively	O
.	O

RESULTS	O
:	O
We	O
found	O
statistically	O
significant	O
differences	O
in	O
the	O
frequency	O
of	O
the	O
p53	B
and	O
p21	B
genotypes	O
between	O
these	O
two	O
groups	O
(	O
P	O
<	O
0.001	O
)	O
,	O
respectively	O
.	O

The	O
p53	B
genotypes	O
containing	O
the	O
Pro	O
allele	O
were	O
significantly	O
associated	O
with	O
endometrial	O
cancer	O
with	O
an	O
odds	O
ratio	O
(	O
OR	O
)	O
of	O
3.56	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
2.10	O
-	O
6.04	O
)	O
.	O

Also	O
,	O
homozygous	O
carriers	O
of	O
the	O
p21	B
Ser	O
allele	O
showed	O
a	O
substantially	O
increased	O
risk	O
of	O
developing	O
endometrial	O
cancer	O
(	O
OR	O
2.68	O
,	O
95	O
%	O
CI	O
1.59	O
-	O
4.51	O
)	O
as	O
compared	O
to	O
homozygous	O
and	O
heterozygous	O
carriers	O
of	O
the	O
Arg	O
allele	O
.	O

In	O
addition	O
,	O
the	O
combination	O
of	O
the	O
pro	O
allele	O
containing	O
genotypes	O
of	O
p53	B
and	O
the	O
Ser	O
homozygous	O
genotype	O
of	O
p21	B
posed	O
a	O
remarkably	O
increased	O
risk	O
(	O
OR	O
9.55	O
,	O
95	O
%	O
CI	O
4.30	O
-	O
21.24	O
)	O
of	O
endometrial	O
cancer	O
development	O
.	O

These	O
significant	O
differences	O
were	O
maintained	O
throughout	O
the	O
groups	O
after	O
they	O
were	O
stratified	O
by	O
menopausal	O
status	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
suggest	O
that	O
there	O
is	O
a	O
significant	O
association	O
between	O
the	O
genetic	O
polymorphisms	O
of	O
p53	B
,	O
p21	B
,	O
and	O
specific	O
combinations	O
of	O
the	O
at	O
-	O
risk	O
genotypes	O
of	O
these	O
genes	O
and	O
the	O
risk	O
of	O
developing	O
endometrial	O
cancer	O
in	O
Korean	O
women	O
.	O

Ethnic	O
differences	O
in	O
polymorphisms	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
,	O
interleukin-10	B
,	O
and	O
transforming	B
growth	I
factor	I
-	I
beta1	I
genes	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
virus	O
infection	O
.	O

Ethnic	O
differences	O
in	O
the	O
outcome	O
of	O
hepatitis	O
C	O
have	O
been	O
described	O
.	O

Our	O
aim	O
was	O
to	O
investigate	O
ethnic	O
differences	O
in	O
the	O
distribution	O
of	O
genotypes	O
associated	O
with	O
polymorphisms	O
of	O
the	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
promoter	O
,	O
interleukin-10	B
promoter	O
,	O
and	O
transforming	B
growth	I
factor	I
-	I
beta1	I
leader	O
sequence	O
in	O
patients	O
with	O
hepatitis	O
C.	O
Genomic	O
DNA	O
was	O
obtained	O
from	O
71	O
Egyptians	O
and	O
67	O
Caucasians	O
(	O
hepatitis	O
C	O
and	O
control	O
patients	O
)	O
.	O

Amplification	O
of	O
appropriate	O
gene	O
segments	O
was	O
followed	O
by	O
direct	O
sequencing	O
.	O

Infrequently	O
occurring	O
polymorphisms	O
were	O
identified	O
at	O
positions	O
-244	O
and	O
-77	O
of	O
the	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
promoter	O
and	O
at	O
positions	O
-851	O
and	O
-657	O
of	O
the	O
interleukin-10	B
promoter	O
.	O

The	O
G	O
/	O
A	O
genotype	O
associated	O
with	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
promoter	O
positions	O
-376	O
and	O
-244	O
was	O
more	O
frequent	O
in	O
Egyptians	O
(	O
P	O
=	O
0.001	O
and	O
P	O
=	O
0.004	O
,	O
respectively	O
)	O
.	O

The	O
-244	O
G	O
/	O
A	O
genotype	O
occurred	O
only	O
in	O
healthy	O
Egyptians	O
(	O
P	O
=	O
0.024	O
)	O
.	O

Thus	O
,	O
ethnic	O
differences	O
in	O
the	O
distribution	O
of	O
genotypes	O
of	O
the	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
promoter	O
exist	O
,	O
which	O
may	O
have	O
clinical	O
implications	O
on	O
the	O
outcome	O
of	O
hepatitis	O
C.	O

Functional	O
consequences	O
of	O
ATM	B
sequence	O
variants	O
for	O
chromosomal	O
radiosensitivity	O
.	O

The	O
ATM	B
[	O
for	O
ataxia	B
-	I
telangiectasia	I
(	I
A	I
-	I
T	I
)	I
mutated	I
]	O
protein	O
plays	O
a	O
key	O
role	O
in	O
the	O
detection	O
and	O
cellular	O
response	O
to	O
DNA	O
double	O
-	O
strand	O
breaks	O
.	O

Several	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
have	O
been	O
described	O
in	O
the	O
ATM	B
gene	O
;	O
however	O
,	O
their	O
association	O
with	O
cancer	O
risk	O
or	O
radiosensitivity	O
remains	O
to	O
be	O
fully	O
established	O
.	O

In	O
this	O
study	O
,	O
the	O
functional	O
consequences	O
of	O
specific	O
ATM	B
SNPs	O
on	O
in	O
vitro	O
radiosensitivity	O
,	O
as	O
assessed	O
by	O
micronuclei	O
(	O
MN	O
)	O
formation	O
,	O
were	O
measured	O
in	O
lymphoblastoid	O
cell	O
lines	O
established	O
from	O
10	O
breast	O
cancer	O
(	O
BC	O
)	O
patients	O
carrying	O
different	O
ATM	B
missense	O
SNPs	O
,	O
six	O
A	O
-	O
T	O
patients	O
,	O
six	O
A	O
-	O
T	O
heterozygotes	O
(	O
A	O
-	O
T	O
het	O
)	O
,	O
and	O
six	O
normal	O
individuals	O
.	O

The	O
BC	O
,	O
A	O
-	O
T	O
het	O
,	O
and	O
A	O
-	O
T	O
cell	O
line	O
groups	O
showed	O
significantly	O
higher	O
mean	O
levels	O
of	O
MN	O
formation	O
after	O
exposure	O
to	O
ionizing	O
radiation	O
(	O
IR	O
)	O
than	O
did	O
the	O
group	O
containing	O
normal	O
cell	O
lines	O
,	O
with	O
similar	O
levels	O
in	O
the	O
BC	O
and	O
A	O
-	O
T	O
het	O
groups	O
.	O

Within	O
the	O
BC	O
lines	O
studied	O
,	O
the	O
group	O
composed	O
of	O
the	O
six	O
carrying	O
the	O
linked	O
2572T	O
>	O
C	O
(	O
858F	O
>	O
L	O
)	O
and	O
3161C	O
>	O
G	O
(	O
1054P	O
>	O
R	O
)	O
variants	O
had	O
a	O
higher	O
level	O
of	O
MN	O
after	O
IR	O
exposure	O
compared	O
to	O
that	O
observed	O
in	O
the	O
remaining	O
four	O
BC	O
or	O
in	O
the	O
normal	O
cell	O
lines	O
.	O

This	O
increase	O
was	O
not	O
related	O
to	O
the	O
constitutive	O
ATM	B
mRNA	O
level	O
,	O
which	O
was	O
similar	O
in	O
these	O
BC	O
and	O
the	O
normal	O
cell	O
lines	O
.	O

Our	O
results	O
indicate	O
that	O
alterations	O
in	O
the	O
ATM	B
gene	O
,	O
including	O
the	O
presence	O
of	O
heterozygous	O
mutations	O
and	O
the	O
2572C	O
and	O
3161	O
G	O
variant	O
alleles	O
,	O
are	O
associated	O
with	O
increased	O
in	O
vitro	O
chromosomal	O
radiosensitivity	O
,	O
perhaps	O
by	O
interfering	O
with	O
ATM	B
function	O
in	O
a	O
dominant	O
-	O
negative	O
manner	O
.	O

Predictive	O
models	O
for	O
breast	O
cancer	O
susceptibility	O
from	O
multiple	O
single	O
nucleotide	O
polymorphisms	O
.	O

Hereditary	O
predisposition	O
and	O
causative	O
environmental	O
exposures	O
have	O
long	O
been	O
recognized	O
in	O
human	O
malignancies	O
.	O

In	O
most	O
instances	O
,	O
cancer	O
cases	O
occur	O
sporadically	O
,	O
suggesting	O
that	O
environmental	O
influences	O
are	O
critical	O
in	O
determining	O
cancer	O
risk	O
.	O

To	O
test	O
the	O
influence	O
of	O
genetic	O
polymorphisms	O
on	O
breast	O
cancer	O
risk	O
,	O
we	O
have	O
measured	O
98	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
distributed	O
over	O
45	O
genes	O
of	O
potential	O
relevance	O
to	O
breast	O
cancer	O
etiology	O
in	O
174	O
patients	O
and	O
have	O
compared	O
these	O
with	O
matched	O
normal	O
controls	O
.	O

Using	O
machine	O
learning	O
techniques	O
such	O
as	O
support	O
vector	O
machines	O
(	O
SVMs	O
)	O
,	O
decision	O
trees	O
,	O
and	O
naive	O
Bayes	O
,	O
we	O
identified	O
a	O
subset	O
of	O
three	O
SNPs	O
as	O
key	O
discriminators	O
between	O
breast	O
cancer	O
and	O
controls	O
.	O

The	O
SVMs	O
performed	O
maximally	O
among	O
predictive	O
models	O
,	O
achieving	O
69	O
%	O
predictive	O
power	O
in	O
distinguishing	O
between	O
the	O
two	O
groups	O
,	O
compared	O
with	O
a	O
50	O
%	O
baseline	O
predictive	O
power	O
obtained	O
from	O
the	O
data	O
after	O
repeated	O
random	O
permutation	O
of	O
class	O
labels	O
(	O
individuals	O
with	O
cancer	O
or	O
controls	O
)	O
.	O

However	O
,	O
the	O
simpler	O
naive	O
Bayes	O
model	O
as	O
well	O
as	O
the	O
decision	O
tree	O
model	O
performed	O
quite	O
similarly	O
to	O
the	O
SVM	O
.	O

The	O
three	O
SNP	O
sites	O
most	O
useful	O
in	O
this	O
model	O
were	O
(	O
a	O
)	O
the	O
+	O
4536T	O
/	O
C	O
site	O
of	O
the	O
aldosterone	B
synthase	I
gene	O
CYP11B2	B
at	O
amino	O
acid	O
residue	O
386	O
Val	O
/	O
Ala	O
(	O
T	O
/	O
C	O
)	O
(	O
rs4541	O
)	O
;	O
(	O
b	O
)	O
the	O
+	O
4328C	O
/	O
G	O
site	O
of	O
the	O
aryl	B
hydrocarbon	I
hydroxylase	I
CYP1B1	B
at	O
amino	O
acid	O
residue	O
293	O
Leu	O
/	O
Val	O
(	O
C	O
/	O
G	O
)	O
(	O
rs5292	O
)	O
;	O
and	O
(	O
c	O
)	O
the	O
+	O
4449C	O
/	O
T	O
site	O
of	O
the	O
transcription	B
factor	I
BCL6	I
at	O
amino	O
acid	O
387	O
Asp	O
/	O
Asp	O
(	O
rs1056932	O
)	O
.	O

No	O
single	O
SNP	O
site	O
on	O
its	O
own	O
could	O
achieve	O
more	O
than	O
60	O
%	O
in	O
predictive	O
accuracy	O
.	O

We	O
have	O
shown	O
that	O
multiple	O
SNP	O
sites	O
from	O
different	O
genes	O
over	O
distant	O
parts	O
of	O
the	O
genome	O
are	O
better	O
at	O
identifying	O
breast	O
cancer	O
patients	O
than	O
any	O
one	O
SNP	O
alone	O
.	O

As	O
high	O
-	O
throughput	O
technology	O
for	O
SNPs	O
improves	O
and	O
as	O
more	O
SNPs	O
are	O
identified	O
,	O
it	O
is	O
likely	O
that	O
much	O
higher	O
predictive	O
accuracy	O
will	O
be	O
achieved	O
and	O
a	O
useful	O
clinical	O
tool	O
developed	O
.	O

Association	O
between	O
nonsyndromic	O
cleft	O
lip	O
with	O
or	O
without	O
cleft	O
palate	O
and	O
the	O
glutamic	B
acid	I
decarboxylase	I
67	I
gene	O
in	O
the	O
Japanese	O
population	O
.	O

Nonsyndromic	O
cleft	O
lip	O
with	O
or	O
without	O
cleft	O
palate	O
(	O
NSCLP	O
)	O
is	O
one	O
of	O
the	O
most	O
common	O
craniofacial	O
malformations	O
.	O

Both	O
genetic	O
and	O
environmental	O
factors	O
are	O
involved	O
in	O
the	O
pathogenesis	O
.	O

In	O
addition	O
to	O
its	O
role	O
as	O
an	O
inhibitory	O
neurotransmitter	O
,	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
)	O
synthesized	O
by	O
glutamic	B
acid	I
decarboxylase	I
(	O
GAD	B
)	O
is	O
presumed	O
to	O
play	O
a	O
role	O
in	O
normal	O
embryonic	O
,	O
especially	O
facial	O
,	O
development	O
.	O

This	O
notion	O
has	O
been	O
substantiated	O
by	O
the	O
fact	O
that	O
Gad67	B
knockout	O
mice	O
have	O
been	O
shown	O
to	O
have	O
cleft	O
palate	O
.	O

We	O
hypothesized	O
that	O
GAD67	B
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
NSCLP	O
and	O
investigated	O
the	O
possible	O
association	O
between	O
the	O
GAD67	B
gene	O
(	O
GAD67	B
)	O
and	O
NSCLP	O
in	O
Japanese	O
patients	O
.	O

We	O
screened	O
50	O
probands	O
for	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
GAD67	B
using	O
denaturing	O
high	O
performance	O
liquid	O
chromatography	O
(	O
DHPLC	O
)	O
and	O
found	O
seven	O
SNPs	O
.	O

Since	O
two	O
SNPs	O
showed	O
complete	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
to	O
the	O
other	O
SNPs	O
,	O
we	O
constructed	O
a	O
5-locus	O
haplotype	O
of	O
GAD67	B
.	O

The	O
frequency	O
distribution	O
of	O
the	O
haplotype	O
differed	O
between	O
NSCLP	O
patients	O
and	O
controls	O
(	O
P	O
=	O
0.0028	O
)	O
.	O

The	O
frequency	O
of	O
-445A	O
,	O
-292A	O
,	O
-147	O
G	O
,	O
111C	O
,	O
and	O
IVS9	O
-	O
39	O
T	O
haplotype	O
in	O
the	O
NSCLP	O
patients	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
controls	O
(	O
P	O
=	O
0.00098	O
)	O
.	O

In	O
a	O
transmission	O
disequilibrium	O
test	O
(	O
TDT	O
)	O
in	O
99	O
parent	O
-	O
offspring	O
trios	O
,	O
we	O
found	O
-445C	O
,	O
-292C	O
,	O
-147	O
G	O
,	O
111C	O
,	O
and	O
IVS9	O
-	O
39C	O
haplotype	O
was	O
preferentially	O
transmitted	O
to	O
the	O
patients	O
with	O
cleft	O
lip	O
and	O
palate	O
(	O
P	O
=	O
0.0077	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
GAD67	B
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
NSCLP	O
in	O
the	O
Japanese	O
population	O
.	O

Association	O
between	O
the	O
brain	B
-	I
derived	I
neurotrophic	I
factor	I
196G	O
/	O
A	O
polymorphism	O
and	O
eating	O
disorders	O
.	O

Several	O
lines	O
of	O
evidence	O
suggest	O
that	O
genetic	O
factors	O
might	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
eating	O
disorders	O
and	O
that	O
brain	B
-	I
derived	I
neurotrophic	I
factor	I
(	O
BDNF	B
)	O
plays	O
a	O
role	O
in	O
the	O
pathophysiology	O
of	O
eating	O
disorders	O
.	O

To	O
investigate	O
the	O
role	O
of	O
the	O
BDNF	B
gene	O
in	O
the	O
susceptibility	O
to	O
eating	O
disorders	O
,	O
we	O
analyzed	O
the	O
BDNF	B
196G	O
/	O
A	O
gene	O
polymorphism	O
in	O
female	O
patients	O
with	O
eating	O
disorders	O
and	O
female	O
normal	O
controls	O
.	O

The	O
difference	O
in	O
the	O
genotype	O
frequency	O
between	O
patients	O
(	O
n	O
=	O
198	O
)	O
and	O
normal	O
controls	O
(	O
n	O
=	O
222	O
)	O
was	O
statistically	O
significant	O
(	O
P	O
=	O
0.029	O
)	O
.	O

Interestingly	O
,	O
a	O
significant	O
(	O
P	O
=	O
0.015	O
)	O
difference	O
in	O
the	O
genotype	O
frequency	O
between	O
normal	O
controls	O
and	O
bulimia	O
nervosa	O
patients	O
(	O
n	O
=	O
101	O
)	O
with	O
binge	O
-	O
purging	O
type	O
was	O
detected	O
.	O

This	O
study	O
suggests	O
that	O
the	O
BDNF	B
196G	O
/	O
A	O
gene	O
polymorphism	O
might	O
be	O
associated	O
with	O
a	O
susceptibility	O
to	O
eating	O
disorders	O
.	O

Copyright	O
2003	O

Wiley	O
-	O
Liss	O
,	O
Inc.	O

Human	O
vitamin	O
K	O
-	O
dependent	O
GAS6	B
:	O
gene	O
structure	O
,	O
allelic	O
variation	O
,	O
and	O
association	O
with	O
stroke	O
.	O

The	O
product	O
of	O
the	O
growth	B
arrest	I
-	I
specific	I
gene	I
6	I
(	O
GAS6	B
)	O
,	O
a	O
ligand	O
for	O
the	O
Axl	B
,	O
Sky	B
,	O
and	O
Mer	B
tyrosine	I
kinase	I
receptors	I
,	O
is	O
a	O
vitamin	O
K	O
-	O
dependent	O
protein	O
,	O
structurally	O
related	O
to	O
anticoagulant	B
protein	I
S.	I
Gas6-deficient	B
mice	O
are	O
protected	O
against	O
thrombosis	O
,	O
demonstrating	O
the	O
importance	O
of	O
this	O
protein	O
in	O
the	O
cardiovascular	O
system	O
.	O

The	O
present	O
study	O
was	O
aimed	O
at	O
determining	O
the	O
human	O
GAS6	B
intron	O
-	O
exon	O
structure	O
and	O
analyzing	O
the	O
gene	O
for	O
the	O
presence	O
of	O
allelic	O
variants	O
that	O
could	O
be	O
associated	O
with	O
atherothrombotic	O
disease	O
.	O

Online	O
analyses	O
allowed	O
us	O
to	O
localize	O
15	O
GAS6	B
exons	O
and	O
to	O
determine	O
the	O
sequence	O
of	O
their	O
intron	O
-	O
flanking	O
regions	O
,	O
in	O
a	O
chromosome	O
13	O
region	O
spanning	O
43.8	O
kb	O
of	O
DNA	O
.	O

SSCP	O
analysis	O
of	O
PCR	O
-	O
amplified	O
GAS6	B
exons	O
with	O
their	O
intron	O
-	O
flanking	O
regions	O
from	O
a	O
minimum	O
of	O
12	O
control	O
DNA	O
samples	O
,	O
revealed	O
the	O
presence	O
of	O
eight	O
different	O
variants	O
,	O
which	O
were	O
confirmed	O
to	O
be	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
.	O

Three	O
of	O
them	O
(	O
c.1263G	O
>	O
C	O
,	O
c.1332C	O
>	O
T	O
,	O
and	O
c.1869T	O
>	O
C	O
)	O
are	O
localized	O
in	O
exons	O
11	O
,	O
12	O
,	O
and	O
14	O
,	O
and	O
appear	O
to	O
be	O
neutral	O
since	O
they	O
do	O
not	O
modify	O
the	O
encoded	O
amino	O
acid	O
.	O

The	O
other	O
SNPs	O
(	O
c.280	O
+	O
170C	O
>	O
G	O
,	O
c.712	O
+	O
26G	O
>	O
A	O
,	O
c.713	O
-	O
155C	O
>	O
T	O
,	O
c.834	O
+	O
7G	O
>	O
A	O
,	O
and	O
c.1478	O
-	O
94C	O
>	O
G	O
)	O
are	O
in	O
introns	O
3	O
,	O
7	O
,	O
8	O
,	O
and	O
12	O
.	O

A	O
preliminary	O
analysis	O
of	O
five	O
of	O
these	O
SNPs	O
in	O
a	O
group	O
of	O
110	O
healthy	O
controls	O
and	O
188	O
patients	O
with	O
atherothrombotic	O
disease	O
has	O
revealed	O
statistically	O
significant	O
differences	O
between	O
controls	O
and	O
stroke	O
patients	O
in	O
the	O
allelic	O
distributions	O
of	O
one	O
of	O
these	O
variants	O
(	O
c.834	O
+	O
7G	O
>	O
A	O
in	O
intron	O
8)	O
.	O

The	O
SNP	O
identification	O
in	O
GAS6	B
reported	O
here	O
would	O
be	O
very	O
useful	O
in	O
future	O
association	O
studies	O
aimed	O
at	O
determining	O
the	O
physiologic	O
role	O
of	O
GAS6	B
in	O
stroke	O
and	O
other	O
human	O
diseases	O
.	O

Human	O
mitochondrial	B
transcription	I
factor	I
B1	I
as	O
a	O
modifier	O
gene	O
for	O
hearing	O
loss	O
associated	O
with	O
the	O
mitochondrial	O
A1555	O
G	O
mutation	O
.	O

Phenotypic	O
expression	O
of	O
the	O
deafness	O
-	O
associated	O
homoplasmic	O
A1555	O
G	O
mutation	O
in	O
the	O
mitochondrial	B
12S	I
rRNA	I
gene	O
varies	O
from	O
profound	O
congenital	O
hearing	O
loss	O
to	O
normal	O
hearing	O
.	O

It	O
has	O
been	O
shown	O
that	O
this	O
variability	O
in	O
clinical	O
expression	O
in	O
most	O
patients	O
is	O
due	O
to	O
the	O
complex	O
inheritance	O
of	O
multiple	O
nuclear	O
-	O
encoded	O
modifier	O
genes	O
.	O

Human	O
mitochondrial	B
transcription	I
factor	I
B1	I
(	O
TFB1	B
M	I
)	O
has	O
been	O
proposed	O
as	O
a	O
candidate	O
for	O
being	O
such	O
a	O
modifier	O
,	O
since	O
it	O
methylates	O
adenine	O
residues	O
in	O
the	O
adjacent	O
loop	O
of	O
the	O
A1555	O
G	O
mutation	O
in	O
the	O
12S	B
rRNA	I
gene	O
.	O

Polymorphic	O
markers	O
within	O
and	O
adjacent	O
to	O
the	O
TFB1	B
M	I
gene	O
were	O
genotyped	O
in	O
214	O
individuals	O
from	O
41	O
multiplex	O
families	O
with	O
the	O
A1555	O
G	O
mutation	O
of	O
Spanish	O
,	O
Italian	O
,	O
and	O
Arab	O
-	O
Israeli	O
origin	O
.	O

Multipoint	O
non	O
-	O
parametric	O
linkage	O
analysis	O
of	O
all	O
families	O
combined	O
revealed	O
an	O
NPL	O
score	O
of	O
1.7	O
(	O
P	O
=	O
0.05	O
)	O
,	O
and	O
a	O
Lod	O
score	O
of	O
1.4	O
(	O
P	O
=	O
0.04	O
)	O
.	O

Linkage	O
disequilibrium	O
by	O
the	O
Transmission	O
Disequilibrium	O
Test	O
at	O
D6S1577	O
,	O
a	O
microsatellite	O
adjacent	O
to	O
TFB1	B
M	I
,	O
showed	O
preferential	O
non	O
-	O
transmission	O
of	O
an	O
allele	O
to	O
affected	O
individuals	O
with	O
chi2	O
=	O
8.76	O
;	O
P	O
=	O
0.003	O
.	O

Sequence	O
analysis	O
of	O
the	O
coding	O
region	O
of	O
the	O
gene	O
and	O
testing	O
of	O
all	O
intragenic	O
SNPs	O
did	O
not	O
reveal	O
a	O
putative	O
causative	O
mutation	O
.	O

These	O
data	O
provide	O
suggestive	O
evidence	O
that	O
TFB1	B
M	I
is	O
a	O
nuclear	O
-	O
encoded	O
modifier	O
gene	O
for	O
phenotypic	O
expression	O
of	O
the	O
A1555	O
G	O
mutation	O
,	O
and	O
that	O
the	O
effect	O
may	O
occur	O
through	O
a	O
regulatory	O
or	O
splicing	O
mutation	O
.	O

Association	O
after	O
linkage	O
analysis	O
indicates	O
that	O
homozygosity	O
for	O
the	O
46C-->T	O
polymorphism	O
in	O
the	O
F12	B
gene	O
is	O
a	O
genetic	O
risk	O
factor	O
for	O
venous	O
thrombosis	O
.	O

In	O
a	O
family	O
-	O
based	O
study	O
called	O
GAIT	O
(	O
Genetic	O
Analysis	O
of	O
Idiopathic	O
Thrombophilia	O
)	O
that	O
included	O
a	O
genome	O
-	O
wide	O
scan	O
we	O
demonstrated	O
that	O
a	O
polymorphism	O
(	O
46C-->T	O
)	O
in	O
the	O
F12	B
locus	O
jointly	O
influences	O
variability	O
of	O
plasma	O
(	O
Factor	B
XII	I
)	O
FXII	B
levels	O
and	O
susceptibility	O
to	O
thrombotic	O
disease	O
.	O

It	O
then	O
became	O
germane	O
to	O
determine	O
the	O
prevalence	O
of	O
the	O
46C-->T	O
polymorphism	O
and	O
its	O
relative	O
risk	O
of	O
thrombotic	O
disease	O
.	O

We	O
followed	O
up	O
evidence	O
for	O
genetic	O
linkage	O
with	O
a	O
case	O
-	O
control	O
study	O
,	O
including	O
250	O
unrelated	O
consecutive	O
Spanish	O
patients	O
suffering	O
from	O
venous	O
thrombotic	O
disease	O
and	O
250	O
Spanish	O
subjects	O
matched	O
for	O
sex	O
and	O
age	O
as	O
a	O
controls	O
.	O

We	O
measured	O
FXII	B
levels	O
and	O
genotyped	O
the	O
46C-->T	O
polymorphism	O
,	O
as	O
well	O
as	O
a	O
number	O
of	O
classical	O
risk	O
factors	O
for	O
thrombotic	O
disease	O
.	O

We	O
confirmed	O
that	O
individuals	O
with	O
different	O
genotypes	O
for	O
this	O
polymorphism	O
showed	O
significant	O
differences	O
in	O
their	O
FXII	B
levels	O
.	O

Most	O
importantly	O
,	O
the	O
mutated	O
T	O
allele	O
in	O
the	O
homozygous	O
state	O
(	O
genotype	O
T	O
/	O
T	O
)	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
thrombosis	O
(	O
adjusted	O
OR	O
of	O
4.82	O
;	O
95	O
%	O
CI	O
1.5	O
-	O
15.6	O
)	O
,	O
suggesting	O
that	O
the	O
polymorphism	O
itself	O
is	O
an	O
independent	O
risk	O
factor	O
for	O
venous	O
thromboembolism	O
.	O

This	O
study	O
confirms	O
that	O
the	O
46C-->T	O
polymorphism	O
is	O
a	O
genetic	O
risk	O
factor	O
for	O
venous	O
thrombosis	O
in	O
the	O
Spanish	O
population	O
.	O

In	O
addition	O
,	O
our	O
results	O
confirm	O
that	O
a	O
genome	O
-	O
wide	O
scan	O
coupled	O
with	O
a	O
classical	O
case	O
-	O
control	O
association	O
study	O
is	O
an	O
extremely	O
valuable	O
approach	O
to	O
identify	O
DNA	O
variants	O
that	O
affect	O
complex	O
diseases	O
.	O

Hypoadiponectinemia	O
is	O
an	O
independent	O
risk	O
factor	O
for	O
hypertension	O
.	O

Adiponectin	B
is	O
one	O
of	O
the	O
key	O
molecules	O
in	O
the	O
metabolic	O
syndrome	O
,	O
and	O
its	O
concentration	O
is	O
decreased	O
in	O
obesity	O
,	O
type-2	O
diabetes	O
,	O
and	O
coronary	O
artery	O
disease	O
.	O

Genetic	O
investigation	O
has	O
revealed	O
that	O
2	O
polymorphisms	O
(	O
I164	O
T	O
and	O
G276	O
T	O
)	O
are	O
related	O
to	O
adiponectin	B
concentration	O
and	O
diabetes	O
.	O

To	O
examine	O
whether	O
adiponectin	B
affects	O
hypertension	O
genetically	O
or	O
biologically	O
,	O
we	O
performed	O
a	O
case	O
-	O
control	O
study	O
.	O

A	O
total	O
of	O
446	O
diagnosed	O
cases	O
of	O
hypertension	O
(	O
HT	O
)	O
in	O
men	O
and	O
312	O
normotensive	O
(	O
NT	O
)	O
men	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

Plasma	O
adiponectin	B
concentration	O
was	O
measured	O
using	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
system	O
.	O

Single	O
nucleotide	O
polymorphisms	O
were	O
determined	O
by	O
TaqMan	O
polymerase	O
chain	O
reaction	O
method	O
.	O

After	O
adjustment	O
for	O
confounding	O
factors	O
,	O
adiponectin	B
concentration	O
was	O
significantly	O
lower	O
in	O
HT	O
(	O
HT	O
:	O
5.2+	O
/	O
-0.2	O
microg	O
/	O
mL	O
;	O
NT	O
:	O
6.1+	O
/	O
-0.2	O
microg	O
/	O
mL	O
;	O
P<0.001	O
)	O
.	O

Furthermore	O
,	O
multiple	O
regression	O
analysis	O
indicated	O
that	O
hypoadiponectinemia	O
was	O
an	O
independent	O
risk	O
factor	O
for	O
hypertension	O
(	O
P<0.001	O
)	O
.	O

Blood	O
pressure	O
was	O
inversely	O
associated	O
with	O
adiponectin	B
concentration	O
in	O
normotensives	O
regardless	O
of	O
insulin	B
resistance	O
.	O

In	O
subjects	O
carrying	O
the	O
TC	O
genotype	O
of	O
the	O
I164	O
T	O
polymorphism	O
,	O
adiponectin	B
concentration	O
was	O
significantly	O
lower	O
(	O
TC	O
:	O
2.6+	O
/	O
-0.9	O
microg	O
/	O
mL	O
;	O
TT	O
:	O
5.5+	O
/	O
-0.1	O
microg	O
/	O
mL	O
;	O
P<0.01	O
)	O
,	O
and	O
most	O
of	O
them	O
had	O
hypertension	O
.	O

In	O
contrast	O
,	O
the	O
G276	O
T	O
polymorphism	O
was	O
not	O
associated	O
with	O
adiponectin	B
concentration	O
or	O
hypertension	O
.	O

In	O
conclusion	O
,	O
hypoadiponectinemia	O
is	O
a	O
marker	O
for	O
predisposition	O
to	O
hypertension	O
in	O
men	O
.	O

Single	O
nucleotide	O
polymorphism	O
(	O
-468	O
Gly	O
to	O
A	O
)	O
at	O
the	O
promoter	O
region	O
of	O
SREBP-1c	B
associates	O
with	O
genetic	O
defect	O
of	O
fructose	O
-	O
induced	O
hepatic	O
lipogenesis	O
[	O
corrected	O
]	O
.	O

To	O
evaluate	O
the	O
genetic	O
susceptibility	O
to	O
metabolic	O
disorders	O
induced	O
by	O
high	O
fructose	O
diet	O
,	O
we	O
investigated	O
the	O
metabolic	O
characteristics	O
in	O
10	O
strains	O
of	O
inbred	O
mice	O
and	O
found	O
that	O
they	O
were	O
separated	O
into	O
CBA	O
and	O
DBA	O
groups	O
according	O
to	O
the	O
response	O
to	O
high	O
fructose	O
diet	O
.	O

The	O
hepatic	O
mRNA	O
expression	O
of	O
the	O
sterol	B
regulatory	I
element	I
-	I
binding	I
protein-1	I
(	O
SREBP-1	B
)	O
in	O
CBA	O
/	O
JN	O
was	O
remarkably	O
enhanced	O
by	O
high	O
fructose	O
diet	O
but	O
not	O
in	O
DBA	O
/	O
2N	O
.	O

Similar	O
results	O
were	O
observed	O
in	O
primary	O
hepatocytes	O
after	O
exposure	O
to	O
fructose	O
.	O

The	O
nucleotide	O
sequence	O
at	O
-468	O
bp	O
from	O
the	O
putative	O
starting	O
point	O
of	O
the	O
SREBP-1c	B
gene	O
was	O
adenine	O
in	O
the	O
DBA	O
group	O
while	O
it	O
was	O
guanine	O
in	O
the	O
CBA	O
group	O
.	O

In	O
hepatocytes	O
from	O
CBA	O
/	O
JN	O
,	O
the	O
activity	O
of	O
CBA	O
-	O
SREBP-1c	B
promoter	O
was	O
significantly	O
increased	O
by	O
2.4-	O
and	O
2.2-fold	O
,	O
in	O
response	O
to	O
30	O
mm	O
fructose	O
or	O
10	O
nm	O
insulin	B
,	O
respectively	O
,	O
whereas	O
the	O
activity	O
of	O
DBA	O
-	O
SREBP-1c	B
promoter	O
responded	O
to	O
insulin	B
but	O
not	O
to	O
fructose	O
.	O

In	O
hepatocytes	O
from	O
DBA	O
/	O
2N	O
,	O
both	O
types	O
of	O
SREBP-1c	B
promoter	O
activities	O
in	O
response	O
to	O
insulin	B
were	O
attenuated	O
.	O

Furthermore	O
,	O
electrophoretic	O
mobility	O
shift	O
assay	O
revealed	O
an	O
unidentified	O
nuclear	O
protein	O
bound	O
to	O
the	O
oligonucleotides	O
made	O
from	O
the	O
region	O
between	O
-453	O
to	O
-480	O
bp	O
of	O
the	O
SREBP-1c	B
promoter	O
of	O
CBA	O
/	O
JN	O
but	O
not	O
to	O
the	O
probe	O
from	O
DBA	O
/	O
2N	O
.	O

Thus	O
,	O
in	O
DBA	O
/	O
2N	O
,	O
the	O
reduced	O
mRNA	O
expression	O
of	O
SREBP-1	O
after	O
fructose	O
refeeding	O
appeared	O
to	O
associate	O
with	O
two	O
independent	O
mechanisms	O
,	O
1	O
)	O
.	O

loss	O
of	O
binding	O
of	O
unidentified	O
proteins	O
to	O
the	O
region	O
between	O
-453	O
to	O
-480	O
bp	O
of	O
the	O
SREBP-1c	B
promoter	O
and	O
2	O
)	O
.	O

impaired	O
insulin	B
stimulation	O
of	O
SREBP-1c	B
promoter	O
activity	O
.	O

Variants	O
in	O
the	O
catechol	B
-	I
o	I
-	I
methyltransferase	I
(	O
COMT	B
)	O
gene	O
are	O
associated	O
with	O
schizophrenia	O
in	O
Irish	O
high	O
-	O
density	O
families	O
.	O

The	O
enzyme	O
catechol	B
-	I
o	I
-	I
methyltransferase	I
(	O
COMT	B
)	O
transfers	O
a	O
methyl	O
group	O
from	O
adenosylmethionine	O
to	O
catecholamines	O
including	O
the	O
neurotransmitters	O
dopamine	O
,	O
epinephrine	O
and	O
norepinephrine	O
.	O

This	O
methylation	O
results	O
in	O
the	O
degradation	O
of	O
catecholamines	O
.	O

The	O
involvement	O
of	O
the	O
COMT	B
gene	O
in	O
the	O
metabolic	O
pathway	O
of	O
these	O
neurotransmitters	O
has	O
made	O
it	O
an	O
attractive	O
candidate	O
gene	O
for	O
many	O
psychiatric	O
disorders	O
.	O

In	O
this	O
article	O
,	O
we	O
reported	O
our	O
study	O
of	O
association	O
of	O
COMT	B
with	O
schizophrenia	O
in	O
Irish	O
families	O
with	O
a	O
high	O
density	O
of	O
schizophrenia	O
.	O

Three	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
were	O
genotyped	O
for	O
the	O
274	O
such	O
families	O
and	O
within	O
-	O
family	O
transmission	O
disequilibrium	O
tests	O
were	O
performed	O
.	O

SNP	O
rs4680	O
,	O
which	O
is	O
the	O
functional	O
Val	O
/	O
Met	O
polymorphism	O
,	O
showed	O
modest	O
association	O
with	O
the	O
disease	O
by	O
the	O
TRANSMIT	O
,	O
FBAT	O
and	O
PDT	O
programs	O
,	O
while	O
the	O
other	O
two	O
SNPs	O
were	O
negative	O
.	O

These	O
SNPs	O
showed	O
lower	O
level	O
of	O
LDs	O
with	O
each	O
other	O
in	O
the	O
Irish	O
subjects	O
than	O
in	O
Ashkenazi	O
Jews	O
.	O

Haplotype	O
analysis	O
indicated	O
that	O
a	O
haplotype	O
,	O
haplotype	O
A	O
-	O
G	O
-	O
A	O
for	O
SNPs	O
rs737865-rs4680-rs165599	O
,	O
was	O
preferentially	O
transmitted	O
to	O
the	O
affected	O
subjects	O
.	O

This	O
was	O
different	O
from	O
the	O
reported	O
G	O
-	O
G	O
-	O
G	O
haplotype	O
found	O
in	O
Ashkenazi	O
Jews	O
,	O
but	O
both	O
haplotypes	O
shared	O
the	O
Val	O
allele	O
.	O

We	O
concluded	O
that	O
COMT	B
gene	O
is	O
associated	O
with	O
schizophrenia	O
and	O
carries	O
a	O
small	O
but	O
significant	O
risk	O
to	O
the	O
susceptibility	O
in	O
the	O
Irish	O
subjects	O
.	O

Two	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
CYP17	B
and	O
COMT	B
Genes	O
--	O
relation	O
to	O
bone	O
mass	O
and	O
longitudinal	O
bone	O
changes	O
in	O
postmenopausal	O
women	O
with	O
or	O
without	O
hormone	O
replacement	O
therapy	O
.	O

The	O
Danish	O
Osteoporosis	O
Prevention	O
Study	O
.	O

Sex	O
steroids	O
are	O
important	O
physiologic	O
regulators	O
of	O
bone	O
mass	O
,	O
and	O
genes	O
regulating	O
sex	O
steroid	O
production	O
and	O
metabolism	O
are	O
obvious	O
as	O
candidate	O
genes	O
for	O
osteoporosis	O
susceptibility	O
.	O

We	O
present	O
data	O
from	O
a	O
study	O
of	O
1795	O
recent	O
postmenopausal	O
women	O
,	O
assigned	O
to	O
either	O
hormone	O
replacement	O
therapy	O
(	O
HRT	O
)	O
or	O
no	O
treatment	O
and	O
followed	O
for	O
5	O
years	O
.	O

The	O
association	O
between	O
bone	O
mass	O
measurements	O
and	O
two	O
single	O
nucleotide	O
polymorphisms	O
,	O
a	O
T	O
(	O
A1	O
)	O
to	O
C	O
(	O
A2	O
)	O
transition	O
in	O
the	O
5'-UTR	O
of	O
the	O
cytochrome	B
P450c17alpha	I
(	I
CYP17	I
)	I
gene	O
and	O
a	O
G	O
(	O
Val	O
)	O
to	O
A	O
(	O
Met	O
)	O
transition	O
in	O
exon	O
4	O
of	O
the	O
catechol-	B
O	I
-	I
methyltransferase	I
(	O
COMT	B
)	O
gene	O
,	O
was	O
evaluated	O
.	O

Association	O
with	O
CYP17	B
genotype	O
was	O
modified	O
by	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
.	O

In	O
lean	O
women	O
,	O
individuals	O
homozygous	O
for	O
the	O
CYP17	B
A2	O
allele	O
were	O
1	O
cm	O
shorter	O
and	O
had	O
lower	O
baseline	O
BMD	O
(	O
bone	O
mineral	O
density	O
)	O
,	O
BMC	O
,	O
and	O
CSA	O
(	O
cross	O
sectional	O
area	O
)	O
in	O
the	O
spine	O
and	O
femoral	O
neck	O
than	O
did	O
other	O
women	O
(	O
BMD	O
spine	O
A2A2	O
:	O
0.975	O
g	O
/	O
cm2	O
versus	O
1.011	O
g	O
/	O
cm2	O
in	O
A1A1	O
+	O
A1A2	O
,	O
P	O
=	O
0.002	O
)	O
.	O

Conversely	O
,	O
an	O
adverse	O
association	O
with	O
A2A2	O
and	O
bone	O
loss	O
over	O
5	O
years	O
seemed	O
present	O
only	O
in	O
overweight	O
women	O
,	O
but	O
differences	O
were	O
small	O
.	O

Response	O
to	O
HRT	O
was	O
not	O
dependent	O
on	O
CYP17	B
genotype	O
.	O

COMT	B
genotype	O
was	O
not	O
associated	O
with	O
bone	O
mass	O
at	O
baseline	O
,	O
bone	O
loss	O
in	O
untreated	O
women	O
,	O
or	O
response	O
to	O
HRT	O
.	O

In	O
conclusion	O
,	O
the	O
A2	O
allele	O
of	O
the	O
CYP17	B
T	O
(	O
27	O
)	O
-C	O
polymorphism	O
is	O
associated	O
with	O
reduced	O
bone	O
mass	O
and	O
bone	O
size	O
in	O
lean	O
perimenopausal	O
women	O
,	O
whereas	O
high	O
BMI	O
protects	O
against	O
this	O
negative	O
association	O
.	O

The	O
COMT	B
G	O
(	O
1947	O
)	O
-A	O
polymorphism	O
is	O
not	O
associated	O
with	O
bone	O
parameters	O
in	O
this	O
study	O
.	O

Modest	O
implication	O
of	O
interleukin-6	B
promoter	O
polymorphisms	O
in	O
longevity	O
.	O

The	O
multifunctional	O
interleukin-6	B
has	O
been	O
suggested	O
to	O
contribute	O
to	O
a	O
chronic	O
low	O
-	O
grade	O
inflammatory	O
status	O
,	O
thereby	O
conferring	O
susceptibility	O
to	O
age	O
-	O
related	O
pathological	O
conditions	O
as	O
well	O
as	O
functional	O
decline	O
and	O
increased	O
mortality	O
.	O

Several	O
polymorphisms	O
have	O
been	O
identified	O
in	O
the	O
interleukin-6	B
promoter	O
,	O
but	O
investigation	O
of	O
the	O
effect	O
of	O
these	O
on	O
interleukin-6	B
levels	O
and	O
disease	O
susceptibility	O
have	O
led	O
to	O
contradictory	O
results	O
.	O

This	O
study	O
investigates	O
the	O
significance	O
of	O
the	O
three	O
single	O
-	O
point	O
polymorphisms	O
(	O
-597G	O
/	O
A	O
,	O
-572G	O
/	O
C	O
and	O
-174G	O
/	O
C	O
)	O
and	O
the	O
AT	O
-	O
stretch	O
polymorphism	O
(	O
-373	O
(	O
A	O
)	O
n	O
(	O
T	O
)	O
m	O
)	O
in	O
ageing	O
,	O
by	O
comparison	O
of	O
the	O
frequency	O
of	O
each	O
single	O
polymorphism	O
separately	O
as	O
well	O
as	O
the	O
entire	O
promoter	O
haplotype	O
in	O
a	O
total	O
of	O
1710	O
Danish	O
subjects	O
ranging	O
in	O
age	O
from	O
47	O
to	O
100	O
years	O
.	O

We	O
found	O
a	O
modest	O
,	O
but	O
significant	O
,	O
increase	O
in	O
the	O
frequency	O
of	O
interleukin-6	B
-174GG	O
homozygotes	O
with	O
age	O
suggesting	O
that	O
this	O
genotype	O
is	O
advantageous	O
for	O
longevity	O
.	O

Association	O
of	O
NQO1	B
polymorphism	O
with	O
spontaneous	O
breast	O
cancer	O
in	O
two	O
independent	O
populations	O
.	O

Eight	O
different	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
six	O
different	O
genes	O
were	O
investigated	O
for	O
possible	O
association	O
with	O
breast	O
cancer	O
.	O

We	O
used	O
a	O
case	O
-	O
control	O
study	O
design	O
in	O
two	O
Caucasian	O
populations	O
,	O
one	O
from	O
Tyrol	O
,	O
Austria	O
,	O
and	O
the	O
other	O
from	O
Prague	O
,	O
Czech	O
Republic	O
.	O

Two	O
SNPs	O
showed	O
an	O
association	O
with	O
breast	O
cancer	O
:	O
R72P	O
inTP53	O
and	O
P187S	O
in	O
NQO1	B
.	O

Six	O
SNPs	O
,	O
Q356R	O
and	O
P871L	O
in	O
BRCA1	B
,	O
N372H	O
in	O
BRCA2	B
,	O
C112R	O
(	O
E4	O
)	O
and	O
R158C	O
(	O
E2	O
)	O
in	O
ApoE	B
and	O
C825	O
T	O
in	O
GNB3	B
,	O
did	O
not	O
show	O
any	O
sign	O
of	O
association	O
.	O

The	O
P187S	O
polymorphism	O
in	O
NQO1	B
was	O
associated	O
with	O
breast	O
cancer	O
in	O
both	O
populations	O
from	O
Tyrol	O
and	O
Prague	O
with	O
a	O
higher	O
risk	O
for	O
carriers	O
of	O
the	O
187S	O
allele	O
.	O

Combining	O
the	O
results	O
of	O
the	O
two	O
populations	O
,	O
we	O
observed	O
a	O
highly	O
significant	O
difference	O
(	O
P=0.0004	O
)	O
of	O
genotype	O
and	O
allele	O
frequencies	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
=1.46	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.16	O
-	O
1.85	O
;	O
P=0.001	O
)	O
and	O
of	O
the	O
homozygote	O
ratio	O
(	O
OR=3.8	O
;	O
95	O
%	O
CI	O
1.73	O
-	O
8.34	O
;	O
P=0.0001	O
)	O
.	O

Combining	O
the	O
two	O
'	O
candidate	O
'	O
SNPs	O
(	O
P187S	O
and	O
R72P	O
)	O
revealed	O
an	O
increased	O
risk	O
for	O
breast	O
cancer	O
of	O
double	O
heterozygotes	O
(	O
P187S	O
/	O
R72P	O
)	O
of	O
the	O
NQO1	B
and	O
TP53	B
genes	O
(	O
OR=1.88	O
;	O
95	O
%	O
CI	O
1.13	O
-	O
3.15	O
;	O
P=0.011	O
)	O
,	O
suggesting	O
a	O
possible	O
interaction	O
of	O
these	O
two	O
loci	O
.	O

A	O
single	O
-	O
nucleotide	O
polymorphism	O
in	O
the	O
RAD51	B
gene	O
modifies	O
breast	O
cancer	O
risk	O
in	O
BRCA2	B
carriers	O
,	O
but	O
not	O
in	O
BRCA1	B
carriers	O
or	O
noncarriers	O
.	O

Variation	O
in	O
the	O
penetrance	O
estimates	O
for	O
BRCA1	B
and	O
BRCA2	B
mutation	O
carriers	O
suggests	O
that	O
other	O
genetic	O
polymorphisms	O
may	O
modify	O
the	O
cancer	O
risk	O
in	O
carriers	O
.	O

The	O
RAD51	B
gene	O
,	O
which	O
participates	O
in	O
homologous	O
recombination	O
double	O
-	O
strand	O
breaks	O
(	O
DSB	O
)	O
repair	O
in	O
the	O
same	O
pathway	O
as	O
the	O
BRCA1	B
and	O
BRCA2	B
gene	O
products	O
,	O
is	O
a	O
candidate	O
for	O
such	O
an	O
effect	O
.	O

A	O
single	O
-	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
,	O
RAD51	B
-	O
135g-->c	O
,	O
in	O
the	O
5	O
'	O
untranslated	O
region	O
of	O
the	O
gene	O
has	O
been	O
found	O
to	O
elevate	O
breast	O
cancer	O
(	O
BC	O
)	O
risk	O
among	O
BRCA2	B
carriers	O
.	O

We	O
genotyped	O
309	O
BRCA1	B
/	O
2	B
mutation	O
carriers	O
,	O
of	O
which	O
280	O
were	O
of	O
Ashkenazi	O
origin	O
,	O
166	O
noncarrier	O
BC	O
patients	O
and	O
152	O
women	O
unaffected	O
with	O
BC	O
(	O
a	O
control	O
group	O
)	O
,	O
for	O
the	O
RAD51	B
-	O
135g-->c	O
SNP	O
.	O

Risk	O
analyses	O
were	O
conducted	O
using	O
COX	O
proportional	O
hazard	O
models	O
for	O
the	O
BRCA1	B
/	O
2	B
carriers	O
and	O
simple	O
logistic	O
regression	O
analysis	O
for	O
the	O
noncarrier	O
case	O
-	O
control	O
population	O
.	O

BRCA2	B
carriers	O
were	O
also	O
studied	O
using	O
logistic	O
regression	O
and	O
Kaplan	O
-	O
Meier	O
survival	O
analyses	O
.	O

The	O
estimated	O
BC	O
hazard	O
ratio	O
(	O
HR	O
)	O
for	O
RAD51	B
-	O
135c	O
carriers	O
adjusted	O
for	O
origin	O
(	O
Ashkenazi	O
vs	O
non	O
-	O
Ashkenazi	O
)	O
was	O
1.28	O
(	O
95	O
%	O
CI	O
0.85	O
-	O
1.90	O
,	O
P=0.23	O
)	O
for	O
BRCA1	B
/	O
2	B
carriers	O
,	O
and	O
2.09	O
(	O
95	O
%	O
CI	O
1.04	O
-	O
4.18	O
,	O
P=0.04	O
)	O
when	O
the	O
analysis	O
was	O
restricted	O
to	O
BRCA2	B
carriers	O
.	O

The	O
median	O
BC	O
age	O
was	O
younger	O
in	O
BRCA2-RAD51	B
-	O
135c	O
carriers	O
(	O
45	O
(	O
95	O
%	O
CI	O
36	O
-	O
54	O
)	O
vs	O
52	O
years	O
(	O
95	O
%	O
CI	O
48	O
-	O
56	O
)	O
,	O
P=0.05	O
)	O
.	O

In	O
a	O
logistic	O
regression	O
analysis	O
,	O
the	O
odds	O
ratio	O
(	O
OR	O
)	O
was	O
5.49	O
(	O
95	O
%	O
CI	O
0.5	O
-	O
58.8	O
,	O
P=0.163	O
)	O
.	O

In	O
noncarrier	O
BC	O
cases	O
,	O
carrying	O
RAD51	B
-	O
135c	O
was	O
not	O
associated	O
with	O
BC	O
risk	O
(	O
0.97	O
;	O
95	O
%	O
CI	O
0.47	O
-	O
2.00	O
)	O
.	O

These	O
results	O
indicate	O
significantly	O
elevated	O
risk	O
for	O
BC	O
in	O
carriers	O
of	O
BRCA2	B
mutations	O
who	O
also	O
carry	O
a	O
RAD51	B
-	O
135c	O
allele	O
.	O

In	O
BRCA1	B
carriers	O
and	O
noncarriers	O
,	O
no	O
effect	O
for	O
this	O
SNP	O
was	O
found	O
.	O

Association	O
of	O
tumor	B
necrosis	I
factor	I
receptor	I
type	I
2	I
+	O
587	O
gene	O
polymorphism	O
with	O
severe	O
chronic	O
periodontitis	O
.	O

BACKGROUND	O
:	O
Genetic	O
polymorphisms	O
for	O
cytokines	O
and	O
their	O
receptors	O
have	O
been	O
proposed	O
as	O
potential	O
markers	O
for	O
periodontal	O
disease	O
.	O

Tumor	B
necrosis	I
factor	I
receptor	I
2	I
(	O
TNFR2	B
)	O
is	O
one	O
of	O
the	O
cell	O
surface	O
receptors	O
for	O
TNF	B
-	I
alpha	I
.	O

Recent	O
studies	O
have	O
suggested	O
that	O
TNFR2	B
gene	O
polymorphism	O
is	O
involved	O
in	O
autoimmune	O
and	O
other	O
diseases	O
.	O

OBJECTIVES	O
:	O
The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
evaluate	O
whether	O
TNFR2	B
(	O
+587T	O
/	O
G	O
)	O
gene	O
polymorphism	O
is	O
associated	O
with	O
chronic	O
periodontitis	O
(	O
CP	O
)	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
ninety	O
-	O
six	O
unrelated	O
subjects	O
(	O
age	O
40	O
-	O
65	O
years	O
)	O
with	O
different	O
levels	O
of	O
CP	O
were	O
identified	O
according	O
to	O
established	O
criteria	O
,	O
including	O
measurements	O
of	O
probing	O
pocket	O
depth	O
(	O
PPD	O
)	O
,	O
clinical	O
attachment	O
level	O
(	O
CAL	O
)	O
,	O
and	O
alveolar	O
bone	O
loss	O
(	O
BL	O
)	O
.	O

All	O
subjects	O
were	O
of	O
Japanese	O
descent	O
and	O
non	O
-	O
smokers	O
.	O

Single	O
nucleotide	O
polymorphism	O
at	O
position	O
+	O
587	O
(	O
T	O
/	O
G	O
)	O
in	O
the	O
TNFR2	B
gene	O
was	O
detected	O
by	O
a	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphisms	O
(	O
PCR	O
-	O
RFLP	O
)	O
method	O
.	O

RESULTS	O
:	O
The	O
frequency	O
and	O
the	O
positivity	O
of	O
the	O
+	O
587	O
G	O
allele	O
were	O
significantly	O
higher	O
in	O
severe	O
CP	O
patients	O
than	O
in	O
controls	O
(	O
p=0.0097	O
;	O
odds	O
ratio=2.61	O
,	O
p=0.0075	O
;	O
odds	O
ratio=3.06	O
)	O
.	O

In	O
addition	O
,	O
mean	O
values	O
of	O
PPD	O
,	O
CAL	O
,	O
and	O
BL	O
were	O
significantly	O
higher	O
in	O
the	O
+	O
587	O
G	O
allele	O
positive	O
than	O
in	O
the	O
negative	O
subjects	O
(	O
p=0.035	O
,	O
0.022	O
,	O
and	O
0.018	O
,	O
respectively	O
)	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
TNFR2	B
(	O
+587	O
G	O
)	O
polymorphic	O
allele	O
could	O
be	O
associated	O
with	O
severe	O
CP	O
in	O
Japanese	O
.	O

Single	O
nucleotide	O
polymorphisms	O
of	O
the	O
SCN5A	B
gene	O
in	O
Han	O
Chinese	O
and	O
their	O
relation	O
with	O
Brugada	O
syndrome	O
.	O

BACKGROUND	O
:	O
Mutations	O
in	O
the	O
cardiac	O
sodium	B
channel	I
gene	I
(	O
SCN5A	B
)	O
may	O
lead	O
to	O
a	O
broad	O
spectrum	O
of	O
familial	O
arrhythmias	O
,	O
including	O
long	O
QT	O
syndrome	O
(	O
LQTS	O
)	O
,	O
idiopathic	O
ventricular	O
fibrillation	O
(	O
IVF	O
)	O
,	O
and	O
isolated	O
cardiac	O
conduction	O
diseases	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
polymorphisms	O
in	O
the	O
SCN5A	B
gene	O
also	O
play	O
an	O
important	O
role	O
in	O
the	O
manifestation	O
of	O
disorders	O
involving	O
cardiac	O
excitability	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
polymorphisms	O
of	O
the	O
SCN5A	B
gene	O
in	O
Han	O
Chinese	O
and	O
its	O
relation	O
to	O
Brugada	O
syndrome	O
(	O
BS	O
)	O
.	O

METHODS	O
:	O
Genomic	O
DNA	O
was	O
isolated	O
from	O
120	O
unrelated	O
healthy	O
volunteers	O
and	O
48	O
unrelated	O
Brugada	O
syndrome	O
patients	O
by	O
means	O
of	O
standard	O
procedures	O
.	O

All	O
exons	O
including	O
the	O
putative	O
splicing	O
sites	O
of	O
the	O
SCN5A	B
gene	O
were	O
amplified	O
by	O
PCR	O
and	O
sequenced	O
directly	O
or	O
after	O
subcloning	O
using	O
an	O
ABI	O
Prism	O
377	O
DNA	O
sequencer	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
5	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
were	O
identified	O
in	O
the	O
Han	O
Chinese	O
population	O
,	O
including	O
3	O
novel	O
ones	O
:	O
G87A	O
(	O
A29A	O
)	O
,	O
4245	O
+	O
82A	O
>	O
G	O
,	O
and	O
G6174A	O
.	O

The	O
allele	O
frequencies	O
of	O
each	O
SNP	O
in	O
the	O
Han	O
Chinese	O
population	O
were	O
as	O
follows	O
:	O
G87A	O
(	O
A29A	O
)	O
27.5	O
%	O
,	O
A1673	O
G	O
(	O
H558R	O
)	O
10.4	O
%	O
,	O
4245	O
+	O
82A	O
>	O
G	O
32.8	O
%	O
,	O
C5457	O
T	O
(	O
D1819D	O
)	O
41.3	O
%	O
,	O
and	O
G6174A	O
44.9	O
%	O
.	O

S1102Y	O
and	O
10	O
other	O
SNPs	O
identified	O
in	O
other	O
ethnic	O
populations	O
were	O
not	O
detected	O
in	O
this	O
study	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
allele	O
frequency	O
of	O
A1673	O
G	O
(	O
H558R	O
)	O
between	O
different	O
ethnic	O
populations	O
(	O
all	O
P	O
>	O
0.5	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
allele	O
frequency	O
of	O
C5457	O
T	O
(	O
D1819D	O
)	O
among	O
Han	O
Chinese	O
was	O
similar	O
to	O
its	O
frequency	O
among	O
Japanese	O
(	O
P	O
>	O
0.5	O
)	O
,	O
but	O
higher	O
than	O
that	O
among	O
Americans	O
(	O
P	O
<	O
0.005	O
)	O
.	O

The	O
allele	O
G1673	O
(	O
R558	O
)	O
was	O
over	O
-	O
represented	O
in	O
BS	O
patients	O
compared	O
to	O
controls	O
(	O
P	O
<	O
0.005	O
)	O
,	O
but	O
there	O
was	O
no	O
significant	O
difference	O
in	O
genotype	O
frequencies	O
at	O
this	O
locus	O
.	O

There	O
were	O
also	O
no	O
differences	O
in	O
either	O
the	O
allele	O
or	O
genotype	O
frequencies	O
of	O
the	O
4	O
other	O
identified	O
SNPs	O
when	O
comparing	O
BS	O
patients	O
with	O
healthy	O
controls	O
.	O

CONCLUSIONS	O
:	O
The	O
distribution	O
of	O
SCN5A	B
SNPs	O
may	O
vary	O
between	O
different	O
ethnicities	O
.	O

The	O
polymorphism	O
of	O
A1673	O
G	O
might	O
be	O
associated	O
with	O
BS	O
and	O
may	O
contribute	O
to	O
a	O
susceptibility	O
to	O
BS	O
in	O
Han	O
Chinese	O
.	O

Melanin	B
-	I
concentrating	I
hormone	I
receptor	I
mutations	O
and	O
human	O
obesity	O
:	O
functional	O
analysis	O
.	O

Melanin	B
-	I
concentrating	I
hormone	I
(	O
MCH	B
)	O
,	O
a	O
neuropeptide	O
highly	O
expressed	O
in	O
the	O
lateral	O
hypothalamus	O
,	O
has	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
energy	O
balance	O
and	O
body	O
weight	O
in	O
rodents	O
.	O

We	O
examined	O
whether	O
mutations	O
in	O
the	O
two	O
known	O
MCH	B
receptors	O
might	O
be	O
associated	O
with	O
obesity	O
-	O
related	O
phenotypes	O
in	O
humans	O
.	O

Among	O
106	O
subjects	O
with	O
severe	O
early	O
onset	O
obesity	O
and	O
a	O
history	O
of	O
hyperphagia	O
,	O
we	O
found	O
two	O
missense	O
variants	O
in	O
MCHR1	B
:	O
Y181H	O
and	O
R248Q	O
.	O

Neither	O
of	O
these	O
was	O
found	O
in	O
192	O
normal	O
weight	O
controls	O
.	O

R248Q	O
cosegregated	O
with	O
obesity	O
across	O
two	O
generations	O
;	O
family	O
data	O
were	O
unavailable	O
for	O
Y181H	O
.	O

When	O
expressed	O
in	O
HEK293	O
cells	O
,	O
R248Q	O
showed	O
no	O
evidence	O
of	O
constitutive	O
activation	O
or	O
ligand	O
hypersensitivity	O
for	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
phosphorylation	O
.	O

In	O
addition	O
,	O
R248Q	O
showed	O
no	O
enhanced	O
suppression	O
of	O
cAMP	O
generation	O
.	O

Two	O
common	O
single	O
-	O
nucleotide	O
polymorphisms	O
were	O
found	O
to	O
be	O
in	O
linkage	O
disequilibrium	O
:	O
g.-114A	O
>	O
G	O
and	O
c.39C	O
>	O
T.	O
No	O
association	O
between	O
either	O
of	O
these	O
single	O
-	O
nucleotide	O
polymorphisms	O
and	O
obesity	O
-	O
related	O
phenotypes	O
was	O
found	O
among	O
a	O
population	O
cohort	O
of	O
541	O
whites	O
.	O

Only	O
two	O
rare	O
noncoding	O
variants	O
were	O
found	O
in	O
MCHR2	B
.	O

In	O
conclusion	O
,	O
mutations	O
in	O
the	O
MCH	B
receptors	O
are	O
not	O
commonly	O
found	O
in	O
humans	O
with	O
severe	O
early	O
onset	O
obesity	O
.	O

Clarification	O
of	O
the	O
relationship	O
of	O
these	O
variants	O
to	O
obesity	O
must	O
await	O
study	O
in	O
other	O
populations	O
and/or	O
in	O
genetically	O
modified	O
mice	O
.	O

